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Molluscum contagiosum virus (MCV) is a dermatotropic poxvirus that solely infects 
humans. MCV infections causes benign neoplastic lesions that can persists for few 
months in children and adults. It is an opportunistic infection in immunocompromised 
patients. Currently there is no FDA approved drug available for MCV infections. The 
knowledge of MCV pathogenesis is rudimentary because there is no proper system of 
propagation nor an animal model to study MCV during infection. The proinflammatory 
cytokine Tumor Necrosis Factor (TNF) is highly expressed in MCV lesions and 
surrounding tissues. Interestingly, MCV causes little to no inflammation despite the 
expression of proinflammatory cytokines. This is because MCV encodes 
immunomodulatory proteins like MC159 protein to antagonize/neutralize TNF and other 
aspects of the proinflammatory immune response. For example, the MCV MC159 protein 
suppresses NF-kB activation, a powerful anti-viral response, via interactions with the 
NEMO subunit of the IKK complex. The exact molecular mechanism that inhibited IKK 
and NF-kB activation remained unknown and the work presented here identifies this 
mechanism. Briefly, I found that MC159 antagonizes cIAP1-NEMO interactions to 
inhibit NEMO polyubiquitination and thus NF-kB activation. This is a novel finding of a 
viral protein to disrupt NEMO-cIAP1 interactions to strategically suppress IKK 
activation (Chapter 2). 
I also found that MC159 can inhibit NF-kB activation triggered by genotoxic stress.  
This signal transduction pathway has some unique features that are missing during TNF-
induced NF-kB activation.  I used mutational analysis of MC159 to identify that there are 
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some regions of MC159 that are important for protecting against genotoxic-stress 
induced NF-kB activation but not TNF-induced NF-kB activation (Chapter 4). 
The importance of MC159 and its homolog MC160 during MCV infection has 
remained unknown, as there is no standard tissue culture for propagation or an animal 
model of infection. All of the functions of MC159 and MC160 were identified by 
expressing MC159 independent of infection.  To bridge this gap in knowledge, I 
investigated if a surrogate virus (vaccinia virus), lacking an inhibitor of NF-kB (DA49), 
could be used to study the functions of MCV proteins during vaccinia virus infections in 
mice.  We created two recombinant vaccinia viruses, vMC159 and vMC160 expressing 
MC159L and MC160L genes, respectively. My hypothesis was that MC159 and MC160 
would functionally substitute for A49 and restore the virulence of the virus (vDA49). I 
found that vMC159 functions in vivo was most striking as it was less virulent in both 
intranasal (IN) and intradermal (ID) route of inoculation. In the ID model of infection, 
vMC159 did not form any lesions in vMC159-infected ear pinnae in spite of harboring 
infectious vMC159 particles 11 days post-infection. Thus, this approach provides, for the 
first time, an examination of how MCV proteins may aid in virus virulence within the 
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Chapter 1: Introduction to thesis 
1.1 Poxviruses 
Overview  
The Poxviridae family is an extensive group of viruses that are large, enveloped, 
double- stranded DNA viruses that infect both vertebrates and invertebrates. Poxviruses 
are unique from other DNA viruses because of their ability to replicate and transcribe 
their genome exclusively in the cytoplasm of the host cell using their own replication 
machinery (60, 70). The best-known members of Poxviridae family belong to 
Orthopoxvirus genus and include Variola virus, Monkeypox virus (MPX) and Vaccinia 
virus (112). VAR is the causative agent of smallpox, the disease that devastated the 
human population until its eradication in 1980 following a global immunization 
campaign led by World Health Organization (WHO). MPX is the causative agent of 
monkeypox, which may produce a smallpox-like disease after rare-zoonotic infections. 
VAC is highly similar to VAR and MPX and was used during the smallpox vaccination 
campaign, and is still used to provide effective and long-lasting immunity against VAR 
and MPX (44, 70). 
 Molluscum contagiosum virus (MCV) is an extremely important yet understudied 
poxvirus. MCV is a dermatotropic poxvirus and is the sole member of the 
Molluscipoxvirus genus. It only infects keratinocytes to cause benign neoplastic lesions in 
humans. Further, there is no system for propagation and genetic manipulation of this 
virus, making study of this virus challenging. Since VAR has been eradicated due to an 
extensive vaccination campaign, MCV is the only circulating poxvirus that affects 
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humans worldwide (70). Poxviruses encode many immunomodulatory proteins to subvert 
the host immune responses. The study of these immunomodulatory proteins encoded by 
various poxviruses has led to significant advances in the fields of virology, immunology 
and cellular biology. The focus of my thesis is to identify and understand how the MCV 
encoded MC159 protein modulates the host cell responses against infection. Specifically, 
I identified the molecular mechanism employed by MC159 to inhibit the activation of 
antiviral NF-kB transcription factor (Chapters 2 and 4). Also, I used a surrogate viral 
system to study the functions of MC159 in vivo (Chapter 3). Before discussing the 
functions of MC159, it is necessary to understand the properties of poxviruses in general. 
This will help clarify what is known about why MCV cannot be propagated in culture. 
This section below will cover poxvirus structure and morphology, classification, and 
replication cycle. 
Genome and morphology 
Poxviruses are one of the most complex viruses known. The genome size of all 
sequenced poxviruses ranges between 134-365 kb and contain between 130-328 
predicted open reading frames (ORFs). All poxviruses have a large brick-shaped virion 
that measures 200 nm high and 300 nm long, which can be visualized using a light 
microscope. Using a transmission electron microscopy, the poxvirus mature viral particle 
appears to be wrapped in a single or double membrane and exhibit a dumbbell shaped 





The Poxviridae family can be classified into two distinct subfamilies: the 
Entomopoxvirinae which infects insects (invertebrates) and the Chordopoxvirinae which 
infects vertebrates. Members of the subfamily Chordopoxvirinae are the most extensively 
studied and can be further subdivided into ten distinct genera. These include 
Orthopoxvirus, Parapoxvirus, Avipoxvirus, Capripoxvirus, Leporipoxvirus, Suipoxvirus, 
Molluscipoxvirus, Yatapoxvirus, Cervidpoxvirus and Crocodylipoxvirus. 
Chordopoxviruses can be also grouped into four phylogenetic categories based on their 
divergence. Group I is the most divergent and includes the Avipoxvirus genera with 
Fowlpox and Canarypox viruses. Group II is the second most divergent group which 
includes Molluscipoxvirus and Parapoxvirus genera.  Groups III and IV are clustered 
together and are often referred to as ‘sister groups’ based on the relative proximity of 
their grouping on the phylogenetic tree. Group III includes members of the 
Capripoxvirus, Leporipoxvirus (such as Myxoma virus), Suipoxvirus and Yatapoxvirus 
genera. Group IV comprises of the seven members of the Orthopoxvirus genus 
(camelpoxvirus, VAR, VAC, MPX, ectromelia virus, and cowpoxvirus) (11, 70).  Of all 
these ten genera, only Orthopoxvirus and Molluscipoxvirus have significance due to their 
ability to cause human disease. Of all the viruses belonging to these two genera, only the 
VAR (Orthopoxvirus) and MCV (Molluscipoxvirus) only infect humans. Since VAR was 
eradicated in 1980, MCV remains the only poxvirus to cause morbidity in humans (70). 
A detailed description of MCV and the disease it causes in humans is discussed later in 
this chapter. Thus, studying and understanding the pathogenesis of MCV is of great 
importance, which is the focus of my thesis work. Without a means to propagate MCV, 
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researchers use other poxviruses as surrogate viruses to express individual MCV genes. 
Members of Orthopoxvirus genera have been used as a model system to study poxviral 
diseases, including VAC, which was used as a vaccine against variola, MPX, and 
ectromelia virus that infects mice. VAC is also studied as a vaccine vector against 
infectious diseases such as AIDS and as an oncolytic therapy against for several cancers. 
Thus, many researchers, including myself, use VAC as a surrogate. 
To date, the complete genomes of 493 poxvirus strains are sequenced. Sequence 
analysis revealed a total of 49 genes to be common among all poxvirus genomes. In the 
Chordopoxvirinae subfamily, all members share 90 genes in common. The majority of 
the conserved regions are located at the center of each genome, and these genes play 
important role in processes such as viral replication, transcription and virion assembly. In 
contrast, genes located at the terminal ends of the genome have great variations among 
the genera. They are mostly involved in regulating host-pathogen interactions and affect 
anti-viral responses. These genome differences are likely the cause of different host-range 
and tissue tropism for each virus (60, 70). 
Poxvirus replication cycle  
The poxvirus life cycle has been well studied using VAC as a model (Figure 1.1) 
Although MCV cannot be cultured and grown in cell cultures, its life cycle is predicted to 
be very similar to VAC. Understanding the life cycle of poxvirus is critical to understand 
the stages where MCV fails to replicate in cultures. This section will review viral 




As mentioned earlier, VAC serve as a prototype to understand poxvirus 
attachment and entry because it productively infects most types of cell lines. However, 
unlike VAC, MCV has a strict host range; as it can infect only human keratinocytes. 
Therefore, it is possible MCV has a different mechanism of attachment and entry to its 
human host skin cells. This will be further discussed later in this chapter. 
To begin a productive infection cycle, a poxvirus virion has to first attach to and 
enter into its host cell (Figure 1.1). However, the exact mechanism involved by poxvirus 
to perform this process still remains unclear. VAC infects different cell types and no 
particular receptor has been identified to be important for carrying out this function (70). 
Since poxviruses can infect such a broad range of hosts and types of cells, it is speculated 
that the mechanism for attachment must involve factors that are global. The poxviruses 
produce two types of infectious particles: mature virions (MVs) and extracellular virions 
(EVs). Since MVs and EVs do not share any common epitopes, they have different 
mechanisms for attachment to host cells. The VAC MVs employ mechanisms that 
involve glycosaminglycans (GAGs) along with other surface molecules like binding of 
viral A27 and H3 to heparin sulfate, and D8 to chondroitin sulfate (16, 21, 50, 51, 62, 
110). Interactions between A26 and extracellular matrix glycoprotein laminin or by the 
viral L1 protein via an unknown factor can lead to GAG-independent binding (70). For 
free EVs, no cellular attachment factors have been yet identified. The phosphotidylserine 
(PS)-binding serum protein Gas6 boosts EV infection with little to no effect on MV 
infection. Although the full gamut of host cell attachment factors exploited by MVs and 
EVs remain to be deciphered, it is evident that redundant attachment modes have 
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developed. This may contribute to the ability of poxviruses to infect a broad range of cell 
types with an infected host.  
Entry 
Although little is known about the poxviral attachment process, poxvirus entry 
has been studied thoroughly using VAC as a prototype (Figure 1.1). There are two ways 
VAC can gain entry to cell. The first is that VAC can enter the host cell using 
macropinocytosis (67, 68) , a form of endocytosis that involves dramatic actin 
rearrangement resulting in engulfing of large amounts of fluid. This form of entry occurs 
when VAC associates with the cell membrane, inducing entry via low-pH-dependent 
endosomal pathway (88, 105). The second method involves entry to host cell via viral 
and cellular membrane fusion facilitated at cholesterol-rich region of the host cell 
membrane called lipid rafts (22). Fusion of viral membrane has been shown to be 
mediated by a complex of 11 proteins embedded in the MV membrane. The 
transmembrane domains of five of the entry fusion complex proteins (A21, A28, G3, H2 
and O3) are N-terminal and the others (A16, F9, G9, J5, L1 and L5) are C-terminal. All 
of these proteins are necessary for viral entry into host cells (70).  
Transcription, translation, and replication of viral genomes 
Once the virus gains entry into the cell, the poxvirus must transcribe the viral 
genome (12). Poxviruses are unique among other DNA viruses as they can replicate 
exclusively in the cytoplasm of the host cell. As a result, each virion core contains the 
transcription machinery, including the viral RNA polymerase, vaccinia early transcription 
factors (VETF), and RNA polymerase associated factor (RAP94) (70). Transcription 
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regulation in poxviruses occurs in temporal manner. First the early genes are transcribed 
followed by the intermediate and late genes (3, 12, 70). It only takes 20 minutes post 
infection to detect the early genes mRNA synthesis.  Studies have revealed that half of 
the VAC genome is transcribed prior to DNA replication (3).  
Transcription of early genes are determined by an A/T rich sequence and are 
located -13 to -25 bases upstream of the RNA start site. Like eukaryotic mRNAs, the 
early viral transcripts are capped and polyadenylylated. The 3’ ends of VAC early mRNA 
frequently occur 20-50 bp downstream of the sequence TTTTTNT (T5NT). But the 
actual termination of the early transcript is mediated by the sequence UUUUU5NU 
(U5NU) in the RNA (94, 95). The viral core becomes disrupted upon termination of early 
gene transcription (70). Studies have shown the importance of two viral mRNA 
decapping proteins, D9 and D10, playing important roles in mediating transcription of the 
early gene transcripts. The early gene transcripts encode proteins for host anti-viral 
responses, DNA replication and intermediate gene transcription factors (78, 79).  
Once the viral core is disrupted, the viral replication process begins. 
Approximately after 1-2 hours post infection, the replication of viral genome is initiated 
in the cytoplasm and can also occur in enucleated cells. The DNA is replicated following 
the rolling hairpin-strand displacement model. According to this model, a nick is created 
at one or both the ends of DNA creating a 3’OH-end for priming replication. The 
replicated DNA strand then folds back on itself and thus the remaining part of the 
genome can be replicated. This result is the formation of concatamers which are 
eventually resolved and the replication process is completed (70).    
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After DNA replication, transcription for intermediate genes begins which peaks at 
2 hours post infection (70, 78). Intermediate gene transcription resembles that of early 
promoters with A/T rich regions but differs only in specific sequence. The tetranucleotide 
(TAAA) sequence serves as the initiator element of intermediate promoters. To date, 
there are only five intermediates genes that have been discovered, and three of these are 
involved in the synthesis of late gene transcription factors.  
The transcription of the late genes immediately follows the intermediate genes 
and persists till the end of the virus life cycle. Like the other promoters, late gene 
promoter is also rich in A/T regions. It differs from early and intermediate promoter as it 
possesses a core sequence of 20 bp with some consecutive T residues, separated by a 
region of 6 bp of a highly-conserved initiator sequence (TAAAT). The late genes encode 
for core proteins and proteins involved in virus assembly and packaging. Late viral genes 
are also involved in the formation of dsRNA late during infection (70).  
Virion assembly and virus egress  
The final stages in the poxvirus replication cycle is virion assembly and viral 
egress (Figure 1.1). The initial stages of virion assembly take place in distinct regions of 
the cytoplasm known as factories. These factories appear as a granular, electron-dense 
areas under the electron microscope. Within these viral factories, mature virions are 
assembled by undergoing proteolytic processing of the viral core proteins and viral 
membranes (12, 70). These factories are also the site for genome packaging. Recent 
studies have shown the importance of A32 ATPase, I6 telomere-binding protein, and the 
AI3 membrane protein to be crucial in carrying out the function of genome packaging. 
An assembled virion in the cell is referred to as a mature virion (MV) or intracellular 
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mature virion (IMV). These MV are infectious progeny and upon release from the cells, 
causes spread of the virus from one host to the other (70).  
MV utilizes the host microtubules to leave the virus factories. Subsequently these 
virions acquire a double membrane from either the trans-golgi apparatus or an endosome. 
This new double membrane virion is termed as enveloped virion (EV) or intracellular 
enveloped virion (IEV). Next, the outer membrane of the virus particle gets fused with 
the cell membrane to facilitate the egress. The spread of these virus particles can occur 
via two modes.  First, the cell associated EVs are transported to the neighboring cells 
with the help of actin filaments. Second, the virus can dissociate itself from the host and 
become extracellular enveloped virus (EEV), allowing cell-cell spread (70).  
In general, this is the pattern of replication cycle observed among all poxviruses 
due to their conserved regions. Further research is needed to elucidate the differences of 
replication cycle between MCV and the orthopoxviruses as MCV has a very narrow host 
range.  
1.2 Molluscum Contagiosum Virus 
Overview  
With the eradication of VAR, the causative agent of smallpox virus, MCV is the 
only circulating poxvirus that solely infects humans (70). It is a dermatotropic poxvirus 
causing a self-limiting infection in keratinocytes of humans. It produces benign 
neoplastic lesions which can persists in healthy individuals for months (107). Currently 
there is no FDA approved drug available nor vaccines against Molluscum Contagiosum 
infections (70, 91). With lack of animal model or culture system to propagate MCV, this 
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virus poses a great challenge to study its pathogenesis. My thesis focuses on the immune 
evasion mechanism of the MC159 protein encoded by MCV. To have a better 
understanding of the functions of MC159 in disease, this section will cover MCV 
pathogenesis and its gap in knowledge.  
MCV pathogenesis 
MCV has yet to be successfully propagated in cultured cells or animal models 
(54). As a consequence, most of our knowledge about MCV pathogenesis is derived from 
histopathological studies of patients with past or present MCV infections. The most 
interesting property of MCV is that it can only replicate in human keratinocytes (IK, 
2013 #26 Tyring, 2003 #24). With the help of light and electron microscopy, histology 
and immunohistochemistry, the initial stages of MCV pathogenesis have been evaluated. 
Recently, the study by Chen et. al. has provided a detailed description of the process of 
MCV infection (20). MCV infection is restricted to the cells in the epidermis and does 
not cross the basement membrane. The epidermis of skin is made up of five layers of 
cells (Figure 1.2). These five layers are stratum corneum (SC), stratum lucidum (SL), 
stratum granulosum (SG), stratum spinosum (SS) and stratum basale (113) with SC being 
the topmost layer of the epidermis (27). MCV cores are most common in SS and SB, the 
deepest layers of the epidermis than SL and SG. More mature MCV virions are found in 
upper layers of epidermis than SS or SB (113). These data suggest that with 
differentiation of keratinocytes, MCV particles also matures. Initially MCV targets the 
cells in SS and SB and MCV maturation occurring as these cells differentiates. The 
process of virus morphogenesis takes about 5 days (27). During the last stage of 
keratinocyte differentiation (SC), molluscum bodies (MBs), which are inclusion bodies 
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that contain large number of virions, also increase. The MBs are a lipid-rich sac-like 
structures which may provide a mechanism for MCV to evade host innate immune 
responses (54).  Finally, these MBs are trapped by the horny layers of the fibrous 
network, which dissolves the center of the lesion, forming a central core comprised of 
virions. Since MCV replication is so intimately dependent upon the differentiation of host 
keratinocytes, then a productive MCV infection in culture cell can occur only when all 
important keratinocyte cofactors or proteins are expressed by the cell (91).  
Although MCV host range is limited to humans, recent studies have reported 
MCV-like infections in other animals like donkeys, chickens, sparrows, pigeons, 
chimpanzees, kangaroos, dogs and horses (31). There is considerable homology between 
human and equine MCV analyzed by in situ hybridization. Like human MCV, these 
MCV-like viruses were unsuccessful to replicate in tissue culture. Interestingly, no 
animal MCV infection has been successfully experimentally transmitted from one animal 
to another. Thus, further research is necessary to understand how these MCV and MCV-
like viruses share common mechanisms for replication as well as viral immune evasion 
(91).  
Epidemiology 
Molluscum Contagiosum (MC) infections are third most common viral skin 
infections in children and one of the five most widespread skin diseases worldwide. It 
also infects sexually active adults and causes giant MC in immunocompromised 
individuals. MCV is transmitted via skin to skin contact with the infected individuals as 
well as through fomites (116) (91). MC in children mainly occur in the face and trunk 
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while in adults are found in the groin (7). MC infections can persist for few days to 
months to even few years in immunocompromised patients (91).  
Since there is no practice of reporting cases of MC to local or national health 
organizations, there is no accurate record of MCV incidence annually in USA and other 
countries. The incidence of past MCV infections have been quantified by measuring the 
presence of anti-MCV antibodies in blood. Using this approach, it was estimated that 6% 
and 23% of general population in Japan and Australia, respectively, were seropositive for 
MCV (56, 114). Anti-MCV antibodies were detected in 14.8% of a surveyed German and 
approximately 30% of tested UK populations (89). A study conducted among American 
Indians and Alaskan native populations found the incidence of MCV infections 
predominantly among individuals under 15 years, with highest incidence between 1-4 
years of age groups. Two studies conducted in Netherlands reported the childhood 
incidence of MCV to be 3% and 17%. Another survey conducted in England and Wales 
found that 90% of new MCV cases were reported in children up to 14 years of age (77). 
Of 100 pediatric dermatologists surveyed in USA in 2009, approximately two-third of 
respondents reported observing between 1 and 10 cases of MC every week (91).  
Restriction fragment length polymorphisms of MCV genome has identified four 
different subtypes of MCV (MCV-1, -2, -3, and -4) (56). MCV-1 is most prevalent in 
healthy individuals while MCV-2 is more common in HIV patients. Incidence of MCV 
infections are higher in immunocompromised patients. 5-8% of HIV positive populations 
suffer from MCV infections while HIV-positive individuals have up to 33% increased 
risk of contracting MCV infections as compared to healthy individuals (2, 91). It is 
estimated that between 5-20% of HIV-infected patients were co-infected with MCV. 
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MCV infections in immunocompromised patients are difficult to treat and persist 
indefinitely. Patients receiving anti-TNF treatment for rheumatoid arthritis also show 
increased susceptibility to MCV infections as well as patients with congenital immune 
suppressive conditions (24). Zhang et. al. showed that mutations in DOCK8 (dictator of 
cytokinesis 8) gene, a guanine nucleotide exchange factor, have been linked to recurrent 
cutaneous viral infections including MCV (119). A patient with homozygous DOCK8 
gene deletion was diagnosed to have extensive, disseminated MC lesions on the hand and 
anogenital regions (119). Interestingly there are reports of MCV associated with student 
athletes who wrestle as well as swim. With swimming, the chances of MCV increases by 
two-fold (91).  
MCV genome 
In 1996, the complete genome of MCV was sequenced (86). The MCV genome 
share some common genes with VAC and with other members of the Orthopoxvirus 
genus. An interesting characteristic of the MCV genome is its high guanidine-cytosine 
(GC) content (64%) as compared to VAC (34%). Sequence analysis revealed that MCV 
encodes approximately 182 predicted proteins. Of these 182 proteins, 105 proteins share 
homology with VAC genes (88). Two similarities were observed between these 
homologs. First, they were localized in the center of the genome. Secondly, they encode 
for proteins that are essential for structure, transcription, and replication (86, 88). 
However, the host range and immunomodulatory genes of MCV differ vastly from those 
of VAC. These unique MCV genes are localized at the ends of the genomes and are 
critical for encoding immunomodulatory proteins which regulate MCV tropism. With 
limitations of MCV culture, little is understood how these immune evasion proteins 
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function. My thesis work focuses on one such immunomodulatory protein called MC159 
(70).  
Phylogenetic analysis of five highly conserved poxvirus genes (DNA polymerase, 
DNA uracil glycosylase, early transcription factor subunit, NTPase-1 and rifampicin-
sensitivity factor) show that MCV and members of the Orthopoxvirus and Leporipoxvirus 
genera have evolved from a common ancestor (87). MCV genome was also compared to 
Orf virus, a member of the Parapoxvirus genus (25). Orf virus causes a skin infection in 
sheep and can cause zoonotic infection in humans. Despite being in different genera, 
sequence analysis revealed great similarity between Orf virus and MCV. These 
similarities include high GC content of the genome, presence of three putative immune 
evasion orthologs, and the lack of viral genes involved in nucleotide metabolism (25).  
MCV tropism 
The research on immunomodulatory proteins of MCV have been greatly 
hampered due to lack of proper culture system to propagate MCV (91). MCV replication 
has been tested in many primary and established human cell lines and tissues. To date, 
there are no confirmed reports of MCV cultivation in vitro. McFadden et. al. analyzed 
several cell lines and found only early gene expression (66). This observation led to the 
theory that MCV core failed to uncoat and thus prevented DNA replication and 
subsequently intermediate and late gene expression. Recently, in human lung fibroblast 
cell line (MRC5), MCV late gene mRNA was detected 5 days post infection by reverse 
transcriptase PCR (13, 14). This implied some MCV virions uncoat and some viral DNA 
is synthesized. However, no increase in MCV virion was detected by PCR amplification 
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as well as no virion morphogenesis stages were observed. Thus, for reasons unknown, 
some late genes were transcribed without undergoing any virion morphogenesis. MCV 
was also reported to replicate in human foreskin fragments that were implanted into the 
renal capsule of mice (29). However, these viruses were not infectious.  
There are several hypotheses proposed for strong tissue tropism of MCV. Since 
MCV can infect only human keratinocytes, it is possible that MCV replication requires 
specific cofactors that are present only in differentiated keratinocytes (15). Another 
hypothesis is that MCV cannot be propagated in tissue culture because it has lost some 
key genes existing in poxviruses that allow for replication in multiple cell lines (15, 87). 
MCV lacks homologs to six VAC genes involved in nucleotide biosynthesis. The 
functions of these six genes are thymidine kinase, thymidylate kinase, guanylate kinase, 
deoxyuridine triphosphatase, and two ribonucleotide reductase subunits (87).  Another 
hypothesis is the lack of homolog of kinase B1 encoded by VAC (86, 87). B1 plays a 
critical role in replication by phosphorylating the cellular BAF, without which VAC 
cannot replicate (75). Alternatively, MCV is unable to overcome the innate immune 
defenses in cell lines. Thus, the lack of a proper tissue culture model presents a challenge 
for understanding MCV replication and pathogenesis. Until this technical barrier is 
overcome, research on MCV will continue by expressing MCV genes independent of 
infection, by a surrogate virus, or by using MCV collected from lesions of patients for 
experimental infections.  In this study, we have developed a surrogate poxvirus (vaccinia) 
that encodes MCV proteins to gain insight into MCV pathogenesis in vitro and in vivo 
(Chapter 3).  
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1.3 Host Innate Immune Signaling 
Overview 
A robust immune response is necessary for the resolution of a virus infection. 
Innate immunity is critical to surmount a defense mechanism against the viral infection 
(Figure 1.5). The innate immune system is comprised of several different classes of 
germ-like encoded pattern recognition receptors (PRRs) that have evolved to recognize 
different conserved motifs on virus denoted as pathogen-associated molecular patterns 
(PAMPs), which are often byproducts of viral infections (dsRNA, dsDNA and 
glycoproteins) (31). These PRRs include several different families such as Toll-like 
receptor (TLRs), Nod-like receptors (NLRs), and Retinoic inducible gene-1 (RIG-I), 
recognize viral PAMPs. Sensing viral PAMPs, these cellular sensors activate many innate 
immune signaling pathways such as NF-kB and Interferon-beta (IFN-b) (34). Once 
activated, these transcription factors can induce type I IFNs and the proinflammatory 
cytokines like tumor necrosis factor alpha (TNFa) and interleukin-1 (IL-1). IFNs and 
cytokines then stimulate multiple outcomes such as inflammation, effector cell 
recruitment, induction of anti-viral state and apoptosis of the infected cell which 
eventually limit viral spread and direct antiviral acquired immunity. All of these 
pathways will become activated during poxvirus infection. To counteract the effects of 
the host innate immunity, poxviruses encode myriad immune evasion proteins. Nearly 30 
percent of their genome is devoted for encoding these immunomodulatory proteins (48, 
49). Like poxviruses, MCV also encodes many immunomodulatory proteins which will 
be discussed later in this chapter. Although there are various triggers to activate NF-kB 
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pathway, my work has mainly focused on TNF mediated NF-kB activation. This is 
because TNF is highly expressed in MC lesions and found to be an important cytokine in 
preventing MC lesions. Also, patients receiving anti-TNFa therapy treatment (such as 
infliximab) are at increased risk of developing MC lesions. Given the importance of 
TNFa in controlling MCV lesions, my work has focused on TNFa mediated innate 
immune responses during MCV infection. Here I will review the three-intrinsic innate 
immune responses (IIRs) that MC159 protein modulates; namely NF-kB, apoptosis and 
IFN-b. 
NF-kB  
TNFa is a potent activator of NF-κB, a cellular transcription factor that regulates 
immune response during infection and is highly expressed at MCV lesion sites (58) 
(Figure1.3). There are five known mammalians NF-kB family proteins: p65 (RelA), 
RelB, c-Rel, p50/p105 and p52/p100 (46, 47). These proteins act as homodimers or 
heterodimers, with each dimmer differently contributing to regulation of NF-kB target 
genes. However, the p65/p50 complex is the best studied and most common heterodimer. 
Prior to stimulation, NF-kB resides in the cytoplasm bound to one of its inhibitory factor: 
IkBa, IkBb and IkBe. The IkB proteins possess ankyrin repeat domains which are 
critical for protein-protein interactions, thus mediating NF-kB-IkB interactions. The IkB 
proteins inhibit NF-kB activity by binding its nuclear localization sequence, thus 
preventing its translocation to the nucleus (11, 69).  
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In chapter 2, I evaluate the detailed mechanism how MC159 inhibits 
TNFa mediated NF-kB activation. Hence, it is important to understand the signaling 
pathway triggered during TNFa stimulation (Figure 1.3). In most cells, TNFa signals 
through its receptor TNF-R1, exerting its effect primarily by activating the 
proinflammatory transcription factor NF-κB. Upon TNFa occupancy, TNF-R1 rapidly 
recruits the TNFR-associated death domain (TRADD) protein and the receptor-
interacting protein 1 (RIP1). TRADD binding in turn recruits the TNFR-associated factor 
2 (TRAF2) to form a large membrane complex. Then, RIP1 is modified with a large 
polyubiquitin chains conjugated at lysine 63 (K63) residues of ubiquitin, a crucial event 
for the propagation of the signal. The E3 ligase responsible for targeting RIP1 is cellular 
inhibitor of apoptosis 1/2 (cIAP1/2). The polyubiquitin chain on RIP1 serve as a docking 
site for both TGF-b-activated kinase 1 (TAK1) and TAK1 binding proteins 2/3 (TAB2/3) 
heterocomplex, and the inhibitor of kB (IkB) kinase (IKK) a/b/g heterocomplex. The 
IKK complex consists of two kinases subunits – IKKa, IKKb and a regulatory subunit 
NF-κB essential modulator (NEMO). After recruitment, NEMO undergoes K63 linked, 
the non-degradative polyubiquitination and thus serve as an integral scaffold protein for 
signal transduction. Upon assembly of this complex, TAK1 phosphorylates IKKβ on its 
activation loop. Phosphorylated IKKb in turn phosphorylates IkBa, an inhibitory protein 
that normally prevents NF-kB dimers (typically p50/p65) from translocating to the 
nucleus. The phosphorylation of IkBa signals for its ubiquitination and proteasomal 
degradation, which allows NF-kB proteins to enter the nucleus and regulate target genes. 
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Unlike K48 ubiquitination, which targets substrates for proteasomal degradation, 
K63-linked and, more recently, linear ubiquitination has been shown to be important for 
NF-kB activation by providing a recruitment platform and signaling cues. The ubiquitin-
binding surface in NEMO called UBAN (Ub binding in ABIN and NEMO; 290-330 
amino acids) or NOA (NEMO-Optineurin-ABIN) is required for signal induced IKK 
activation. However, NEMO contains another ubiquitin-binding domain at the C 
terminus; zinc finger (ZF) domain, and it was shown that a NEMO fragment containing 
UBAN and ZF domains have increased affinity for K63 polyubiquitin chains (59). Eric D 
Tang et. al. showed that cIAP1 is the E3 ligase responsible for polyubiquitination of 
NEMO by binding to NEMO (101). cIAP1 and cIAP2 are highly homologous in amino 
acid sequences and domain structures. Both contain a RING finger domain that functions 
as an E3 ubiquitin ligase and regulate NF-kB signaling in response to TNFa. Either 
cIAP1 or cIAP2 is required for proper polyubiquitination of RIP1 and activation of NF-
kB pathway as they are functionally redundant (63). Understanding these ubiquitination 
machineries will be critical to dissect the inhibitory mechanism of MC159 during TNFa 
mediated NF-κB activation (Chapter 2). 
Other reagents or events stimulate NF-kB.  Recently, it was discovered that 
genotoxic stress triggers NF-kB activation.  MCV infects keratinocytes and, with UV 
irradiation of the skin, it is easy to imagine that MCV-infected keratinocytes may also be 
exposed to genotoxic stress.  Like TNF-induced NF-kB activation, genotoxic stress 
activates NF-kB via IKK activation.  However, there are steps in the NF-kB activation 
pathway, with respect to NEMO activation, that differ.  The goal of Chapter 4 was to ask 
if MC159 could also block genotoxic stress. 
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Apoptosis 
Apoptosis or programmed cell death is a potent antiviral response (72). It is 
important for execution and clearance of virally infected cells (Figure 1.5). Therefore, 
many viruses encode myriad proteins to subvert apoptosis of host cell (55). MC159 also 
manipulates the apoptotic pathway to its benefit. Apoptosis can be triggered by two 
cellular pathways: the intrinsic and extrinsic pathways. Apoptosis is initiated by various 
stimuli including DNA damage, cellular stress, and infection. The extrinsic pathway is 
triggered by binding of ligands such as Fas ligand (FasL), TNFa, or TNF related 
apoptosis-inducing ligand (TRAIL) to their respective receptors. Once a cytokine has 
bound to its receptor, the recruitment of adaptor proteins such as Fas-associated death 
domain protein (97), TNF-receptor (TNFR)-associated death domain protein (TRADD), 
TNFR2-associated factor 2 (TRAF2) or receptor-interacting protein 1 (RIP1) can occur. 
Next, these proteins assemble to form the death-inducing signaling complex (DISC). 
DISC provides the scaffold necessary to recruit and activate the initiator caspase, pro-
caspase-8 through FADD’s death effector domain (39). Pro-caspase-8 is activated via 
proteolytic cleavage and the release of its active form can subsequently cleave caspase-3. 
The caspase-3 in turn cleaves Poly(ADP-ribose) polymerase 1 (PARP-1), resulting in 
apoptosis (55, 72).  
The intrinsic apoptosis pathway is induced by numerous intracellular stress 
responses, including those induced during viral infection. Intrinsic apoptosis is mediated 
through the host cell mitochondria. One of the critical steps in intrinsic apoptosis is 
mitochondrial membrane permeabilization (MMP). Released cytochrome c (cyt c) and 
ATP/dATP then stimulate Apaf-1 oligomerization. Monomeric, inactive procaspase-9 is 
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recruited to Apaf-1 via CARD-CARD interactions. Next, caspase-9 activation occurs via 
two apoptosome-mediated mechanisms. First, proximity-induced homodimerization 
resulting in procaspase-9 activation and followed by autocleavage at Asp 315. Second 
mechanism is formation of procaspase-9-Apaf-1 or cleaved caspase-9-Apaf-1 
heterodimers that result in caspase-9 activation. Upon activation, caspase-9 cleaves and 
activates caspase-3, which in turn cleaves cellular PARP-1 and other protein substrates, 
culminating in cell death. Importantly, the intrinsic and extrinsic apoptosis pathways are 
not mutually exclusive. Activation of one pathway can lead to the secondary activation of 
the other (72). 
Like all poxviruses, MCV also encodes proteins which hijack the host innate 
immune response of apoptosis (91). It encodes proteins which affect both the intrinsic 
and extrinsic pathways of apoptosis. These MCV proteins will be discussed later in the 
chapter. Briefly MC159 protein binds to FADD and procaspase 8 to inhibit TNFa and 
FasL-induced activation of the extrinsic apoptotic pathway. Recently Coutu J et. al. has 
shown that N-terminal part of MCV MC163 localizes to mitochondria and prevent 
intrinsic apoptosis by blocking MMP (23). Understanding MCV immunomodulatory 
proteins’ role in apoptosis is critical for gaining knowledge about host-virus interactions 
in vivo which is the focus of the chapter 3. 
IRF3 activation and IFN-b production 
Type I interferons are critical for mounting an antiviral state in virus infected 
cells. Interferon alpha (IFN-a) and interferon beta (IFN-b) are critical for anti-viral 
response (81). When cells are infected with virus, IFN-b triggers an immediate antiviral 
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response, whereas IFN-a contributes a delayed response. IFN-b produces the most robust 
anti-viral responses and therefore will be the focus of this review. 
During poxvirus infection, TLRs and RIG-I are the major activators of IFN-
b (108). The next steps leading to IRF3 activation are shown in Figure 1.4.  By-products 
of viral infection, like ds-RNA, are detected by upstream cellular sensors like RIG-I, 
melanoma differentiation-associated factor gene 5 (MDA5), and STING. RIG-I and 
MDA5 proteins then interact with mitochondrial antiviral signaling (MAVS) adaptor 
protein to stimulate MAVS activation. Activation of MAVS proteins result in 
phosphorylation and activation of kinases TANK binding kinase-1(TBK-1) and I-kappa-
B kinase epsilon (IKKe). Alternatively, the TLRs and STING molecules also activate the 
TBK1:IKKe. The TBK1:IKK-e heterodimer phosphorylates the key transcription factor, 
interferon regulatory factor 3 (IRF3). IRF3 homodimerizes, migrates to the nucleus, and 
initiates IFN-b expression, as well as other interferon stimulated genes (ISGs) (39, 76). 
This pathway is a common target for viral immunomodulatory proteins. My work in 
collaboration with C.M.H. Randall has shown how MCV encoded immune evasion 
proteins target this TBK1:IKK-e complex (80).  
IRF proteins consists of two domains: a DNA binding domain (DBD) and a IRF 
associated domain (IAD) (102). These domains are critical for DNA binding or protein-
protein interactions, respectively. Of all the nine IRF proteins known, only IRF3 and 
IRF7 are involved in IFN-b expression (102). The IRF3 is constitutively expressed in 
most cell types while IRF7 is only expressed during viral infection or other stimuli. IRF7 
activates transcription of both IFN-a and IFN-b while IRF3 can only activate IFN-
	 23	
b production (102). Once IFN-b is produced, it gets secreted and binds to IFN receptors 
on virally infected cells as well as neighboring cells. This interaction leads to the 
activation of Janus activates kinase (JNK)-STAT (signal transducer and activator of 
transcription) signaling cascade which eventually activates IRFs and ISGs. IFN-
b regulates various ISGs which are key for mounting an antiviral state (98).  
Due to the potent anti-viral properties of IFN-b, MCV encoded MC159 target the 
IRF3 driven expression of IFN-b production (80). This will be discussed in detail later in 
this chapter. Briefly, MC159 binds to kinases TBK1 and IKK-e to inhibit IRF3. MCV 
also encode another homologue of MC159, MC160 which is also capable of inhibiting 
IRF3 as well as IRF7 phosphorylation (80). Thus, MC159 is a multifunctional immune 
evasion protein encoded by MCV, which is potent to hijack the innate immune responses; 
namely apoptosis, NF-kB, and IFN-b. Hence, studying the MC159 viral protein can shed 
light on the viral mechanisms and strategies employed to counteract host innate antiviral 
immune response and better understand MCV replication and spread. 
1.4 FLIP Regulation of NF-kB, Apoptosis and IFN-b 
Overview 
The FLICE inhibitory proteins (FLIPs) are a family of proteins encoded by both 
viruses (vFLIP; poxviruses, herpesviruses) and cells (cFLIP) (Figure 1.6) (90). This 
family of proteins was discovered during early studies of apoptotic pathways. Since these 
FLIP proteins contain death effector domains (DEDs), they were thought to be critical for 
apoptotic regulation (109). However, recent studies have shown that FLIP proteins also 
	 24	
play a crucial role in modulating the cellular pathways like, NF-kB, and IFN-b (80, 90). 
All FLIP proteins contain DEDs and a variable C terminus. The DED does not have any 
enzymatic functions, but its structure of six-a helices promote protein-protein 
interactions. The sequence similarity of the viral FLIPs (MC159 and MC160) DEDs is 
~43% identical while the sequence similarity of the viral and cellular FLIP (MC159 and 
cFLIPL) is ~ 30% identical (92). Interestingly, although these FLIPs are highly 
homologous, they are functionally very different. Here, I will discuss the vFLIPs encoded 
by MCV; MC159 and MC160 as well as by herpesvirus and cellular FLIPs. Also 
highlight their mechanisms by which they modulate various cellular pathways.  
MC159 
The 25 kDa MC159 protein comprises of 241 amino acids (aa) (Figure 1.7). It is 
characterized by the presence of two tandem DEDs (DEDA and DEDB) separated by a 
linker sequence of 14 aa and 64 aa of C-terminal tail. These domains were termed as 
DED because of their presence in cellular apoptotic proteins like FADD and procaspase 8 
(FLICE). Each DED comprises of 6-a helices (26). However, in MC159, the helix 3 in 
DEDA is truncated into a rigid loop. Also, these DED domains possess an RXDL motif 
at the C-terminal end of each DED. Although these DEDs are structurally very similar, 
they have different functions as discussed below. Crystal structure of the MC159 protein 
describes the protein as having a rigid dumbbell structure in which the two DEDs tightly 





The MC159 protein inhibits TNF-R1 and CD95 mediated apoptosis pathways (71, 
92) (Figure 1.8). The molecular mechanisms involved in this inhibition has been studied 
extensively. Garvey et. al. has shown that MC159 inhibits apoptosis by binding to FADD 
or procaspase 8 through an RXDL motif which is present in both DEDs (35). Hence, both 
the DEDs are essential for MC159’s anti-apoptotic functions. MC159 was shown to co-
immunoprecipitate with FADD and procaspase 8 which prevented the self-
oligomerization and DISC assembly (8, 35, 92). Additionally, the anti-apoptotic function 
of MC159 is bolstered by its interaction with adaptor protein TRAF3 (103). MC159 has a 
TRAF binding motif in its C-terminus, which facilitates MC159:TRAF3 interactions. 
Although, the binding partners necessary for apoptotic inhibition is debatable, there is 
consensus that MC159 inhibits apoptosis by blocking the DISC assembly. 
NF-kB inhibitory function 
Several studies have shown that MC159 inhibits TNF-induced NF-kB activation 
(37, 71, 81) (Figure 1.8). Previous studies from our lab has shown that DEDA of MC159 
was sufficient to inhibit the NF-kB activation and that there is correlation between NF-
kB inhibition and TRAF2 binding (71, 81). Although there was enough evidence to 
support MC159’s inhibitory function, the detailed molecular mechanism how MC159 
inhibited this pathway was unknown. A clue to this inhibitory mechanism was provided 
from the findings of Randall et. al. where it was shown that the MC159 protein 
coimmunoprecipitated with the members of the IKK complex (81). IKK complex is 
composed of IKKa, IKKb and NEMO subunits, and NEMO regulates the IKK complex. 
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Using mouse embryonic fibroblasts (MEFs) lacking IKKa, IKKb or NEMO, it was 
determined that MC159 interacted with the NEMO subunit of this complex. This 
MC159-NEMO interaction was observed when MC159 was ectopically expressed or 
during a surrogate virus infection or a wild type MCV infection (81). 
A recent report by Challa et. al. suggested that MC159 stimulates NF-kB 
activation in Jurkat T cells (17). We have also observed very low levels of NF-kB 
activation during MC159 ectopic expression. However, this activation is negligible 
compared to the inhibitory phenotype we consistently observe (9, 71, 81). How the 
MC159 protein accomplishes both NF-kB activation as well as NF-kB inhibitory 
functions and their impact on MCV pathogenesis is not fully understood. Although we 
know that MC159 binds to NEMO of the IKK complex to inhibit the NF-kB activation, 
the exact molecular mechanism involved in NEMO-MC159 interactions that inhibited 
NF-kB activation is not known. Chapter 2 details my work showing that MC159 inhibits 
the polyubiquitination of NEMO, a critical signaling event, to inhibit the NF-kB 
activation. 
IFNb inhibitory functions 
The first indirect evidence that MC159 inhibits IFNb expression is shown by 
Balachandran et. al. In this study, they show that overexpression of MC159 inhibits the 
activation of IFNb enhancer, a promoter that is regulated by IRF3 and NF-kB (5). Hence, 
it is unclear whether the inhibitory function of MC159 was specific to IFNb or an indirect 
result of MC159 induced inhibition of NF-kB. I, in collaboration with C.M.H. Randall 
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found that MC159 inhibits IFNb expression independently of NF-kB by blocking the 
activation of the IRF3 transcription factor (80) (Figure 1.8).  
There were three strategies employed to prove that MC159 directly inhibited the 
IFNb expression. First, luciferase reporter assays were performed using MEFs that lack 
the p65 subunit of NF-kB. With the lack of a functional NF-kB, there is no confounding 
factor. Under these conditions, MC159 was found to inhibit IFNb controlled luciferase 
activity (80). In a second approach, a luciferase reporter gene under the control of a 
synthetic IRF3 promoter was used. Here, ectopic overexpression of MC159 protein 
inhibited the IRF3 activation triggered by overexpression of different upstream molecules 
of MAVS-IRF3 activation pathway, including MAVS, TBK1 and IKKe. Finally, the 
DEDB of MC159 was found to possess the IRF3 inhibitory function.  Since DEDB was 
not sufficient to inhibit apoptosis and NF-kB activation, MC159 inhibition of IRF3 is a 
novel inhibitory function (80). Since, MC159 protein was found to inhibit TBK1 
activation and also coimmunoprecipitated with TBK1-IKKe, it was thought the MC159-
TBK1 interactions were critical for inhibiting TBK1 activation (80). The exact 
mechanism how MC159 prevents TBK1 activation is the focus of the future study.  
MC160 
MCV MC160 is a 52 kDa vFLIP protein (92). Like MC159, it has two tandem 
DED domains (residues 5-79 and 97-175), and each DED contain RXDL motif (Figure 
1.6). The C-terminal region (residues 175-371) of MC160 is unique and has no known 
homology to any proteins. The DEDA and DEDB of MC160 are 45% and 33% similar to 
DEDA and DEDB of MC159, respectively (92). Recently it was reported that, unlike 
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MC159, the RXDL motif of MC160 is not required for the functions of the viral protein 
(6). 
Anti-apoptosis function 
Since MC160 contains DEDs like other FLIPs, it was predicted that the MC160 
protein would also inhibit apoptosis (86, 87). Only one report showed the anti-apoptosis 
function of MC160 while several reports showed that MC160 does not inhibit apoptosis 
either when expressed transiently or during a surrogate poxvirus infection (52) (92, 93). 
Although MC160 interacts with FADD and procaspase-8, these interactions are not 
sufficient to block apoptosis (Figure 1.8) 
There are several known caspase cleavage sites within MC160 protein, which 
undergoes cleavage when cells are triggered for apoptosis (92). The cleavage of MC160 
is blocked when MC159 is co-expressed with MC160 due to the inhibitory function of 
MC159, an event that would occur naturally during an MCV infection (92). Currently, it 
is unknown whether the MC160 cleavage products have any biological significance.  
NF-kB inhibitory function 
Like MC159, MC160 also inhibits TNF induced NF-kB activation (Figure 1.8). 
Studies in our lab has shown that MC160 employs two distinct mechanisms to inhibit 
NF-kB activation (73, 74). While MC159 targets the NEMO subunit of the IKK complex 
to inhibit NF-kB activation (81), MC160 targets IKKa degradation, preventing the 
formation of the IKK complex (74). Mutational analysis has revealed that DEDB and the 
C-terminal region of MC160 are important for NF-kB inhibition. Hsp90, a part of the 
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mature IKK complex, is critical for binding and stabilizing IKKa (74). Work from our 
lab has shown that C-terminus of MC160, competes with Hsp90 for IKKa, resulting its 
degradation. The second mechanism of MC160 to inhibit NF-kB activation is provided 
by the DEDB. DEDB of MC160 inhibits procaspase-8 mediated NF-kB activation by 
binding to procaspase-8.  
IFNb inhibitory functions 
Recently Randall et. al. showed that MC160 inhibits IFNb expression by 
inhibiting IRF3 and TBK1 activation (80). The exact mechanism of IRF3 inhibition by 
MC160 is still unclear. Unlike MC159, MC160 does not coimmunoprecipitate with 
TBK1 and IKKe suggesting a different mechanism of IRF3 inhibition. Since MC160 
interacts with other DED-containing molecules; like FADD, TRADD and procaspase-8, 
which are shown to inhibit IRF3, it is speculated that perhaps MC160 uses one of these 
molecules to inhibit IRF activation. It was also shown that MC160 is able to inhibit IRF7 
phosphorylation, suggesting it possesses more than one mechanism to oppose type I IFN 
production. Mutational analyses show that DEDB of MC160 is important for IRF3 
inhibition (80). 
K13 
Human Herpes Virus 8, the etiological agent of Kaposi’s sarcoma (KS), encodes a 
vFLIP called K13. Kaposi sarcoma herpes virus (KSHV) causes lymphoproliferative 
disorders including primary effusion lymphoma and multicentric Castleman’s disease 
(33). KSHV expresses K13 during latency, and inhibits the lytic phase of the virus (42). 
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The K13 protein shares sequence and structural homology to MC159 protein (Figure 1.8). 
Like MC159, K13 also inhibits apoptosis by inhibiting caspase-8 activation. This anti-
apoptosis function of K13 is physiologically relevant because there is a correlation 
between increase in the expression of K13 and reduction in apoptosis in KS lesions (42, 
104).  
Unlike MC159, K13 activates NF-kB during infection which is important to 
promote cell survival, propagation, transformation and cytokine production (Figure 1.8). 
K13 expression by KSHV during latency plays a critical role for viral oncogenesis (19, 
100). Hence, extensive research has been done to elucidate the mechanism of K13 
mediated NF-kB activation. K13 targets NEMO subunit of the IKK complex to induce 
NF-kB activation (19, 43). Mutational analyses have shown that K13 binds to NEMO at 
residues 150-272 (28). The crystal structure of K13-NEMO was solved, revealing it to be 
dimer of K13-NEMO complexes (4). The DEDA of K13 form two deep clefts that are 
crucial for binding a NEMO molecule. Once NEMO is bound to K13, it induces a 
conformational change to induce NF-kB activation (4). However, K13 was not found to 
have any effect on IFNb expression. Randall et al. overexpressed vFLIPs (MC159, 
MC160, and K13) and showed that MC159 and MC160 could inhibit IRF3-driven IFNb 
transcription while K13 had little to no effect (80). 
cFLIP 
Soon after the discovery of vFLIP, its cellular homologue (cFLIP) was identified 
(38, 85). Although there are multiple variants of cFLIP, only three splice variants have 
been studied extensively. These are the long variant (cFLIPL), and the two short variants, 
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cFLIPS and cFLIPR (38, 85). The C-termini of cFLIPs are highly variable from vFLIPs 
(Figure 1.6). The cFLIPL is a 55 kDa protein and possesses a caspase-like domain (CLD). 
cFLIPS and cFLIPR proteins are 26 and 24 kDa, respectively and lack a CLD. cFLIPS and 
cFLIPR are reported to inhibit apoptosis by binding to procaspase-8 (38, 85). The cFLIPL 
effect on  apoptosis is more complex as it can either activate or inhibit apoptosis 
depending on its expression levels (18). When cFLIPL is expressed at high 
concentrations, it acts as an anti-apoptotic protein by binding to procaspase-8 and 
inhibiting its activation (18, 57). However, when cFLIPL is expressed in low 
concentration, it triggers procaspase-8 activation to promote apoptosis (18). Recent study 
by Flicker et. al. has shown that the function of cFLIPL is also dependent upon other 
events like strength of the receptor stimulation and relative amounts of cFLIPS/R (32). 
Given the reports that MC159 activates NF-kB, perhaps MC159 protein levels may also 
dictate its effect on NF-kB activation. 
Like K13, cFLIPL also activates the NF-kB pathway (Figure 1.8). During NF-kB 
activation, procaspase-8 interacts with cFLIPL, resulting in cFLIPL cleavage generating 
p43 or p22 products. The p43 version allows RIP1 and TRAF2 to bind to the procaspase-
8-p43 complex, inducing IKK activation. p22 instead binds to NEMO subunit of the IKK 
complex to activate NF-kB. Like K13, the DEDA of cFLIPL is sufficient to activate the 
NF-kB (65). 
Although there are several reports showing cFLIPL regulates type I IFN 
production, these studies show conflicting effects of cFLIPL, in which cFLIPL either 
activates or inhibits type I IFN production. Since cFLIPL interacts with procaspase-8, it 
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was hypothesized that cFLIPL also regulates IRF3 activation. Work from our lab has 
shown that overexpression of cFLIPL prevents MAVS induced IRF3 activation (80). 
Also, work by Handa et. al. showed that cFLIPL-/- MEFs have increased levels of IRF3, 
bolstering the concept that cFLIPL inhibited IRF3 activation (45). Recently, Gates et. al. 
showed that cFLIPL inhibited IRF3 mediated gene transcription when triggered with 
various stimuli (e.g., virus infection, poly I:C and TBK1 overexpression) (36). cFLIPL 
promoted IRF3 phosphorylation and nuclear translocation. Coimmunoprecipitations 
assay showed that cFLIPL interacts with IRF3 and colocalizes in the nucleus which is 
important for its inhibitory functions. However, cFLIPL inhibits formation of the IRF3 
enhanceosome, blocking IRF3 mediated promoter interaction, gene transcription and 
IRF3-CBP interactions (36). 
Thus, although these FLIP proteins are structurally similar to each other, they are 
functionally very diverse (Figure 1.8). Currently it is unknown what characteristics 
amongst these FLIP proteins and their DEDs allow them to modulate the apoptosis, NF-
kB activation, and IFNb expression by such different mechanisms. Therefore, studying 
and understanding the functions and mechanisms of each of these FLIP proteins can 
provide valuable information into protein-protein interactions that are critical for 
modulating the intrinsic immune responses. My PhD focus has been on elucidating the 





1.5 Vaccinia Virus Animal Models of Infection 
Overview 
To date, there is no culture system or laboratory animal model to study the 
pathogenesis and replication of MCV (91). Due to this technical barrier, researchers have 
studied MCV genes either by ectopically expressing in culture systems (e.g., by plasmid 
transfection) or by using a surrogate system expressing MCV genes.  Much of the 
understanding of MCV gene function has come from the transient expression studies. A 
few researchers have attempted to study MC159, in a surrogate animal system or in 
transgenic mice expressing the viral protein. Recently Hüttmann et. al. has investigated 
the role of MC159 in a murine cytomegalovirus (MCMV) surrogate system (53). In this 
study, MC159 was inserted into MCMV genome, replacing two genes (M45 or M36) of 
MCMV, that function similarly to MC159. In this model, MCMV expressing MC159 was 
inhibits TNF-mediated apoptosis of infected cells, but only could partially restores 
MCMV replication in macrophages. Unlike the M45 protein, MCMV expressing MC159 
inhibited TNFa, but not IL-1, mediated NF-kB activation. Although MCMV expressing 
MC159 showed selective tissue tropism, such studies are important for understanding the 
biological relevance of MCV viral proteins (53). 
Like MCV, VAC also encode myriad immune evasion proteins that target the 
innate immune responses of the host (96). The focus of my thesis was to determine how 
MC159-NEMO interactions impact NF-kB activation and viral pathogenesis. I was 
successful in elucidating the mechanism employed by MC159-NEMO interactions to 
inhibit NF-kB activation in vitro (Chapter 2 and 4). However, to study the viral 
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pathogenesis of MC159 and MC160 in vivo, I utilized a vaccinia surrogate model system 
(lacking A49 virulence protein) in which these MCV genes were inserted and studied in 
mice (Chapter 3). 
To study the effect of VAC encoding MCV proteins in vivo, VAC can be 
inoculated into mice to cause disease using one of the seven routes; intravenous, 
intradermal, intraperitoneal, intranasal, intracranial, subcutaneous or footpad. Of all these 
routes of inoculation, intranasal and intradermal are the two most-widely used routes to 
study viral pathogenesis. Additionally, the intranasal and intradermal routes mimic a 
natural (inhalation) and dermal vaccination, respectively. Thus, these two routes will help 
us better understand the pathogenesis of smallpox like diseases and immune response to 
vaccination with VAC. 
Intranasal model 
Intranasal inoculation (IN) of mice with VAC leads to an acute systemic infection 
of the lower respiratory tract (83, 115). There are no skin lesions associated with IN 
route. However, it mimics the smallpox infection because it causes systemic infection. 
Lungs are the primary site of virus replication during an IN inoculation. Since VAC 
western reserve (118) strain is neurovirulent, WR spreads from the lungs to the brains of 
the inoculated mice. Finally, the virus disseminates to other organs including like liver, 
spleen, kidney and ovaries (82). Classically, there are three methods used for monitoring 
the disease progression. The first method is examine changes in weights of mice with 
weight loss indicating virulence. Second is reporting the clinical signs of illness such as 
ruffled fur, conjunctivitis, hunched posture, difficulty in breathing and socializing. The 
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last method is to measure the virus titers from organs like brain, lungs, kidneys, spleen 
and ovaries, with virus titers used as a quantitative measure of virulence (115). 
The immune responses during an IN injection is also well characterized. Within 
24 hours of IN injection, several cytokines and chemokines are expressed in lungs like 
TNFa, IL-6, IL-2, CXCL9 and CXCL10 (99). By 48 hours post-infection, there is 
increased immune cell infiltration in the bronchoalveolar lavage fluids. These immune 
cells are mainly macrophages, natural killer (NK) cells, neutrophils, and lymphocytes like 
CD4+ and CD8+ T cells (82). Dendritic cells and macrophages play a critical role in 
mounting an early innate immune response against VAC (10, 84). CD8+ mediated IFNg 
secretion is crucial for protection against VAC-induced mortality (40, 41). Recently, NK 
cells are reported to be the primary producers of IFNg in lungs to provide protection 
during a VAC infection (1). Thus, both types of immune cells are important.   
Intradermal model  
The intradermal (ID) inoculation was established as an alternative to IN route of 
infection (106). In this method, the virus is injected to the ear pinna, causing a highly-
localized infection that form a lesion on the ear. There is no systemic infection associated 
with this model. The lesion formed during ID infection closely resembles to that formed 
during a smallpox infection. Typically, during an ID infection, a lesion forms 5-7 days 
post-infection and continues to grow in size until day 12 post-infection. The lesion size 
decreases and starts to resolve at 12-14 days post-infection. Mice are generally inoculated 
with 104 PFU of virus. Regardless of the inoculum, the peak virus titers on ears are 
observed at day 5 post-infection, and start to decrease at 11-12 days post-infection. 
	 36	
The localized immune response to an ID infection is also very well characterized. 
The inflammation and cellular infiltration is minimal during first three days after 
infection. Then there is immune cell infiltration of monocytes which peaks at 5 days post-
infection. Along with macrophages and neutrophils, there are several cytokines and 
chemokines like CXCL9 and CXCL10, are produced which peak by day 5 post-infection 
(30). Eventually, infiltration of all these immune cell leads to the formation of lesion. 
Type I IFNs and reactive oxygen species (77) are produced by neutrophils which protects 
tissue against damage (30). The lymphocytes count keeps on increasing until to 17 days 
post-infection, with peak amount being around 9-11 days post-infection. In ID models, 
phagocytes are found to be critical in controlling spread and replication of VAC (30, 82). 
Vaccinia virus virulence factors 
Vaccinia virus encodes several immune evasion proteins which target the innate 
immune responses like NF-kB and apoptosis. To date, VAC encodes 10 proteins that 
target the NF-kB pathway; namely A46, A49, A52, B14, C4, E3, K1, K7, M2 and N1 
(96).  Of these, E3 and N1 can also modulate the apoptosis pathway (72, 111). In addition 
to these 2 proteins that affect the apoptosis pathway, VAC also encodes four 
immunomodulatory proteins that target this apoptotic pathway (111). They proteins are 
B13, B22, F1 and GAPP. Each of these immune evasion proteins have different 
mechanisms to target the innate immune responses which has been detailed in the Table 
1.1 and 1.2. 
The use of ID and IN models have been instrumental in discovering these immune 
evasion proteins as virulence factors in vivo. Interestingly, deletion of some of the genes 
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(e.g. K1L, A49L) decreases the virulence of the virus compared to wild-type VAC while 
others (e.g. A41L, B15R) increases the virulence of the virus during IN and ID models. 
Although it is unclear why there is discrepancies in the outcome, extensive research is 
done to understand the role of these immune evasion proteins in in vivo. Interestingly, 
VAC encodes multiple proteins that target the same cellular pathway and yet loss of each 
protein individually alters the virus phenotype in vivo, indicating that these immune 
evasion proteins have non-redundant functions. Summary of these virulence factors 
encoded by VAC during IN and ID infections are listed, with special focus on those that 
inhibit NF-kB as well as apoptosis pathways. 
To study the physiological relevance of MCV genes during infection, MC159 and 
MC160 was inserted into an attenuated VAC (Chapter 3). As mentioned earlier, VAC are 
excellent models of pathogenesis and very closely related to MCV and thus, can be used 
as a surrogate virus to study the MCV genes in vivo. The VAC lacking the A49 gene 
(vDA49) was used as the parental virus because A49R gene also encode an NF-kB 
antagonist just like MC159 and MC160 genes and the vDA49 VAC was found to be less 
virulent in IN model (64). Thus, the strategy was to insert separately MC159 and MC160 
in the background of vDA49 VAC to generate recombinant viruses and study the 
virulence effect of these MCV immune evasion proteins in mice (Chapter 3). 
1.6 Thesis Outline 
The goal of my thesis project is to elucidate the mechanism of how MC159-
NEMO interactions impact NF-kB activation as well as establish an animal model system 
to study the MCV pathogenesis in vivo. 
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Chapter 2 describes a novel mechanism of how MC159 inhibits NF-kB activation 
by binding to NEMO. Initially, Randall et. al. has shown that MC159 inhibits NF-kB 
activation by interacting with NEMO subunit of the IKK complex. However, this 
MC159-NEMO interaction did not disrupt the IKK complex, suggesting a novel 
mechanism for NF-kB inhibition. In this chapter, I have discovered that MC159 inhibits 
the NEMO polyubiquitination, a posttranslational modification of NEMO required for 
IKK and downstream NF-kB activation. Cellular inhibitor of apoptosis protein 1 (cIAP1) 
is a cellular E3 ligase that ubiquitinates NEMO by binding to the N-terminus of NEMO. I 
found that MC159 competitively inhibits cIAP1-NEMO interactions thereby preventing 
NEMO polyubiquitination and NF-kB activation. My work is also the first study to report 
a viral protein disrupting cIAP1-NEMO interactions as a novel strategy employed by the 
virus to manipulate the host environment. 
Despite MCV’s importance as a human pathogen, it has not been studied 
extensively due to technical difficulties. Neither there is a culture system suitable for 
propagation of MCV nor an animal model that recapitulate MCV replication. To 
overcome this barrier, I have developed a VAC surrogate system to study the functions of 
MCV immune evasion proteins; MC159 and MC160, using IN and ID models of 
infection. These MCV genes are inserted in an attenuated VAC (vDA49) and studied in 
mice. I discovered that vMC159 and vMC160 viruses have different effects during IN 
and ID infections in mice.  In both routes of infection, vMC159 was less virulent than 
vMC160. However, vMC159 dramatically altered the virulence of vaccinia virus in the 
ID model of infection with no trace of lesion formation. 
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Chapter 4 describes the various mutants of MC159 generated to study the 
functions of each domain important for NF-kB inhibition. These mutants are also utilized 
to elucidate and characterize the function of MC159 and MC160 to inhibit NF-kB 
activation during a genotoxic stress as well as NF-kB activation. I have been able to 
characterize the preliminary employed by MC159 to inhibit the genotoxic induced NF-
kB activation. 
Finally, Chapter 5 includes a summation of the findings in this thesis project as 
well as future directions that should be approached.  My thesis has been the first to report 
a novel strategy to hijack the host immune system as well as an examination of how 














1.7 Figures and Tables 
Figure 1.1 Poxvirus replication cycle using vaccinia virus as a model. Upon entry into 
the host cell, the poxvirus initiates early transcription and proteins are made. Next, 
uncoating of the viral DNA occurs followed by replication. Once DNA is replicated, 
transcription and translation of intermediate and late genes occur which leads to assembly 
and morphogenesis of intracellular mature virions (IMV). IMV acquire another layer to 
become intracellular enveloped virion (IEV) and exit of extracellular enveloped virions 
(EEV) which are capable of infecting the adjacent cells. (See text for more details) Note 




   Modified from https://cnx.org/contents/RxywCGkA@5/Layers-of-the-Skin 
 
Figure 1.2 Layers of the epidermis where MCV undergoes replication. The epidermis 
of thick skin has five layers: stratum basale (113), stratum spinosum (70), stratum 
granulosum (SG), stratum lucidum (SL) and stratum corneum (SC). MCV cores are most 
common in SS and SB, while more mature MCV virions are found in upper layers of 










Figure 1.3 A model depicting NF-kB signaling pathway. TNF-TNFR1 interactions 
trigger the formation of a signalsome consisting of TRADD, RIP1, TRAF2 and cIAP1/2. 
Next RIP1 is K63-linked polyubiquitinated, as indicated by the dark blue ubiquitin balls 
associated with RIP1. Next, IKK (consisting of IKKa, IKKb and NEMO) migrates to 
RIP1, and the NEMO subunit of IKK interacts with the polyubiquitin tail of RIP1. The 
TAB-TAK1 complex also migrates to the polyubiquitinate tail of RIP1, but is not shown 
here for the sake of simplicity. Next, cIAP1 binds to the N-terminus of NEMO and 





Figure 1.4 Activation of IFNb expression and Interferon Stimulated Genes (ISGs) 
by IRF3 activation. Viral replication results in the production of dsRNA that are 
recognized by endosomal TLR3 or cytoplasmic sensors like MDA-5 and RIG-I. The 
adapter protein, MAVS, recruit kinases TBK1 and IKKe, which form a complex and 
phosphorylate IRF3 and IRF7. IRF3 dimerizes, translocates to the nucleus, and drives 
















Figure 1.5 Summary of TNFR1-mediated apoptosis and NF-kB activation. 
Apoptosis: stimulants like TNF bind to the TNFR1 lead to the recruitment of TRADD, 
FADD, and procaspase-8 forming the death induced signaling complex (DISC). 
Procaspase-8 is cleaved and activated to caspase-8. Caspase-8 activates downstream 
caspases to initiate apoptosis. NF-kB: Engagement of the TNFR1 leads to a complex 
containing TRADD, TRAF2, and RIP1. This complex recruit and activates the IKK 
















Figure 1.6 Schematic representation of viral and cellular FLIPs. FLIPs contain 
tandem death effector domains (DEDs), which are important for protein-protein 
































Figure 1.7 Crystal structure and linear diagram of the MC159 protein. The MC159 
protein contains two tandem death effector domains (39). Each DED is made up of six 
alpha helices (DEDA=red and DEDB=cyan). The crystal structure contains both DEDs 
connected by a linker region shown in green. The linear MC159 diagram shows the full-





















Figure 1.8 Summary of FLIP modulations of various cellular pathways. Function of 
each FLIP proteins on three different innate immune responses. For apoptosis, all but 
MC160 inhibit the pathway. cFLIPL, cFLIPS, and K13 activate NF-kB while MC159 and 
MC160 inhibit its activation. cFLIPL, MC159 and MC160 inhibit IRF3 activity, while 





























Table 1.1 Effects of single deletion of each of the six VACV Apoptosis inhibitors. 

















































Intrinsic and Extrinsic 
B22 No effect ND Extrinsic  
N1 Attenuated Attenuated Intrinsic  
E3 Attenuated ND Intrinsic  
F1 Attenuated ND Intrinsic  
vGAAP More virulent ND Intrinsic and extrinsic  
	 49	













Mechanism of inhibition 
in vitro 
A46 Attenuated ND Binds to several ligands like 
TRIF, TRAM, TIRAP and 
MyD88 
A49 Attenuated No effect Binds to b-TrCP and prevents 
IkBa ubiquitination and 
degradation 
A52 Attenuated ND Binds to IRAK2 and TRAF6 
B14 No effect Attenuated Binds to IKKb and prevents 
its phosphorylation 
C4 Attenuated No effect Inhibits IKK activation by an 
unknown 
E3 Attenuated ND dsRNA binding protein 
K1 Attenuated Attenuated Inhibits acetylation of p65 
K7 Attenuated Attenuated Binds to IRAK2 and TRAF6 
M2 ND ND Inhibits ERK2 
phosphorylation and prevents 
p65 nuclear translocation 
N1 Attenuated Attenuated Forms a dimer  
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Chapter 2: Molluscum Contagiosum Virus MC159 abrogates cIAP1—NEMO 
interactions and inhibits NEMO polyubiquitination 
 
Originally published in the Journal of Virology. Sunetra Biswas and Joanna L. Shisler. 
91(15). pii: e00276-17. doi: 10.1128/JVI.00276-17. Published in partial fulfilment of the 
requirements for the degree of doctor of philosophy in Microbiology. 
 
2.1 Introduction 
Molluscum contagiosum virus (MCV) is a member of the Poxviridae family, and 
is the etiological agent of molluscum contagiosum (MC)(19). MCV infections are 
common and worldwide (57, 60); approximately 122 million MCV infections occurred in 
2010 (70). MCV infects keratinocytes, resulting in small neoplasms that persist for 
months to years (19). There is little inflammation at the borders of these long-lasting 
lesions (19), suggesting that MCV encodes molecules that dampen the immune response 
(13, 59, 61). Unfortunately, the absence of a cell culture or efficient animal models for 
MCV replication has greatly hampered MCV research. This has limited the field’s 
understanding of how MCV evades the immune response to persist. To date, knowledge 
about MCV immune evasion strategies is derived from expressing individual MCV 
proteins independent of infection or during infection with a surrogate virus, and these 
strategies include antagonism of apoptosis (4, 17, 35, 63), NF-kB activation (7, 52, 56), 
IRF3 activation (55), and chemokine (18) and IL-18 (74) actions.  
Tumor necrosis factor (TNF) is upregulated in MC lesions (41). This has potential 
anti-viral consequences because TNF-TNFR1 interactions trigger anti-viral events 
including NF-kB activation (8). The canonical IKK complex controls NF-kB activation 
and is comprised of NEMO (IKKg) regulatory and IKKa and IKKb kinase subunits (15, 
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58, 76). NEMO is instrumental in controlling NF-kB activation because it regulates the 
IKKa-IKKb signaling axis during NF-kB activation.  
NEMO has several important functions during TNF-induced NF-kB activation. 
First, the C-terminus of NEMO facilitates IKK binding to polyubiquitinated RIP1 (21, 
73), which is part of the TNFR1-based signalsome. Second, NEMO itself is 
polyubiquitinated, allowing for subsequent IKK activation. K63-linked 
polyubiquitination of NEMO was reported first (21, 73), followed by M1-linked 
ubiquitination (27, 30, 68). Most recently, K63/M1 hybrid polyubiquitination of NEMO 
was reported (22). Although there is debate about the relative importance of each type of 
ubiquitination, it is likely that each type of ubiquitination is necessary for optimal NF-kB 
activation (31). Regardless, covalent linkage of ubiquitin to a protein substrate occurs via 
cellular E1, E2 and E3 ligases (39). cIAP1 is one such E3 ligase that polyubiquitinates 
NEMO in addition to other cellular proteins (37, 65, 78). 
The MCV encoded MC159 protein is perhaps the best-studied MCV molecule 
(61). MC159 expression neutralizes NF-kB activation and MC159 interacts with the 
NEMO subunit of the IKK complex (56). Interestingly, MC159 does not disrupt the IKK 
complex (56), suggesting that MC159 antagonizes IKK activation in a manner that is 
distinct from other known viral NEMO inhibitors. We show here that MC159 prevented 
NEMO polyubiquitination, leading us to further examine how MC159 prohibited this 
post-translational event. Here, data indicated that MC159 competitively binds to NEMO 
in a manner that prevents cIAP1 from interacting with and polyubiquitinating NEMO.  
This is the first report of a viral protein blocking cIAP1-NEMO interactions to block 
NEMO polyubiquitination. As such, this work extends the repertoire of mechanisms that 
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viruses use to evade the anti-viral immune responses, and illuminates one strategy that 
may allow for a sustained presence of replicating MCV in skin neoplasms. 
2.2 Materials and Methods  
Cell lines and plasmids 
Human embryonic kidney 293T cells and human cervical carcinoma (HeLa) cells 
were obtained from the American Type Culture Collection. NEMO -/- MEFs were 
obtained from Dr. Tak Mak (University of Toronto). Rabbit kidney cell (RK13) was a 
kind gift from Dr. Grant McFadden (University of Florida). All cells were cultured in 
Eagle’s MEM supplemented with 2 mM L-glutamine, 10% fetal bovine serum (FBS; 
Fisher).   
Plasmids pCI and pcDNA3.1 were obtained from Promega and Invitrogen, 
respectively. Plasmids encoding the MCV MC159 gene (pMC159) or an HA epitope-
tagged MC159 gene (pMC159-HA) were described previously (51, 55, 56). pK13-FLAG 
encodes a FLAG-tagged KSHV K13 gene and was provided by Dr. Jeffery Cohen 
(National Institutes of Health). Plasmid RIP-1 (pRIP1-HA) was a kind gift from Dr. Preet 
Chaudary (University of Texas Southwestern Medical Center)(11). pNEMO-FLAG and 
pNEMO-HA express epitope-tagged version of NEMO.  p1-250-FLAG and p251-419-
FLAG plasmids were provided by Dr. Kunitada Shimotohno (Chiba Institute of 
Technology). p1-250-FLAG encodes residues 1-250 of NEMO while p251-419-FLAG 
encodes residues 251-419 of NEMO. pIKKγΔZnF (called pNEMOΔZnF here) encodes a 
mutant NEMO in which the zinc finger (ZnF) domain of NEMO is absent and cannot be 
ubiquitinated (65). Plasmids pWT-Ub-HA (Dr. Yossi Yarden, Weizmann Institute of 
Science) and pUb-Myc (Dr. Kunitada Shimotohno) encode an HA or Myc epitope-tagged 
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ubiquitin, respectively (1). Constructs pK48-Ub-HA and pK63-Ub-HA are kind gifts 
from Dr. Derek Abbott (Case Western Reserve University). Plasmids pcIAP1-FLAG and 
pcIAP1-Myc, which produces a FLAG and Myc epitope-tagged cIAP1 protein, 
respectively, was purchased from Addgene. Plasmid pNF-κBluc encode the firefly 
luciferase gene under the control of a synthetic NF-κB promoter (Promega). Plasmid 
pRL-TK (Promega) expresses constitutively low levels of sea pansy luciferase and is 
used to determine transfection efficiency.  
For all experiments involving plasmids, DNA was transfected into cells using 
FuGene 6 transfection reagent (Promega), following manufacturer’s protocol.    
Viruses 
vDA49 and vDA49rev were described previously (48). A recombinant virus was 
created in which the MC159L gene, under the control of the synthetic p7.5 promoter, was 
inserted into a mutant vaccinia virus (vDA49) that deleted nucleotides 113-473 of the 
A49R gene (48). The first step in this process was to create a pDA49MCS plasmid that 
had multiple cloning sites for insertion of the MC159L gene.   
A plasmid lacking nt 113-473 of the A49R gene (pDA49Z11) was used as a source 
of DNA.  From this plasmid, two regions were PCR amplified: the A48 flank and the 
A50 flank.  A48 begins at A48R nt 457 and continues through to A49R nt 112 for a 338 
bp product.  The primers used to PCR amplify this product are: A48R forward 5’-ATCG 
GGATCCAACAAAAGGTATTACAAGAATAT-3’ and A48R reverse: 5’-CGCGG 
ATACTAGTATCGATATAGTTTCTATCTTGGCAATAACTAATTG-3’.  The 
underlined regions are regions of vaccinia virus DNA.  The forward primer introduces a 
Bam HI restriction enzyme site (in italics).   The reverse primer introduces the Cla I and 
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Spe I restriction enzyme sites (in italics). The A50 flanking region was PCR amplified 
from pDA49Z11.  This PCR product begins at A49R nt 474 and ends at A50R nt 293 to 
PCR amplify a 339 bp product.  The A50 forward primer is: 5’-GAAACTAT 
ATCGATACTAGTATCCGCGAACGATATTTGTGA-3’.  The A50 reverse primer is: 
5’-ATATGAATTCGATTTCTGTGTTCTCTTTGAAGAAAGTC-3’.  The underlined 
nucleotides are in the vaccinia virus genome.  The forward primer introduces the Cla I 
and Spe I restriction enzyme sites (in italics). The reverse primer introduces an Eco RI 
restriction enzyme site.  Next, 50-100 ng of each gel-purified PCR product was stitching-
of-ends (SOE) joined (the DNA regions that overlapped for using SOE are in boldface) 
and PCR amplified using the A48R forward and A50R reverse primers. The resultant 
PCR product was restriction enzyme digested with Bam HI and EcoRI and inserted into 
pUC13/gpt/EGFP that was digested with Bam HI and Eco RI and SAP modified. This 
plasmid is referred to as pDA49MCS. 
To create an MC159L-containing plasmid to use for insertion of MC159L into the 
vaccinia virus genome, the MCV MC159L gene was PCR amplified from MC159/pCI 
using forward primer 5’-CGGATCTATAATCATGTCCGACTCCAAG GAGG-3’ and 
reverse primer 5’- GAAAACTAGTTCAAGTCGTTTGCTCGGGG-3’ to yield a 726 bp 
PCR product.  The MC159 nucleotides are underlined.  The reverse primer engineered in 
the Spe I restriction enzyme digestion site (italicized). The p7.5 promoter was PCR 
amplified from pUC13/gpt/EGFP.  The forward primer is 5’-TTTTATCGAT 
TAAATAATAAATACAATAATTAATTTCTCGT-3’ and the reverse primer is 5’-
GGAGTCGGACATGATTATAGATCCGTCACTG-3’ and this yielded a 121 bp PCR 
product.  The forward primer introduced a Cla I restriction enzyme site (italicized).  Next, 
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50-100 ng of each gel-purified PCR product was SOE joined and PCR amplified using 
the A48R forward and A50R reverse primers.  The DNA regions that overlapped for 
using SOE are in boldface.  The resultant PCR product of 847 bp was restriction enzyme 
digested with Cla I and Spe I and inserted into pDA49MCS that was digested with Cla I 
and Spe I and SAP modified. This plasmid was called MC159/pDA49MCS. 
To create vMC159ΔA49R, BSC-1 cells were infected with vΔA49R and 
transfected with MC159/pΔA49R. Recombinant viruses were collected 24 h later selected 
in the presence of mycophenolic acid, xanthine and hypoxanthine (24).  This process was 
repeated three times to isolate recombinant viruses away from parental viruses. 
Intermediate EcoGPT+ viruses were resolved into vΔA49 or vMC159ΔA49 by plaquing 
on BSC-1 cells in the absence of drugs. The genotype of each virus was confirmed by 
using PCR to amplify MC159L and the flanking A48R and A50R regions. 
MC159 expression in vMC159ΔA49-infected cells was assessed by 
immunoblotting.  RK13 cellular monolayers were infected with vΔA49, vΔA49rev or 
vMC159vΔA49 (MOI = 10 PFU/cell). At 2 or 6 h pi, cells were removed from the plate 
by scraping and collected by centrifugation (18,000 X g for 5 min). Cellular pellets were 
resuspended and lysed in 150 µl CE buffer (10 mM HEPES, 10 mM KCl, 0.1 mM EDTA 
pH 8, 0.1 mM EGTA pH 8, 0.05% Nonidet P-40) that was supplemented with HALT 
protease inhibitors (Fisher) for 30 min at 4°C. Cellular lysates were centrifuged at 18,000 
X g for 5 min. Clarified supernatants were removed to new tubes, and 15 µg of protein 




Luciferase reporter assay 
A dual reporter luciferase assay was performed to quantify NF-κB activation 
using previously published protocols (51, 55, 56). Briefly, subconfluent cellular 
monolayers of 293T cells in 12-well plates were co-transfected with 225 ng pNF-κBluc, 
12.5 ng pRL-TK and 750 ng of pcDNA3.1, pMC159 or pK13. Cells were additionally co-
transfected with 250 ng, 500 ng, 750 ng, or 1000 ng pcIAP1. All transfections were 
performed in triplicate. Cells were lysed in 1X passive lysis buffer (PLB, Promega) and 
lysates were analyzed for firefly and sea pansy luciferase activities. For each lysate, the 
ratio of firefly luciferase activity to sea pansy luciferase activity was calculated to correct 
for differences in transfection efficiencies. The triplicates were averaged. The resultant 
values were used to compare the expression of the firefly luciferase gene in stimulated 
cells to that in unstimulated, pcDNA3.1-transfected cells, whose value was set to one. 
Values are shown as mean ± S.D. The Student’s t-test was used to determine the 
statistical significance.  Statistically significant inhibition of luciferase activity is 
indicated by asterisks (*P < 0.05, **P < 0.001).  
Lysates from luciferase assays were also analyzed for the presence of relevant 
proteins by immunoblotting. In this case, 20 µg of protein from each lysate was separated 
by using SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. 
Membranes were probed with polyclonal rabbit anti-MC159 (1:1,000)(62) rabbit anti-
FLAG (1:2,000; Sigma-Aldrich, F7425) and goat anti-cIAP1 (1:400; R&D Systems, 
AF8181) and then HRP-conjugated goat anti-rabbit IgG (1:10,000; CalBiotech) or HRP-
conjugated rabbit anti-goat IgG (1:5,000; R&D Systems) to detect MC159, K13 or cIAP1 
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expression levels.  Antibody-antigen reactions were detected using chemiluminescence 
reagents (Thermo Scientific) and autoradiography. 
Immunoblotting and Antibodies 
For all immunoblots, the protein concentration of lysates was determined by using 
the 660 nm protein assay (Pierce). 20 µg of clarified cellular lysates were subjected to 
SDS-PAGE, and proteins were transferred to PVDF membranes (Millipore). Membranes 
were blocked in 5% (w/v) milk or BSA in Tris-Buffered Saline and Tween 20 (TBST; 
150 mM NaCl, 50 mM Tris base, 0.05% Tween 20) for at least 30 min at room 
temperature. Membranes were incubated with the indicated primary antibodies overnight 
at 4°C. Next, membranes were washed three times in large volumes of TBST, and 
incubated with the appropriate HRP-conjugated secondary antibodies. Immunoblots were 
developed using chemiluminescence reagents (Thermo Scientific) and autoradiography. 
Primary antibodies used in these experiments were polyclonal rabbit anti-MC159 
(1:1,000)(62), anti-FLAG (1:2,000; Sigma-Aldrich, F3165, F7425), anti-HA (1:2,000; 
Cell Signaling Technology, 3724), anti-Myc (1:2,000; Cell Signaling Technology, 2272, 
2276), anti-NEMO (1:1,000; Santa Cruz Biotechnology, sc8330) and anti-cIAP1 (1:400; 
R&D Systems AF8181).  Monoclonal mouse anti-E3 (1:5,000) was a kind gift from Dr. 
Stuart Isaacs (University of Pennsylvania)(72). Secondary HRP-conjugated antibodies 
were obtained from either Thermo Scientific (goat anti-mouse IgG; 1:10,000), 





Ubiquitination Assay  
There were two approaches used to stimulate NEMO polyubiquitination. The first 
approach was to over-express NEMO in sufficient amounts that ensure NF-kB activation. 
For the first approach, 293T cells were seeded in 6-well plates at 5x105 cells/well and 
transfected with 500 ng pUb-Myc, 500 ng pNEMO-FLAG and 1000 ng pCI or pMC159. 
In some cases, plasmids encoding an HA-epitope tagged wild-type (pWT-Ub-HA) or 
mutant (pK63-Ub-HA or pK48-Ub-HA) ubiquitin were used instead of pUb-Myc. The 
second approach provided the opportunity to examine TNF-induced NEMO 
polyubiquitination.  In this case, 293T cells were transfected with 250 ng pUb-Myc, 250 
ng pNEMO-FLAG and 1000 ng pCI or pMC159. At 24 h post-transfection, cells were 
incubated with TNF (10 ng/ml; Roche) for 15 min.  
To examine RIP1 polyubiquitination, cells were instead transfected with 500 ng 
pRIP1-HA and 500 ng pUb-Myc. At 24h post-transfection, cells were incubated in 
medium lacking or containing TNF. To examine MC159 ubiquitination, cells were 
instead transfected with 500 ng pMC159 and 500 ng pUb-Myc. At 24 h post-transfection, 
cells were incubated in medium lacking or containing TNF (10 ng/ml) for 15 min. For 
reverse immunoprecipitation, cells were transfected with 250 ng pNEMO-HA, 250 ng 
pcIAP1-Myc, 250 ng either pWT-Ub-HA, pK48-Ub-HA or pK63-Ub-HA and 1000 ng 
pCI or MC159. 
In all cases, cells were removed from the plate by scraping and collected by 
centrifugation (18,000 X g for 5 min). Cellular pellets were resuspended in 150 µl Ub 
lysis buffer (50 mM Tris, pH 7.6, 250 mM NaCl, 1 % Triton X-100, 0.5% Nonidet P-40, 
3mM EGTA, 3 mM EDTA, 10 % glycerol, 0.1 mM Na3VO4, 10 µM N-ethylmaleimide) 
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supplemented with a mixture of protease inhibitors (HALT; Fisher-Pierce) for 30 min at 
4°C as previously described (65). Cellular lysates were centrifuged at 18,000 X g for 5 
min. Clarified supernatants were collected. 50 µl of the supernatants were set aside and 
used to detect protein expression levels. The remaining 100 µl of clarified lysates were 
used for immunoprecipitations (IP) to detect polyubiquitination of the protein of 
interest.  In this case, lysates were pre-cleared for no more than 2 h with Protein G-
Sepharose beads (Invitrogen) at 4°C with rotation. Beads were collected by 
centrifugation. Clarified lysates were removed to new tubes and incubated with 1 µg 
mouse anti-FLAG (Sigma-Aldrich; F3165), anti-HA (Sigma Aldrich; H9658) or anti-
Myc (Cell Signaling Technology; 2276) antibodies or mouse IgG isotype control 
antibodies (Sigma-Aldrich; I5381) for 2 h at 4°C with constant rotation. After 2 h, 50 µl 
protein G-Sepharose beads were added to each sample and incubated overnight with 
constant rotation at 4 °C. Beads were collected by centrifugation (18,000 X g for 5 min), 
and washed three times with 750 µl Ub lysis buffer and once with Ub lysis buffer 
supplemented with 3M urea.  
Co-immunoprecipitation Assays 
To detect NEMO-MC159 interactions, subconfluent 293T or NEMO -/- MEF 
cellular monolayers were co-transfected with 500 ng pUb-Myc, 500 ng of either 
pNEMO-FLAG, p1-250-FLAG or p251-419-FLAG, and 1000 ng pCI or pMC159.  At 24 
h post-transfection, cells were incubated in media lacking or containing TNF (10 ng/ml) 
for 15 min. Cells were lysed in 150 µl of IP lysis buffer (50 mM Tris, pH 8.0, 150 mM 
NaCl, 0.5% Nonidet P-40, 50 mM NaF, 0.1 mM Na3VO4, 1 mM DTT) supplemented 
with a mixture of protease inhibitor (HALT; Fisher-Pierce) as previously described (65). 
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50 µl of the supernatants were set aside and used to detect protein expression levels. The 
remaining 100 µl of clarified lysates were used for immunoprecipitations (IP) to detect 
protein-protein interactions.  Clarified lysates were pre-cleared for 1-2 h with Protein G-
Sepharose beads (Invitrogen) at 4°C with rotation. Next, clarified lysates were incubated 
with 1 µg anti-FLAG or IgG overnight at 4° C. 50 µl of protein G-Sepharose beads were 
added to each tube and reactions were incubated for an additional 4 h at 4° C with 
constant rotation.  
To detect endogenous NEMO-cIAP1 interactions, 10 cm2 dishes of subconfluent 
HeLa cell monolayers were transfected with 5000 ng of pCI or pMC159-HA. At 24 h 
post-transfection, cells were incubated in medium containing TNF (10 ng/ml) for 10 min. 
Next, cells were dislodged from plates by scraping into 1 ml chilled PBS and collected by 
centrifugation (1000 X g for 10 min). Cellular pellets were incubated in 150 µl IP lysis 
buffer for 30 min at 4°C. Cellular lysates were centrifuged (18,000 X g for 5 min). 50 µl 
of the supernatants were set aside and used to detect protein expression levels. The 
remaining 100 µl of clarified lysates were used for immunoprecipitations (IP) to detect 
protein-protein interactions. For IPs, lysates were pre-cleared for 2 h with Protein G-
Sepharose beads (Invitrogen) at 4°C with rotation. Beads were removed by centrifugation 
and clarified lysates were incubated with 2 µg mouse monoclonal anti-cIAP1 (sc-271419; 
Santa Cruz) or IgG isotype control (Sigma-Aldrich; I5381) antibodies for 2 h at 4°C with 
constant rotation. After incubation with anti-cIAP1 Ab, 50 µl protein G-Sepharose beads 
was added and supernatants were incubated for additional 1 h with constant rotation at 4° 
C.  
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For all IPs, pelleted bead-protein complexes were suspended in 30 µl of 2X 
Laemmli buffer containing 5% 2-ME and boiled for 5 min. Immunoprecipitated samples 
(IP) or a portion of the remaining clarified lysates were electrophoretically separated by 
SDS-PAGE and proteins were transferred to PVDF membranes for immunoblotting (IB). 
2.3 Results  
MC159 inhibits NEMO polyubiquitination 
We published that the MC159 inhibits NF-κB activation, and this inhibition 
correlated with MC159-NEMO interactions (56). MC159-NEMO interactions did not 
disrupt the IKK complex (56), and this implied that MC159 may prevent post-
translational modifications of NEMO or interaction with NEMO binding partners that are 
critical for NF-κB activation.  
NEMO polyubiquitination is one such post-translational modification that is 
required for TNF-induced NF-κB activation (65). We used well-characterized 
immunoprecipitation assays to examine if MC159 altered NEMO polyubiquitination. For 
these assays, epitope-tagged versions of NEMO and ubiquitin were expressed in cells 
(Fig. 2.1A). Immunoprecipitated NEMO was then separated by SDS-PAGE and 
polyubiquitinated NEMO was detected by immunoblotting. In this system, NEMO 
polyubiquitination was detected only when cells expressed both NEMO-FLAG and Ub-
myc (Fig. 2.1A, lanes 1-3). Maximal NEMO ubiquitination was observed when using 500 
ng each of pNEMO-FLAG and pUb-Myc (Fig. 2.1A, lane 4). Figure 1A showed that the 
lower band in the IP-ed samples represented monoubiquitinated NEMO, which is 56 kDa, 
while the remaining, higher molecular weight NEMO-containing bands represented 
polyubiquitinated NEMO.  This same pattern is indicated for remaining figures. 
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Next, the optimized conditions from Figure 2.1A were used to examine the impact 
of MC159 on NEMO polyubiquitination. NEMO polyubiquitination was stimulated by 
either over-expression of NEMO (Fig. 2.1B) or by TNF stimulation of cells (Fig. 2.1C). 
For the latter case, we used a lower amount of pNEMO-FLAG such that NEMO was not 
stimulating NF-kB activation but polyubiquitination of NEMO could still be detected.  
TNF was used as a stimulus because TNF is upregulated at MCV lesions (41) and the 
signal transduction events leading from TNF-TNFR1 interactions to NF-kB activation are 
well-characterized (8). Cells were also co-transfected with empty vector (pCI) or a 
plasmid containing the MC159L gene. 
It was necessary to express MC159 independent of infection for two reasons.  
First, MCV cannot be propagated in cell culture (61). Second, there are two other MCV 
proteins that inhibit NF-kB activation (MC160 and MC132) (7, 52). Thus, the 
examination of MC159 function in cells infected with MCV isolated from patient lesions 
may be confounded by the presence of these or other as-yet-identified MCV NF-kB 
inhibitory proteins.  We chose to express MC159 via transient transfection. Of course, 
one weakness to using transient transfections is that MC159 ectopic expression may not 
necessarily reflect MC159 protein expression levels during infection. Indeed, natural 
MC159 expression levels are not known because there is no method to currently 
propagate MCV in cell culture. We attempted to create cell lines expressing MC159. 
However, the MC159 protein levels dramatically decrease each time after passaging of 
these cell lines, such that MC159 is no longer detectable by the 5th passaging of cell lines. 
However, transient transfection systems afford the opportunity to use reagents (e.g., 
TNF) that trigger NF-kB activation via well-defined signal transduction pathways. 
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Figures 1B and 1C showed that the quantity and intensity of polyubiquitinated 
NEMO was decreased in MC159-expressing versus pCI-transfected cells, indicating that 
MC159 antagonized NEMO polyubiquitination. Namely, the intensity of bands 
representing polyubiquitinated NEMO were decreased when MC159 was present versus 
absent when comparing band intensity within each gel shown in Figure 1B and 1C. 
NEMO protein levels were not decreased in transfected cells, indicating that this decrease 
in ubiquitination was not due to a decrease in NEMO protein levels. A separate set of 
cells was co-transfected with a plasmid encoding a mutant NEMO that lacks its lysines, 
substrates for ubiquitin (NEMOΔZnF)(16, 65). Thus, NEMO polyubiquitination also was 
greatly reduced when cells expressed NEMOΔZnF, as would be expected. In Figures 1B 
and 1C, parallel immunoprecipitations were performed in which a non-specific IgG was 
used in place of anti-FLAG antibody.  NEMO was not immunoprecipitated under these 
conditions, showing specificity of the immunoprecipitation conditions. MC159 also co-
immunoprecipitated with FLAG-NEMO, agreeing with previous publications (36, 56). 
Thus, these results suggest that MC159 antagonized NEMO polyubiquitination, likely by 
interacting with NEMO, and warranted further study into how MC159 prevented NEMO 
polyubiquitination. 
MC159 inhibits K63-linked NEMO ubiquitination 
Ubiquitination is an important post-translational modification and can trigger 
events as diverse as protein degradation or protein activation (38, 39). For example, K48-
linked polyubiquitination triggers proteasomal degradation of a protein (38, 39). In 
contrast, K63-linked polyubiquitination is important for intracellular signaling (21, 31, 
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42, 46, 73). Indeed, K63-linked NEMO polyubiquitination was the first type of 
ubiquitination to be reported during TNF-induced NF-κB activation (21, 31, 42, 46, 73).   
Given that MC159 blocks TNF-induced NF-κB activation (56), we queried if 
MC159 could prevent K63-linked polyubiquitination of NEMO.  To answer this 
question, ubiquitin constructs were used in which only the lysine (K) 48 or K63 residues 
remained intact (Fig. 2.2A), affording examination of K48- or K63-linked 
polyubiquitination in isolation. All cells were treated with TNF to trigger NEMO 
polyubiquitination (Fig. 2.2B).  As shown in Figure 2.2B, TNF-stimulated NEMO 
polyubiquitination occurred when wild-type ubiquitin was present (lane 2). 
Polyubiquitinated NEMO was still detected when a mutant ubiquitin expressing lysine 
only at residue 63 was present (lane 6). In this case, there was an increase in the 
molecular mobility of polyubiquitinated NEMO proteins as compared to cells expressing 
wild-type ubiquitin. NEMO polyubiquitination was greatly reduced when pK48-Ub was 
expressed (lane 5). This was expected because TNF does not stimulate K48-linked 
ubiquitination of NEMO (73). FLAG-tagged NEMO protein levels were similar 
regardless of wild-type or mutant ubiquitin. Thus, the diminished NEMO ubiquitination 
profile was not due to K48-mediated NEMO degradation. 
MC159 inhibited TNF-induced NEMO polyubiquitination when either wild-type 
or the pK63-Ub plasmids were expressed (lanes 9 and 11). Thus, MC159 inhibited K63-
linked ubiquitination of NEMO during TNF stimulation. MC159 co-immunoprecipitated 
with NEMO regardless of the expression of wild-type or mutant ubiquitin. As seen 
before, polyubiquitinated NEMO was greatly decreased when cells expressed 
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NEMOΔZnF. These results suggest that MC159 blocked K63-linked ubiquitination of 
NEMO during TNF stimulation. 
MC159 does not inhibit RIP1 ubiquitination 
RIP1 polyubiquitination is essential for TNF-induced IKK activation (21). The 
K63-linked ubiquitin chains on RIP1 serve as a platform to recruit IKK (via the NEMO 
protein) and TAB-TAK1 (via the TAB2 protein)(8). Next, TAK1 phosphorylates and 
activates IKK (21). MC159 is reported to co-immunoprecipitate with RIP1 (10, 11). It 
was of interest to ask if MC159 could prohibit polyubiquitination of RIP1. Epitope-
tagged versions of RIP1 and ubiquitin were expressed in cells. Immunoprecipitated RIP1 
was then probed for polyubiquitination by immunoblotting. Ectopic RIP1 expression 
resulted in RIP1 polyubiquitination when a myc-tagged ubiquitin was co-expressed (Fig. 
2.3A). A similar trend was observed during incubation of cells with TNF also increased 
RIP1 polyubiquitination (Fig. 2.3B).  For both Figure 2.3A and 2.3B, RIP1 
polyubiquitination did not decrease – in fact it appeared to be enhanced -- when MC159 
was present when comparing ubiquitination patterns between pCI- versus MC159-
expressing cells within each gel shown in Figures 2.3A and 2.3B. These data suggested 
that MC159 was not a global inhibitor of polyubiquitination. RIP1 over-expression is also 
know to activate apoptosis (29).  While none of the cellular monolayers used in these 
experiments showed apoptotic morphologies (e.g. cellular blebbing or cellular 
detachment), we cannot rule out the possibility that this increase in polyubiquitination is 
due to an increase in cellular viability when the anti-apoptotic MC159 protein is co-
expressed.  
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We also observed that MC159 co-immunoprecipitated with RIP1, in agreement 
with previous reports (10, 11). Interestingly, HA-tagged RIP1 protein levels were slightly 
higher in lysates and in immunoprecipitates when MC159 was expressed. The reason for 
this remains unclear, but suggests that MC159 may enhance RIP1 stability.  We also 
observed a higher molecular weight form of RIP1 in immunoprecipitates and lysates from 
TNF-stimulated cells (Fig. 2.3B). One possibility is that this band represents a 
phosphorylated form of RIP1 based on similar findings from others (43). Nevertheless, 
these data suggested that MC159 was not acting as a global inhibitor of 
polyubiquitination.  
MC159 does not inhibit RIP1-NEMO interactions 
Our and others’ data showed that MC159 co-immunoprecipitates with RIP1 (10, 
11) and NEMO (36, 56). IKK must interact with RIP1 for NF-kB activation (21). Thus, 
an alternative explanation for MC159 inhibition of NF-kB activation could be that 
MC159 inhibited RIP1-NEMO interactions (21).  To test this possibility, epitope-tagged 
versions of NEMO and RIP1 were co-expressed in the presence or absence of MC159. 
FLAG-tagged NEMO was immunoprecipitated, and RIP1 presence was evaluated by 
using immunoblotting (Fig. 2.3C). NEMO-RIP1 interactions were detected in cells 
lacking or expressing MC159, implying that MC159 did not prevent IKK from 
interacting with RIP1. This interaction was not due to non-specific binding of proteins to 
protein G Sepharose beads because RIP1 was not detected when using IgG in place of 
anti-FLAG for co-immunoprecipitations. Similar to Figure 2.3B, MC159 protein 
expression correlated with an increase in RIP1 proteins present in immunoprecipitates 
and cellular lysates (Fig. 2.3C).  
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MC159 is not ubiquitinated by the cell but associates with ubiquitin 
Ubiquitination involves covalent attachment of an ~8 kDa ubiquitin to a lysine on 
a recipient protein (15). MC159 has five lysine residues. Thus, one possible reason for 
the observed decrease in NEMO polyubiquitination would be if MC159 outcompeted 
cellular proteins for host cell ubiquitin machinery. To test this possibility, MC159 was 
co-expressed with a myc-tagged ubiquitin in cells. In this case, myc-tagged ubiquitin was 
immunoprecipitated, and this immunoprecipitate was probed for the presence of MC159 
by immunoblotting (Fig. 2.4). MC159 was present in immunoprecipitates collected from 
either unstimulated or TNF-stimulated cells, as indicated by a 31 kDa band (62), and this 
is the same size of the MC159-containing band observed in cellular lysates. We conclude 
that it is unlikely that MC159 itself received covalent ubiquitin linkages because covalent 
ubiquitin linkages would be expected to increase the molecular weight of MC159 to at 
least 39 kDa. Because MC159 co-immunoprecipitated with the myc-tagged ubiquitin 
under these conditions (Fig. 2.4A, B), one possibility is that MC159 may interact with 
unanchored, non-covalently linked forms of ubiquitin. However, it is not clear if this 
modification to MC159 is beneficial.  
MC159 binds to the N-terminal region of NEMO 
NEMO has two C-terminal regions that contain lysines that are targeted for 
covalently-linked ubiquitinations: UBAN (249-339), and ZnF (389-419)(15). Since 
MC159 inhibited NEMO polyubiquitination, one hypothesis was that MC159 binds to the 
C-terminus of NEMO to physically cloak lysine substrates. This possibility was 
examined by mapping NEMO-MC159 interactions using wild-type or mutant NEMO 
constructs shown in Figure 2.5A. In Figure 5B, 293T cells were transfected with plasmids 
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expressing NEMO, MC159 and ubiquitin to duplicate conditions used for ubiquitination 
assays shown in Figures 2.1 and 2.2. All transfected cells were treated with TNF to 
trigger NEMO polyubiquitination. These conditions were conducive for NEMO-MC159 
interactions because MC159 co-immunoprecipitated with the FLAG-tagged wild-type 
NEMO as expected (Fig. 2.5B).   Interestingly, MC159 did not interact with NEMO 
residues 250-419, the NEMO region that contains the lysines that receive ubiquitin 
linkages. Instead, MC159 interacted with the N-terminal region of NEMO (1-250), a 
region that does not possess known ubiquitination sites (Fig. 2.5B).  
Additional experiments were performed using NEMO -/- MEFs (Fig. 2.5C) that 
were reconstituted with NEMO constructs from Figure 5A. This second experimental 
approach was used to rule out contributions of endogenous NEMO. Once again, MC159 
co-immunoprecipitated with wild-type NEMO and the NEMO construct consisting of 
residues 1-250. No MC159-NEMO interactions were detected when using a NEMO 
construct expressing NEMO residues 251-419. These data suggested that MC159 
interacted with the N-terminal region of NEMO and not with the NEMO regions that are 
known to contain lysines that are targeted for ubiquitination.  
MC159 reduces cIAP1-induced NF-κB activation and NEMO ubiquitination  
cIAP1 and cIAP2 are similar proteins and both are required to activate NF-kB 
during TNF stimulation (47). Each protein acts as an E3 ligase to covalently link 
ubiquitin to cellular proteins including RIP1 and NEMO (5, 47, 65). cIAP1 interacts with 
the N-terminus of NEMO (64-106 amino acids)(37). Moreover, cIAP1 is known to K63-
link ubiquitinate cellular substrates under certain conditions (78).  Since MC159 and 
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cIAP1 each interact with the N-terminus of NEMO, one possibility was that MC159 
prevented cIAP1-NEMO interactions as a mechanism to inhibit NEMO ubiquitination.  
To test our hypothesis, we chose to over-express an epitope tagged version of 
cIAP1 instead of siRNA silencing cIAP1.  This is because both cIAP1 and cIAP2 must be 
siRNA silenced to completely block TNF-induced NF-kB activation. Unfortunately, the 
siRNA silencing of both cIAP1 and cIAP2 also triggers apoptosis (47).  Thus, over-
expression of cIAP1 (instead of siRNA silencing of cIAP1) avoids confounding effects. 
As an initial test of this hypothesis, we capitalized on reports that cIAP1 over-
expression stimulates NF-kB activation (65). Luciferase activity assays were developed 
using conditions similar to those for examining NEMO ubiquitination (Fig. 2.1B). Figure 
6A showed that cIAP1-induced luciferase activity was highest when cells were 
transfected with 750 or 1000 ng of a cIAP1-containing plasmid. MC159 expression 
greatly reduced cIAP1-mediated NF-kB activation (Fig. 2.6A). The Kaposi’s sarcoma 
herpesvirus K13 protein contains two tandem death effector domains, similar to MC159 
(79). K13 also binds to NEMO, but is known to activate NF-kB (25, 49).  Thus, K13 
expression would be expected to enhance cIAP1-induced NF-kB activation, and this 
trend was observed (Fig. 2.6A). Examination of lysates used for luciferase activity assays 
showed that MC159 and FLAG-NEMO protein expression was similar under all 
conditions examined. K13-FLAG protein levels were also similar in cells receiving 750 
or 1000 ng cIAP1. cIAP1 levels appeared slightly lower in K13-expressing cells when 
lower amounts of cIAP1-containing plasmid were present, but this trend did not continue 
when higher amounts of cIAP1-containing plasmid was transfected in to cells. 
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A second strategy to examine if MC159 negatively regulated cIAP1 was to 
determine cIAP1-induced NEMO polyubiquitination in the presence or absence of 
MC159.  In this case, cells were co-expressing epitope-tagged NEMO, cIAP1 and 
ubiquitin.  HA-tagged NEMO was immunoprecipitated and probed for polyubiquitination 
by immunoblotting (Figure 2.6B and C). Cells overexpressing cIAP1 showed more 
polyubiquitinated forms of NEMO in comparison to cells lacking cIAP1, and 250 ng 
pcIAP1 was the best inducer of NEMO polyubiquitination (Figure 2.6B). This suggests 
cIAP1 facilitates polyubiquitination of NEMO. While these reactions each contained 
higher molecular weight bands indicative of polyubiquitinated NEMO, these higher 
molecular weight bands were less intense when MC159 was present, suggesting that 
MC159 partially inhibited cIAP1 ubiquitination of NEMO (Figure 2.6C). 
MC159 inhibits NEMO-cIAP1 interactions 
When examining immunoprecipitates in Figure 2.6B, we observed that cIAP1 was 
absent from NEMO-based immunoprecipitations in MC159-expressing cells. This 
suggested that MC159 prevented cIAP1-NEMO interactions. This seemed likely because 
cIAP1 binds to residues 64-106 of NEMO (37) while MC159 binds to a region in the first 
250 residues of NEMO.  
Additional immunoprecipitations were performed (in which the plasmid 
expressing ubiquitin was absent) to further investigate if MC159 could interfere with 
cIAP1-NEMO interactions (Figure 2.7). Figure 2.7A showed immunoprecipitations of an 
HA-tagged version of NEMO.  The FLAG-tagged cIAP1 co-immunoprecipitated with 
NEMO only when MC159 was absent (Figure 2.7A). MC159 is a viral FLIP (vFLIP) and 
there are other viral FLIPs expressed by herpesviruses. Expression of the KSHV K13 did 
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not perturb the cIAP1-NEMO interactions (Figure 2.7B), indicating that MC159 
inhibition of cIAP1-NEMO interactions was a unique property of this MCV vFLIP.  We 
also asked if cIAP1 was an MC159 binding partner (Figure 2.7C). In this case, FLAG-
tagged cIAP1 was immunoprecipitated, and immunoprecipitates were probed for the 
presence of HA-tagged NEMO or HA-tagged MC159.  While cIAP1-NEMO interactions 
were detectable, cAIP1-MC159 interactions were not (Figure 2.7C).  This suggested that 
MC159 specifically targets NEMO.  
The above experiments detected interactions of epitope-tagged proteins that were 
over-expressed in 293T cells. Additional experiments were performed to show that 
MC159 blocked the interactions of endogenous cIAP1 and NEMO (Figure 2.7D). In this 
case, cells were transfected only with pCI or MC159/pCI. While TNF was added to these 
cells, note that cIAP-NEMO interactions can be detected in the absence or presence of 
TNF (65). cIAP1 was immunoprecipitated using anti-cIAP1 antibodies and 
immunoprecipitates were probed with antibodies against NEMO or HA-tagged MC159.  
While cIAP1-NEMO interactions were detected in pCI-transfected cells, these 
interactions were reduced when MC159 was present.  
Figure 2.7E used a reverse approach to examine the effect of MC159 on cIAP1-
mediated ubiquitination of NEMO. In this case, cells were transfected with HA-tagged 
Ub constructs from Figure 2.2 (WT, K48 or K63), and ubiquitinated proteins were 
immunoprecipitated using anti-HA antibodies. Immunoprecipitates were probed with 
antibodies specific for NEMO.  When NEMO and ubiquitin were over-expressed (Figure 
2.7E, lane 3), a 56 kDa NEMO protein was detected, representing the monoubiquitinated 
form of NEMO. This was expected because NEMO has a UBAN (ubiquitin binding 
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region) domain. Also, the diubiquitinated form of NEMO (64 kDa) was also observed. 
When cIAP1 was over-expressed a third, higher migrating band of NEMO was detected 
(approximately 72 kDa), indicating that cIAP1 could facilitate NEMO polyubiquitination 
(Figure 2.7E, lane 4). This banding pattern changed when the K48 or K63 mutant 
ubiquitins were expressed.  When K48 was expressed, monoubiquitinated NEMO was 
observed but there was a dramatic reduction in diubiquitinated NEMO levels.  This was 
expected because K48-linked ubiquitination is usually associated with proteosomal 
degradation.  When K63 ubiquitin was expressed, we instead observed a doublet NEMO 
band with a slightly higher molecular weight than the diubiquitin NEMO observed in 
lanes 3 and 4 of Figure 2.7E.  We speculate that this doublet may represents a mixed 
population of NEMO that have ubiquitin binding to UBAN region versus the zinc finger 
domain region, but have no means to prove this. It was most interesting that, when 
MC159 was expressed, only monoubiquitinated NEMO was detected in Figure 2.7E. In 
summary, these data suggest that MC159 greatly reduced cIAP-NEMO interactions and 
this cIAP1-mediated NEMO polyubiquitination.  
MC159 inhibits NEMO-cIAP1 interactions during a surrogate virus infection 
Vaccinia virus and other poxviruses are genetically tractable because these viruses 
can be propagated in vitro.  However, MCV cannot be propagated in cell culture (13, 61), 
making it difficult to assess if MC159 inhibits NEMO-cIAP1 interactions during an MCV 
infection.  As an alternative strategy to study MC159 function during infection, the MCV 
MC159L gene was stably inserted into a vaccinia virus that lacked the vaccinia virus 
A49R gene, a gene that encodes an NF-kB inhibitory protein (48). MC159 protein 
expression was detected in infected cells at both 2 and 6 h post-infection, and this was 
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expected because MC159 was under the control of a synthetic early/late promoter (Figure 
2.8A). The parental virus (vDA49) and the revertant virus, in which the A49R gene was 
re-introduced into vDA49, did not express MC159 (Figure 2.8A).  
Next, viruses were used to infect cells expressing epitope-tagged versions of 
NEMO and cIAP1 (Figure 2.8B). In this case, NF-kB activation was triggered by over-
expressing cIAP1 and NEMO. cIAP1 co-immunoprecipitated with NEMO in mock-
infected cells or in cells infected vΔA49 or vΔA49rev.  However, these interactions were 
greatly reduced when cells were infected with vMC159ΔA49. E3, a vaccinia virus 
protein expressed early in infection, was present in similar amount in lysates of all 
infected cells, demonstrating similar extents of virus infection (Fig. 2.8B). An identical 
set of lysates were incubated with IgG antibodies. Under these conditions, neither 
NEMO, cIAP1 nor MC159 were detected in immunoprecipitation reactions, indicating 
that these proteins were not non-specifically binding to Protein G Sepharose beads. In 
summary, these data indicate that MC159 interferes with cIAP1-NEMO interactions 
during virus infection. 
2.4 Discussion  
There is no reliable FDA-approved treatment of MCV infections (13, 61). 
Understanding how MC159 represses NEMO activation may provide a rationale to 
design compounds that may have therapeutic value for MCV infections. We show here 
that MC159 inhibited NEMO polyubiquitination, piquing curiosity as to how MC159 
might interact with NEMO to interfere with its post-translational modification. MC159 
probably is not a competitive substrate for the host cell ubiquitination machinery because 
MC159 is not covalently linked to ubiquitin. MC159 also does not physically cloak the 
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C-terminal lysine residues of NEMO that are known substrates of the ubiquitin 
machinery because MC159 did not interact with the C-terminal region of NEMO.  
A potential mechanism for MC159 antagonist function became apparent when we 
observed that MC159 interacted with the N-terminus of NEMO, the same region that 
cIAP1 binds (37). Here, several lines of evidence support the model that MC159 binds to 
NEMO to prevent cIAP1 from interacting with and polyubiquitinating NEMO. First, 
cIAP1 no longer co-immunoprecipitated with NEMO when MC159 was present. Second, 
cIAP1 had a greatly reduced capacity to polyubiquitinate NEMO when MC159 was 
present. Third, cIAP1-induced NF-kB activation was greatly reduced by MC159. This is 
the first reporting of a viral protein disrupting cIAP1-NEMO interactions as a strategy to 
antagonize NF-kB activation.  The current model is that, by competitively inhibiting 
cIAP1-NEMO interactions, MC159 prevents cIAP1-induced polyubiquitination of 
NEMO. Thus, MC159 represents a novel viral strategy to antagonize IKK activation. One 
caveat is that our co-immunoprecipitation data do not rule out the possibility that MC159 
is indirectly binding to NEMO. We think that this possibility is less likely because a viral 
homolog of MC159 (K13) binds directly to NEMO in a cell-free system (25). 
We used TNF to trigger signal transduction events in many experiments here 
because TNF is expressed at MC lesions (41). Also, many of the signal transduction 
events that occur from TNFR1 to NF-kB transcriptional activation are well-known (8), 
which would aid in determining how MC159 may alter IKK activation. For example, 
K63-linked polyubiquitination of NEMO was the first type of ubiquitination event shown 
to be important for TNF-induced NF-kB activation (21, 73). TNF also stimulates the 
formation of M1-linked and K63/M1-ubiquitin hybrid chains on NEMO (22, 23). K63-
	 86	
linked chains are substrates for M1-linked polyubiquitination (21, 23). Since MC159 
inhibited K63-linked ubiquitination (Figure 2), it is predicted that MC159 would also 
block the formation of K63/M1 hybrid chains and, as such, may also inhibit NF-kB 
activation triggered via other innate immune signaling pathways such as those triggered 
by the IL-1 receptor (22,23).  
RIP1 polyubiquitination is critical for IKK and NF-kB activation, and cIAP1 
ubiquitinates RIP1 (20, 21, 27, 30, 45, 75). Thus, it was quite surprising to observe that 
MC159 did not prevent RIP1 polyubiquitination despite RIP1-MC159 co-
immunoprecipitations. Since these are co-immunoprecipitations, it cannot be discerned if 
MC159 binds directly to RIP1 or indirectly to RIP1 via NEMO. Nevertheless, our results 
raise the question of why inhibiting NEMO but not RIP1 polyubiquitination may be 
beneficial to MCV. TNF-TNFR1 interactions possess the capacity to trigger either NF-
kB activation, apoptosis, or necroptosis (8, 67). The ubiquitination status of RIP1 can 
control this outcome (14, 21, 33, 45). The general consensus is that polyubiquitinated 
RIP1 allows NF-kB activation (21). However, if RIP1 is unmodified, then apoptosis (50, 
54, 71) or necroptosis (33, 34, 69, 80) signaling events may occur. Thus, a strategic 
allowance of RIP1 polyubiquitination would decrease signaling events associated with 
cell death and increase events associated with virus survival. There are publications that 
show that MC159 inhibits TNF-induced necroptosis (36) and programmed necrosis (10, 
66) that support this hypothesis. MC159 is already known to bind to and inhibit 
procaspase-8 to inhibit apoptosis (4, 35, 62). Thus, allowance of RIP1 ubiquitination for 
the purposes of cell survival would represent a second (albeit indirect) anti-apoptosis 
mechanism of MC159.  
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cIAP1 is an E3 ligase that polyubiquitinates RIP1(5, 47). Other publications show 
that cIAP1 also ubiquitinates NEMO (37, 65).  For example, using recombinant proteins, 
Tang et al. show that cIAP1 conjugates K6-linked ubiquitin to NEMO (65). cIAP1 also is 
reported to add K63-linked ubiquitin to BCL10 to stimulate IKK activation in B cell 
lymphoma cell lines (78). No reports show that cIAP1 ubiquitinates NEMO during TLR2 
or IL1R-induced NF-kB activation.  Instead, TRAF6 ubiquitinated NEMO for TLR2-
induced and IL1R-induced NF-kB activation (32). Thus, it is difficult to predict if 
MC159 would inhibit TRAF6-induced NEMO ubiquitination. While there is no 
published evidence to show that cIAP1 adds K63-linked ubiquitin chains to NEMO, 
cIAP1 has been reported to K63-link ubiquitinate Bcl-10 (78) and RIP1 (6). Thus, we 
became interested in the possibility that cIAP1 may act as an E3 ligase in our system of 
study because of the coincidence that MC159 interacted with the N-terminus of NEMO, 
where cIAP1 was reported to bind (37).  We show here that MC159 inhibited NEMO-
cIAP1 interactions, and cIAP1-induced NF-kB activation and NEMO polyubiquitination. 
From these data, our current model that MC159 prevents cIAP1-induced NEMO 
polyubiquitination. We observed that MC159 did not completely abolish NEMO 
polyubiquitination under any condition examined. It has been proposed that there are 
multiple E3 ligase that ubiquitinate NEMO (15). We speculate that perhaps MC159 does 
not prevent these other ligases from interacting with and modifying NEMO. The 
biological relevance of this remains unclear. We also observed that MC159 was a 
stronger inhibitor of NEMO polyubiquitination when cells were stimulated with TNF 
than with over-expression of cIAP1. Perhaps this latter result is due to competition 
between cIAP1 and MC159 for NEMO in this transfection system used here.  
	 88	
MCV cannot be propagated in cell culture, making it difficult to examine the 
biochemical function of MC159 during infection. Here, we expressed the MCV MC159L 
gene in vaccinia virus as a strategy to explore MC159 functions during poxvirus 
infections. We show that MC159 prevented cIAP1-NEMO interactions during virus 
infection, implying that MC159-NEMO interactions are biologically relevant during 
MCV infections. We purposefully did not examine NEMO ubiquitination or NF-kB 
activation in virus-infected cells because the parental vaccinia virus (vDA49) expresses at 
least nine other NF-kB inhibitory proteins that inhibit NF-kB activation, including some 
that act upstream of IKK activation (e.g.; A52, A46, K7)(64).  Thus, NEMO is expected 
to remain in its non-ubiquitinated state during vDA49 infection due to these other 
vaccinia virus proteins. Because of this, it would be technically impossible to detect 
MC159’s effects on NEMO polyubiquitination in these virus-infected cells. 
To date, MCV encodes three proteins that target the NF-kB activation pathway: 
MC159, MC160 and MC132 (7, 61). MC159 and MC160 each target the IKK complex 
(52, 53, 56).  MC159 binds to the NEMO subunit of the IKK complex (56). In contrast 
MC160 triggers IKKa degradation (53).  MC132 acts at a step downstream of MC159 
and MC160; MC132 degrades the p65 subunit of the NF-kB complex (7). The 
mechanism of each MCV protein described above was determined by expressing each 
protein independent of infection because MCV cannot be propagated in cell culture.  Of 
course, all three proteins are predicted to be expressed simultaneously during an MCV 
infection.  It is not clear why MCV codes for proteins with seemingly redundant function.  
Similar questions are raised with vaccinia virus, a virus that expresses at least 10 different 
NF-kB inhibitors (64). One prevailing theory for vaccinia virus is that each NF-kB 
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inhibitory protein is important to block NF-kB activation triggered at different stages of 
infection or by different signal transduction pathways.  Perhaps MCV encodes multiple 
proteins for similar reasons. For example, MC159 may targets canonical IKK activation 
while MC132 may be a means to neutralize NF-kB activation that occurs through the 
non-canonical (IKK-independent NF-kB activation) pathway.  
This report focuses on MC159 inhibition of NF-kB activation (11, 36, 51, 56). 
However, there are several reports showing that MC159 activates NF-kB pathway when 
MC159 is expressed at low levels (9, 36, 51, 56). This begs the question of which 
phenotype has biological relevance. Interestingly, the murine cytomegalovirus (MCMV) 
M45 protein induces NF-kB early after infection (40) and then inhibits NF-kB during 
later times post-infection (26). For M45, the former function is due to virion-associated 
M45 molecules, and it is proposed that NF-kB activation is important for initial virus 
infection (40). In contrast, de novo synthesized M45 proteins inhibit NF-kB, and this may 
be important for MCMV persistence (26).  An attractive hypothesis is that the reports of 
MC159 activating and inhibiting NF-kB activation may reflect MC159 up- or down-
regulating NF-kB activation temporally during infection to re-organize the cell landscape 
in a manner that is beneficial for a persistent infection. Unfortunately, this hypothesis 
cannot be tested currently because MCV cannot be propagated in cell culture or in 
animals. In an elegant approach to further examine MC159 within the context of a virus 
infection, Huttman et al examined MC159 properties within the context of an M45-less 
MCMV infection (36). MC159 did not inhibit MCMV-induced NF-kB activation at late 
times post-infection (36), which implies that the NF-kB inhibitory properties of MC159 
are important during the initial phases of infection.  
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The IKK complex is a powerful means to activate NF-kB (15). Several viruses 
manipulate NEMO to antagonize IKK. For example, the Merkel cell polyomavirus 
(McPyV) small T antigen (ST) and the murine cytomegalovirus (MCMV) M45 protein 
each bind to NEMO to prevent IKK activation (26, 28). Each protein uses a different 
mechanism to antagonize NEMO, and this likely reflects the different needs of a virus 
during infection. McPyV ST draws the cellular PP4C and (PP2A) Ab to NEMO to 
presumably dephosphorylate and inactivate IKK (28). In contrast, M45-NEMO 
interactions target NEMO to the autophagosome for subsequent NEMO degradation (26). 
Here, MC159 inhibits NEMO polyubiquitination. Other viral proteins target other IKK 
subunits. The vaccinia virus B14 protein binds to IKKb to prevent IKKb phosphorylation 
by upstream kinases (12). The MCV MC160 protein degrades IKKa to destroy the IKK 
complex (52, 53). These viral proteins exemplify the importance of IKK for the anti-viral 
response, and that multiple viruses antagonize IKK activation using multiple strategies.  
On the other side of the coin some oncogenic viruses encode NEMO-binding 
proteins to stimulate IKK activation and induce transformation of infected cells. This 
includes the KSHV K13 protein (25, 49). MC159 and K13 are members of the FLIP 
family of proteins (79). These proteins are also present in cells (e.g. cFLIPL and cFLIPS), 
and these proteins were characterized originally by two tandem death effector domains 
and their ability to block extrinsic apoptosis (79). It is rather striking that MC159 and 
K13 each bind to the N-terminus of NEMO, but MC159-NEMO interactions inhibit IKK 
activation while K13-NEMO interactions trigger IKK activation (25, 49, 56). How do 
these seemingly similar proteins interact with NEMO but cause such disparate biological 
outcomes? The solved crystal structures of MC159 (44, 77) and a K13/NEMO complex 
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(2) have not shed light on potential mechanisms.  It was originally proposed that K13 
would induce major conformational changes of NEMO that favors IKK activation. 
However, Bagneris et al. recently published that K13 binding only causes subtle 
conformational changes of NEMO, suggesting that K13 may rely on other binding 
partners to stimulate IKK (3). In our hands, MC159 prevented cIAP1-NEMO interactions 
while K13 did not (Figure 2.7B). One hypothesis for future research is that K13 may 
enhance cIAP1-NEMO interactions to activate IKK whilst MC159 prevents such 
interactions to inhibit IKK. Although much is known about IKK activation, there are still 
many questions remaining about NEMO and IKK, including is temporal regulation under 
by different stimulants and different cell types. It is proposed that the parallel study of 
structural homologs like MC159 and K13 provide a unique platform to learn how to 
















Figure 2.1 MC159 inhibits NEMO polyubiquitination. (A) 293T cells were transfected 
as follows: 1000 ng pCI (lane 1); 500 ng pCI, 500 ng pUb-Myc (lane 2); 500 ng pCI, 500 
ng pNEMO-FLAG (lane 3); 250 ng pNEMO-FLAG, 750 ng pUb-Myc (lane 4), 500 ng 
pNEMO-FLAG, 500 ng pUb-Myc (lane 5), 750 ng pNEMO-FLAG, 250 ng pUb-Myc 
(lane 6). At 24 h post-transfection, cells were lysed in Ub lysis buffer. (B) 293T cells 
were co-transfected with 500 ng pNEMO-FLAG, 500 ng pUb-Myc, and 1000 ng of either 
pCI, pMC159 or pNEMOΔZnF. At 24 h post-transfection, cells were lysed in Ub lysis 
buffer. (C) 293T cells were transfected with 250 ng pNEMO-FLAG, 250 ng pUb-Myc, 
and 1000 ng of either pCI, pMC159 or pNEMOΔZnF. At 24 h post-transfection, cells 
were incubated in medium containing 10 ng/ml TNF for 15 min prior to lysis in Ub lysis 
buffer. (A, B and C) For all experiments, a portion of each lysate prior to 
immunoprecipitation was set aside to detect protein expression by using immunoblotting 
(IB). The remaining cellular lysates were immunoprecipitated (IP) with anti-FLAG 
antibody or IgG isotype control antibody conjugates to protein G-Sepharose beads. IP’ed 
samples or cellular lysates were separated by SDS-PAGE, and proteins were transferred 
to PVDF membranes for IB. Membranes were probed with the indicated antibodies to 
detect polyubiquitinated NEMO, MC159, or actin. Monoubiquitinated (Mono-Ub) and 






Figure 2.2 MC159 inhibits K63-linked NEMO polyubiquitination. (A) Schematic 
representation of wild-type or mutant Ub proteins that indicate lysine (K) or arginine (R) 
at a specific residue. (B) 293T cells were co-transfected with 250 ng pNEMO-FLAG, 250 
ng of pWT-Ub-HA, pK48-Ub-HA or pK63-Ub-HA, and 1000 ng of either pCI, pMC159 
or pNEMOΔZnF for 24 h. Next, cells were incubated in medium containing 10 ng/ml 
TNF for 15 min. Cells were lysed in Ub lysis buffer. A portion of each lysate was set 
aside to monitor protein expression. For the remaining clarified cellular lysates, 
immunoprecipitations (IP) were performed using either anti-FLAG or IgG antibodies 
conjugated to protein G-Sepharose beads. IP’ed samples or cellular lysates were 
separated by SDS-PAGE, and proteins were transferred to PVDF membranes for 
immunoblotting (IB). Membranes were probed with the indicated antibodies to detect 
ubiquitinated forms of NEMO, MC159, or actin. For IP’ed samples probed with anti-HA 
to detect ubiquitin, anti-FLAG or anti-MC159 antibodies, lanes from the same gel were 
spliced to show the relevant samples for the experiment. The corresponding cellular 
lysates were probed by immunoblotting in a subsequent assay, avoiding the need for 
splicing. Monoubiquitinated (Mono-Ub) and polyubiquitinated (Poly-Ub) forms of 





Figure 2.3 MC159 does not inhibit RIP1 polyubiquitination and still allows RIP1-
NEMO interactions. 293T monolayers were co-transfected with 1000 ng pCI or 
pMC159, 500 ng pUb-Myc and 500 ng pRIP1-HA. At 24 h post-transfection, cells were 
incubated in medium (A) lacking or (B) containing 10 ng/ml TNF for 15 min to trigger 
RIP1 ubiquitination. Cells were lysed in Ub lysis buffer 24 h later. Some lysates were set 
aside to monitor protein expression. For the remaining clarified cellular lysates, 
immunoprecipitations (IP) were performed using IgG or anti-HA antibodies conjugated 
to protein G-Sepharose beads. IP’ed samples or cellular lysates were separated by SDS-
PAGE, and proteins were transferred to PVDF membranes for immunoblotting (IB). 
Membranes were probed with the indicated antibodies to detect RIP1, MC159, or actin. 
(C) 293T monolayers were co-transfected with 1000 ng pCI or pMC159, 500 ng pUb-
Myc and 500 ng pRIP1-HA. Cells were lysed in IP lysis buffer at 24 h post-transfection. 
A portion of each lysate was set aside to monitor protein expression. For the remaining 
clarified cellular lysates, IP was performed using IgG or anti-FLAG antibodies 
conjugated to protein G-Sepharose beads. IP’ed samples or cellular lysates were 
separated by SDS-PAGE, and proteins were transferred to PVDF membranes for 
immunoblotting (IB). Membranes were probed with the indicated antibodies to detect 






Figure 2.4 MC159 co-immunoprecipitates with ubiquitin but is not covalently linked 
to ubiquitin. Subconfluent 293T cellular monolayers were co-transfected with 500 ng 
pUb-Myc and 500 ng pMC159. At 24 h post-transfection, cells were incubated in either 
medium (A) lacking or (B) containing 10 ng/ml TNF.  After 15 min, cells were lysed in 
Ub lysis buffer. A portion of each lysate was set aside to monitor protein expression. For 
the remaining clarified cellular lysates, IP was performed using IgG or anti-myc 
antibodies conjugated to protein G-Sepharose beads. IP’ed samples or cellular lysates 
were separated by SDS-PAGE, and proteins were transferred to PVDF membranes for 
immunoblotting (IB). Membranes were probed with the indicated antibodies to detect 





















Figure 2.5 MC159 binds to the N-terminal region of NEMO. (A) A schematic 
representation of wild-type and mutant NEMO constructs used here. NEMO domains 
including the two coiled-coil regions (CC1 and CC2), a leucine zipper (LZ) and a zinc 
finger domain (ZnF) domain are shown here. (B) Subconfluent 293T cellular monolayers 
were co-transfected with the indicated plasmids (1000 ng pMC159, 500 ng of pNEMO-
based plasmids, 500 ng pUb-Myc). Where necessary, pCI was present in transfection 
reactions to bring total DNA in each transfection reaction up to 2000 ng. At 24 h post-
transfection, cells were incubated with medium containing TNF (10 ng/ml) for 15 min. 
(C) NEMO -/- MEFs were co-transfected with the indicated plasmids (1000 ng pMC159, 
500 ng of pNEMO-based plasmids). Where necessary, pCI was present in transfection 
reactions to bring total DNA in each transfection reaction up to 1500 ng. At 24 h post-
transfection, 293T or MEFs were lysed in 150 µl of IP lysis buffer.  A portion of each 
lysate was set aside to monitor protein expression. For the remaining clarified cellular 
lysates, IP was performed using IgG or anti-FLAG antibodies conjugated to protein G-
Sepharose beads. IP’ed samples or cellular lysates were separated by SDS-PAGE, and 
proteins were transferred to PVDF membranes for immunoblotting (IB). Membranes 









Figure 2.6 MC159 reduced cIAP1-mediated NF-κB activation and NEMO 
polyubiquitination. (A) 293T cells were co-transfected for 24 h with 225 ng pNF-κBluc, 
25 ng pRL-TK, 250 ng pUb-myc, 250 ng pNEMO-FLAG and 750 ng of pcDNA3.1 
(VC), pMC159 or pK13-FLAG, and increasing amounts of pcIAP1. Cells were lysed and 
luciferase activities were quantified. Results are shown as fold-induction of luciferase 
activity relative to those of cells transfected with empty vector. * P < 0.05 and **P < 
0.001 as compared with cells transfected with empty vector.  Immunoblot analysis of 
lysates also was performed. (B) 293T cells were co-transfected with 250 ng pNEMO-HA, 
250 ng pUb-Myc, 250 or 500 ng pcIAP1, and pCI sufficient to make 1500 ng present in 
all reactions.  (C) 293T cells were co-transfected with 250 ng pNEMO-HA, 250 ng pUb-
Myc, 250 ng pcIAP1 and 1000 ng of either pCI or pMC159. (B and C) At 24 h post-
transfection, cells were lysed in 150 µl of Ub lysis buffer. A portion of each lysate was 
set aside to monitor protein expression. For the remaining clarified cellular lysates, IP 
was performed using indicated antibodies conjugated to protein G-Sepharose beads. 
IP’ed samples or cellular lysates were separated by SDS-PAGE, and proteins were 
transferred to PVDF membranes for immunoblotting (IB). Membranes were probed with 
the indicated antibodies to detect cIAP1, NEMO, MC159, K13 or 























Figure 2.7 (continued) 
 
 
Figure 2.7 MC159, but not the K13 homolog, inhibits NEMO-cIAP1 interactions. 
(A and B) 293T cells were co-transfected with 500 ng pcIAP1-FLAG, 500 ng pNEMO-
HA, and 1000 ng of pCI or (A) pMC159 or (B) pK13-FLAG. At 24 h post-transfection, 
cells were collected and lysed in IP lysis buffer. A portion of each lysate was set aside to 
monitor protein expression. Remaining clarified cellular lysates were incubated with IgG 
or anti-HA antibody conjugated to protein G-Sepharose beads. (C) 293T cells were co-
transfected with 500 ng pcIAP1-FLAG, and 500 ng pCI, pNEMO-HA or pMC159-HA. 
At 24 h post-transfection, cells were collected and lysed in IP lysis buffer. Clarified 
cellular lysates were incubated with IgG or anti-HA antibodies conjugated to protein G-
Sepharose beads. (D) 10 cm2 dishes of subconfluent monolayers of HeLa cells were 
transfected with 5000 ng of pCI or pMC159-HA. At 24 h post-transfection, cells were 
incubated in medium containing TNF (10 ng/ml) for 10 min. Cells were collected and 
lysed in IP lysis buffer. A portion of each lysate was set aside to monitor protein 
expression. For the remaining clarified cellular lysates, IPs were performed using IgG or 
anti-cIAP1 antibodies conjugated to protein G-Sepharose beads. (E) 293T cells were co-
transfected with 250 ng pcIAP1-Myc, 250 ng pNEMO-FLAG, 250 ng pWT-Ub-HA, 
pK48-HA or pK63-Ub-HA and 1000 ng pCI or pMC159, as indicated. At 24 h post-
transfection, cells were collected and lysed in IP lysis buffer. A portion of each lysate 
was set aside to monitor protein expression. For the remaining clarified cellular lysates, 
IPs were performed using IgG or anti-HA antibodies conjugated to protein G-Sepharose 
beads. For all experiments, IP’ed samples or cellular lysates were separated by SDS-
PAGE, and proteins were transferred to PVDF membranes for immunoblotting (IB). 
Membranes were probed with the indicated antibodies to detect cIAP1, NEMO, Ub, 






















Figure 2.8 MC159 inhibits NEMO-cIAP1 interactions during a surrogate virus 
infection. (A) RK13 cellular monolayers were infected with vΔA49, vΔA49rev or 
vMC159ΔA49 (MOI = 10). At 2 or 6 hours p.i., cells were collected and lysed in CE 
buffer. A portion of each lysate was electrophoretically separated by using SDS-
12%PAGE, and proteins were transferred to PVDF membranes. Membranes were probed 
with antibodies to detect MC159 or actin.  (B) 293T cellular monolayers were co-
transfected with 500 ng pNEMO-HA and 500 ng pcIAP1-FLAG. At 24 h post-
transfection, cells were either mock-infected or infected with vΔA49, vΔA49rev or 
vMC159ΔA49 (MOI = 10). At 24 h post-infection, cells were collected and lysed in IP 
lysis buffer. A portion of each lysate was set aside to monitor protein expression. For the 
remaining clarified cellular lysates, IPs were performed using IgG or anti-HA antibodies 
conjugated to protein G-Sepharose beads. IP’ed samples or cellular lysates were 
separated by SDS-PAGE, and proteins were transferred to PVDF membranes for 
immunoblotting (IB). Membranes were probed with the indicated antibodies to detect 
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Chapter 3: A comparison of the effect of molluscum contagiosum virus MC159 and 




Molluscum contagiosum virus (MCV) is a member of the Poxviridae family, and 
is the etiological agent of molluscum contagiosum (MC) (12). MC-related outpatient 
visits are estimated to be 1 in 500 in the US, and there were over 120 million MCV cases 
worldwide in 2010 (19). MCV infections occur in 5 – 18% of HIV-infected people (17). 
Despite its ubiquity, there are currently no FDA-approved cures for MC. 
MCV infections provide an opportunity to learn about virus-host interactions 
during persistent infections. MCV infects keratinocytes and infections can persist for 
months to years (33). MC neoplasms are small and have little inflammation at the site of 
the lesion (12). Lesions that spontaneously regress have increased numbers of apoptosing 
cells, cytotoxic T cells, natural killer cells, and type I IFN-expressing plasmacytoid 
dendritic cells (44). Thus, it is presumed that one key to MCV persistence lies in MCV 
modulating the host response. MCV encodes at least 40 known or predicted immune 
evasion molecules (31, 32). Several of these proteins are characterized (5, 8, 10, 33). 
However, these characterizations occurred by studying proteins independent of MCV 
infection. This approach currently is required because MCV is refractive to growth in 
standard tissue culture. Thus, it remains unknown how these MCV immune evasion 
molecules play a role in viral pathogenesis.  
The MCV MC159 and MC160 immune evasion proteins are the focus of this 
manuscript. MC159 and MC160 each possess tandem death effector domains (DED) at 
their N-termini (49). Also, MC159 and MC160 each inhibit NF-kB activation by 
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targeting the IKK complex (4, 26, 27, 29). The IKK complex is comprised of three major 
molecules (IKKa, IKKb and NEMO), and active IKK phosphorylates IkBa, resulting in 
NF-kB activation (9). MC159 binds to and prevents ubiquitination of the NEMO to halt 
IKK activation (4, 29).  In contrast, MC160 binds to IKKa, resulting in IKKa 
degradation (4, 26, 27, 29). Thus, MC159 and MC160 each have unique binding partners.  
Vaccinia virus (VACV) is the best-studied poxvirus (25). Also, there are several 
excellent animal models of VACV infection that afford studying the impact of viral 
immune evasion molecules on viral pathogenesis (30, 36, 41, 42). VACV encodes at least 
10 proteins that inhibit NF-kB, including A49 (24, 36). The removal of any one NF-kB 
antagonist decreases VACV virulence, indicating that these proteins, while targeting the 
same signal transduction pathway, are not redundant (7, 14, 18, 24, 37). It is currently 
thought that VACV encodes multiple NF-kB antagonists to neutralize cell- and tissue-
specific immune responses. We suspect that MCV encodes MC159 and MC160 for 
similar reasons.  
The impact of MC159 and MC160 during MCV infection cannot be tested 
directly because of the inability to propagate MCV and a lack of an animal model of 
disease. To overcome this technical barrier, we chose to deliver MCV proteins to mice 
during a related poxvirus (VACV) infection.  We used the moderately attenuated VACV 
(vDA49) that lacks A49, an NF-kB antagonist (24). The hypothesis was that MC159 or 
MC160 would functionally substitute for A49 during infection, resulting in a recombinant 
virus with increased virulence as compared to vDA49. This approach should provide the 
opportunity to ask how expression of an MCV gene alters the host environment in the 
presence of an intact immune response. It also capitalizes on the deep knowledge base of 
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immune responses to VACV infections in vivo (16, 20, 21, 42). Of course, an ideal 
situation would be the use of a mouse-tropic MCV or humanized mice that allow for 
development of dermatotropic MCV neoplasms. However, until such systems are 
developed, our approach provides, for the first time, an examination of how MCV 
proteins may aid in virus virulence within the context of a complete and complex immune 
system.  
3.2 Materials and Methods 
Cells 
Mouse embryonic fibroblasts (MEF) and BSC40 cells were cultured in 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin and streptomycin (Fisher) and 2 mM L-glutamine. Virus 
medium (DMEM supplemented with 2.5% FBS) was used for virus adsorption phases 
and for virus infections. Viruses used for the inoculation of mice were purified by sucrose 
density gradient centrifugation as described previously (6). 
Virus construction 
vDA49 and vDA49rev were described previously (24). A recombinant virus 
(vMC159) was created in which the MC159L gene, under the control of the synthetic 
p7.5 promoter, was inserted into a mutant vaccinia virus (vDA49) that deleted nucleotides 
113-473 of the A49R gene (24). A second virus, vMC160, was created in which the 
MC160L gene under the the control of the synthetic p7.5 promoter, was inserted into 
vDA49. The first step in this process was to create a pDA49MCS plasmid that had 
multiple cloning sites for insertion of the MC159L or MC160L genes.   
	 112	
A plasmid lacking nt 113-473 of the A49R gene (pDA49Z11) was used as a source 
of DNA.  From this plasmid, two regions were PCR amplified: the A48 flank and the 
A50 flank.  A48 begins at A48R nt 457 and continues through to A49R nt 112 for a 338 
bp product.  The primers used to PCR amplify this product were A48R forward 5’-
ATCGGGATCCAACAAAAGGTATTACAAGAATAT-3’) and A48R reverse: 5’-
CGCGGATACTAGTATCGATATAGTTTCTATCTTGGCAATAACTAATTG-3’.  
The underlined regions are regions of vaccinia virus DNA.  The forward primer 
introduces a Bam HI restriction enzyme site (in italics).  The reverse primer introduces 
the Cla I and Spe I restriction enzyme sites (in italics). The A50 flanking region was PCR 
amplified from pDA49Z11.  This PCR product begins at A49R nt 474 and ends at A50R 
nt 293 to PCR amplify a 339 bp product.  The A50 forward primer was 5’-
GAAACTATATCGATACTAGTATCCGCGAACGATATTTGTGA-3’. The A50 
reverse primer was 5’-ATATGAATTCGATTTCTGTGTTCTCTTTGAAGAAAGTC-3’. 
The underlined nucleotides are in the vaccinia virus genome.  The forward primer 
introduces the Cla I and Spe I restriction enzyme sites (in italics). The reverse primer 
introduces an Eco RI restriction enzyme site.  Next, 50-100 ng of each gel-purified PCR 
product was stitching-of-ends (SOE) joined (the DNA regions that overlapped for using 
SOE are in boldface) and PCR amplified using the A48R forward and A50R reverse 
primers. The resultant PCR product was restriction enzyme digested with Bam HI and 
Eco RI and inserted into pUC13/gpt/EGFP that was digested with Bam HI and Eco RI 
and SAP modified. This plasmid is referred to as pDA49MCS. 
 To create an MC159L-containing plasmid to use for insertion of MC159L into the 
vaccinia virus genome, the MCV MC159L gene was PCR amplified from MC159/pCI 
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using forward primer 5’-CGGATCTATAATCATGTCCGACTCCAAGGAGG-3’ and 
reverse primer 5’- GAAAACTAGTTCAAGTCGTTTGCTCGGGG-3’ to yield a 726 bp 
PCR product.  The MC159 nucleotides are underlined.  The reverse primer engineered in 
the Spe I restriction enzyme digestion site (italicized). The p7.5 promoter was PCR 
amplified from pUC13/gpt/EGFP.  The forward primer was 5’-
TTTTATCGATTAAATAATAAATACAATAATTAATTTCTCGT-3’ and the reverse 
primer was 5’-GGAGTCGGACATGATTATAGATCCGTCACTG-3’ and this yielded 
a 121 bp PCR product.  The forward primer introduced a Cla I restriction enzyme site 
(italicized).  Next, 50-100 ng of each gel-purified PCR product was SOE joined and PCR 
amplified using the A48R forward and A50R reverse primers.  The DNA regions that 
overlapped for using SOE are in boldface.  The resultant PCR product of 847 bp was 
restriction enzyme digested with Cla I and Spe I and inserted into pDA49MCS that was 
digested with Cla I and Spe I and SAP modified. This plasmid was called 
MC159/pDA49MCS. 
To create an MC160L-containing plasmid to use for insertion of MC160L into the 
vaccinia virus genome, the MC160L gene was PCR amplified from MC160/pCI using 
forward primer primer 5’-GGATCTATAATCATGGCGCACGAGCCA -3’ and reverse 
primer 5’- CTAGACTAGTCTAGTAGGAAGCTTTCGTT-3’ 
to yield a 1212 bp PCR product.  The MC160 nucleotides are underlined.  The reverse 
primer for MC160 engineered in the Spe I restriction enzyme digestion site (italicized). 
The p7.5 promoter was PCR amplified from pUC13/gpt/EGFP, yielding a 121 bp 
product.  The forward primer is 5’-TTTTATCGATTAAATAATAAATACAATAATTAA 
TTTCTCGT-3’ and the reverse primer is 5’- CTCGTGCGCCATGATTATAG 
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ATCCGTCACTG-3’ and this yielded a 121 bp PCR product.  The forward primer 
introduced a Cla I restriction enzyme site (italicized).  Next, 50-100 ng of each gel-
purified PCR product was SOE joined and PCR amplified using the A48R forward and 
A50R reverse primers.  The DNA regions that overlapped for using SOE are in boldface.  
The resultant PCR product (1433 bp) was restriction enzyme digested with Cla I and Spe 
I and inserted into pA49MCS that was digested with Cla I and Spe I and SAP modified. 
 To create vMC159 and vMC160, CV-1 cells were infected with vΔA49 and 
transfected with MC159/pΔA49R or MC160/ pΔA49R. Recombinant viruses were 
collected 24 h later selected in the presence of mycophenolic acid, xanthine and 
hypoxanthine (15).  This process was repeated three times to isolate recombinant viruses 
away from parental viruses. Intermediate EcoGPT+ viruses were resolved into vΔA49 or 
vMC159ΔA49 by plaquing on BSC-1 cells in the absence of drugs. Viruses were 
propagated in BSC-1 cells and purified using sucrose cushions.  
Genomic DNA isolation and PCR analysis 
The genotype of each virus was confirmed by using PCR to amplify MC159L or 
MC160L and the flanking A48R and A50R regions. BSC40 cells were infected with 
vA49, vΔA49, vΔA49rev, vMC159 or vMC160 (MOI = 10). At 24 h post-infection, cells 
were collected and, total DNA was isolated using Qiagen kit as per manufacturer’s 
protocol. DNA was PCR amplified using forward primer A48 (5’-CGAGGAAGATGT 
AAAGAAGGAGTTG-3’) and reverse primer A50 (5’- CTATCGTCTAATCCGG 
GAAGCAATAG-3’). After a 25 amplification cycle, a portion of each reaction was 
analyzed by electrophoresis using a 1% agarose gel.  Amplicons were detected by 
ethidium bromide staining of the gel. 
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Detection of MC159 and MC160 protein expression by using immunoblotting 
Subconfluent BSC40 cellular monolayers in six-well plates were infected with 
vDA49, vMC159, vMC160 (MOI = 10 PFU/cell) or mock for the times indicated. At 24 h 
post-infection, cells were collected by scraping and collected by centrifugation (18,000 X 
g for 5 min).  Cellular pellets were resuspended and lysed in 70 µl CE buffer (10 mM 
HEPES, 10 mM KCl, 0.1 mM EDTA pH 8, 0.1 mM EGTA pH 8, 0.05% Nonidet P-40) 
that was supplemented with HALT protease inhibitors (Fisher) for 30 min at 4°C.  
Cellular lysates were then centrifuged (18,000 x g for 10 min). Clarified supernatants 
were collected and transferred to new tubes. 
The protein concentration of lysates from each sample was determined by using 
the 660 nm protein assay (Pierce). 15 µg of clarified cellular lysates were subjected to 
SDS-PAGE, and proteins were transferred to PVDF membranes (Millipore). Membranes 
were blocked in 5% (w/v) milk in Tris-Buffered Saline and Tween 20 (TBST; 150 mM 
NaCl, 50 mM Tris base, 0.05% Tween 20) for at least 30 min at room temperature. 
Membranes were incubated with the indicated primary antibodies overnight at 4°C. Next, 
membranes were washed three times in large volumes of TBST, and incubated with the 
appropriate HRP-conjugated secondary antibodies. Immunoblots were developed using 
chemilluminescence reagents (Thermo Scientific) and autoradiography. Primary 
antibodies used in these experiments were polyclonal rabbit anti-MC159 (1:1,000) (34), 
polyclonal rabbit anti-MC160 (1:1,000) (34), and anti-β-Actin (1:5,000; Sigma, 
A5060).  Monoclonal mouse anti-E3 (1:5,000) was a kind gift from Dr. Stuart Isaacs  
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(University of Pennsylvania) (45). Secondary HRP-conjugated antibodies were obtained 
from either Thermo Scientific (goat anti-mouse IgG; 1:10,000), Calbiochem (goat anti-
rabbit IgG;1:10,000). 
In vitro growth curves 
One-step and multistep growth curves were performed as described previously 
(6).  Briefly, confluent MEF cellular monolayers were infected with vDA49, vDA49rev, 
vMC159, vMC160 or vA49 at an MOI of 0.01 or 10 PFU/cell. After the initial 1 h 
adsorption phase, the cellular monolayers were washed three times to remove unattached 
viruses. At the indicated times post-infection, the cellular supernatants were collected to a 
new tube. The supernatants were subjected to centrifugation (800 X g for 10 min at 4° C), 
and cell-free supernatants were transferred to new tubes. Cellular monolayers were 
collected by scraping into 1 ml virus medium. Samples were centrifuged at 800 X g for 
10 min at 4° C. The cell pellets were resuspended in 1 ml of virus medium. Cells and 
supernatants were lysed by freeze-thawing three times. All samples were sonicated to 
release virions from cellular debris. Cellular lysates or supernatants were serially diluted, 
and 0.5 ml of each dilution was inoculated onto BSC40 cell monolayers in duplicate.  
After 48 hours, cellular monolayers were incubated with a crystal violet dye-based 
solution to visualize plaques. Data were expressed as the mean titer per sample ± SEM. 
Detection of plaque sizes 
 Plaque sizes were determined as described in Unterholzner et al (43). MEF or 
BSC40 cellular monolayers in six-well plates were infected in duplicate (MOI = 50 
PFU/well) with either vA49, vDA49, vMC159, vMC160 or vDA49rev for at least 48 h to 
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allow formation of well separated plaques. After 48 h (BSC40) or 72 h (MEF), cells were 
washed once with PBS and stained for 30 min with crystal violet (5% (v/v) crystal violet 
solution (Sigma), 25% (v/v) ethanol). Wells were then washed with water, air dried and 
the sizes of plaques per well were measured using Image J software. Images of plaques 
were taken using a Powershot SD1300 IS camera (Canon).  The diameters of plaques 
were measured using pixels that were scaled to mm by determining the number of pixels 
needed to draw a 1 mm using the ruler as a reference, and plaques were subsequently 
measured using this scale.  Plaque size is represented as mean size ± SEM of 6 (MEF) or 
8 (BSC40) plaque per sample.  The one-way analysis of variance (ANOVA) followed by 
Tukey’s multiple comparison test was used to determine statistically significant 
differences in size amongst experimental conditions using GraphPad. 
Murine intranasal and intradermal modes of infection 
Female BALB/c and C57BL/6 mice (6-8 weeks old) were purchased from 
Jackson Laboratory (Bar Harbor, ME) and housed in AAALAC-approved ABL-2 
facilities at the University of Illinois at Urbana-Champaign (UIUC). All animal 
experiments and procedures were approved by the Institutional Animal Care and Use 
Committee at the UIUC. All animal studies were performed as a blinded study to 
minimize potential bias. 
For intranasal inoculations, BALB/c mice (n = 5 per group) were anesthetized by 
isoflurane (5% in O2) inhalation using a vaporizer unit (Vetland, Louisville, KY). The 
mice were inoculated with 5 X 103 PFU vDA49, vDA49rev, vMC159, vMC160 or PBS in 
a 20 µl volume (10 µl per nostril). Mice were weighed and monitored for signs of illness 
daily daily for 15 days. A clinical score for each mouse was assigned daily, based on a 
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metric published by Berhanu et al. (3) to assess sickness. Briefly, the scoring was as 
follows: 0, normal; 1, slightly ruffled fur; 2, significantly ruffled fur; 3, score 2 combined 
with eyes with pus/conjunctivitis; 4, score 3 combined with hunched posture, difficulty in 
breathing, socializing, and/or moving; and 5, death. Clinical scores were expressed as the 
mean for each group. Weight data were expressed as the percentage of the mean of each 
individual animal’s weight loss from day 0 +/- SEM. This was performed as a blinded 
study to minimize potential bias.  
For intradermal inoculations, anesthetized C57BL/6 mice (n = 5 per group) were 
inoculated intradermally in the left ear dorsal pinna with 104 PFU vDA49, vDA49rev, 
vMC159, or vMC160 in a 10 µl volume using a Hamilton (Reno, NV) syringe and a 30-
gauge needle as described previously (6). The infected ears were examined daily for the 
next 18 days for the presence of lesions. The lesion size was measured by using a 0.01-
mm digital caliper (Neiko Tools, Homewood, IL). Lesion size was expressed as the mean 
for the group +/- SEM.  
Virus titers in tissues 
To determine virus replication during intradermal infections, mice (n = 5 per 
group) were inoculated intradermally, and ears were harvested at 3, 5, or 11 days post-
infection. Ears were flash frozen in liquid nitrogen. The ears were thawed on ice, 
weighed, and placed in 2 ml RB sample tubes (Qiagen, Valencia, CA) with 0.5 ml of 
virus medium and a sterile 7-mm stainless steel bead (Qiagen, Valencia, CA). Samples 
were subjected to two homogenization rounds at 50 Hz for 3 min using a TissueLyser LT 
(Qiagen, Valencia, CA). The lysates were serially diluted, and 0.5 ml of a dilution was 
used to inoculate BSC40 cellular monolayers in duplicate. Forty-eight hours later, viral 
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titers were detected by plaque assays. Virus titers were expressed as the amount of 
infectious virus per ear and per gram of tissue.  
 Statistical analyses 
To determine statistically significant differences between weight loss and lesion 
size during virus infection, two-way analysis of variance (ANOVA), followed by 
Tukey’s multiple comparison test, was performed. For determining the clinical scores 
during the IN model, one-way ANOVA was performed followed by Tukey’s multiple 
comparison test. To determine the plaque size differences between the viruses, one-way 
ANOVA was performed followed by Tukey’s multiple comparison test. For viral 
replication in the ear pinnae, the nonparametric Kruskal-Wallis test, followed by Dunn’s 
multiple-comparison test, was used to determine the statistically significant differences 
between vDA49, vDA49rev and vMC159. All analyses were executed using GraphPad 
(La Jolla, CA) Prism software. 
 
3.3 Results 
MCV genes are stably inserted into and expressed by a surrogate vaccinia virus  
 MC159 and MC160 each antagonize TNF-induced NF-kB activation (4, 26, 27, 
29). These functions were identified independent of MCV infection because MCV cannot 
be propagated in cultured cells (8, 33). As a first step towards assessing the biological 
relevance of MC159 and MC160 during infection, our strategy was to stably insert the 
MC159L or MC160L gene into the genome of a poxvirus (vDA49) that is (i) attenuated in 
vivo and (ii) devoid of one of its NF-kB inhibitors (e.g., A49). Then, the relative 
virulence of the MC159- or MC160-expressing viruses then could be compared to their 
	 120	
parental virus. One expectation was that one or both MCV proteins would functionally 
substitute for A49 during infection, as would be evidenced by a gain in virulence. 
 vDA49 was the parental virus used for these experiments (24)(Fig. 3.1A). Each 
MCV gene was stably inserted into the mutated A49R locus of vaccinia virus (Fig. 3.1B). 
Note that the 362 bp amplicon from vDA49-infected cells increased in size to 1,173 bp 
and 1,562 bp, reflecting insertion of the 723 bp and 1,113 bp MC159L and MC160L 
inserts, respectively. The MC159L and MC160L promoters are predicted to be early 
promoters based on their similarity to the early gene promoters for vaccinia virus (32). 
We chose to use the synthetic p7.5 promoter for expression of MC159L and MC160L 
instead of their natural promoters to ensure that MCV genes would be expressed 
throughout VACV infection. MC159 is a 31-kDa protein and MC160 is a 55-kDa protein 
(34), and each protein was detected as early as 2 h pi and remained detectable at 24 h pi 
(Figure 3.2). The VACV E3 protein, an early protein, was detected throughout infection, 
as predicted. 
Addition of MCV genes does not alter virus replication in vitro 
 It was important to establish that the insertion of MC159L or MC160L did not 
alter virus replication because an increase or decrease in virus replication in vitro may 
affect virus virulence in vivo. Virus replication was characterized in mouse embryonic 
fibroblasts (MEFs) (Fig. 3.3). MEFs were infected with a high MOI (10 PFU/cell) to 
examine virus replication during a one-step growth curve or a low MOI (0.01 PFU/cell) 
to examine virus replication and spread during a multi-step growth curve.  Cell-
associated (intracellular mature virions) or cell-free viruses (extracellular virions) were 
quantified by using plaque assays (Fig. 3.3). vMC159 and vMC160 replicated to the same 
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levels as vDA49 using either one-step (Fig. 3.3A and 3.3B) or multi-step (Fig. 3.3C and 
3.3D) growth curve assays. We also observed that vDA49 replicated to the same levels as 
wild-type vaccinia virus (vA49), similar to data from Mansur et al (24). A revertant virus 
(vDA49rev) in which the A49R gene was stably inserted into vDA49, was also tested. 
This virus is genetically identical to wild-type VACV. As expected, this virus had growth 
properties similar to vA49 (Fig. 3.3) (24). In summary, neither MC159L nor MC160L 
alters virus replication or cell-to-cell spread in MEFs. Furthermore, the presence of the 
MC159L or MC160L genes did not alter plaque sizes in infected monolayers of MEFs 
and BSC40 after 72 h or 48 h, respectively (Fig. 3.3E).  
Huttman et al. inserted the MC159L gene into a mutant murine cytomegalovirus 
(MCMV) that lacks an NF-kB antagonist, and show that MC159 inhibits NF-kB 
activation in infected murine cell lines (22). Unfortunately, a similar experiment could 
not be performed with vMC159 or vMC160. This is because VACV expresses at least 9 
other NF-kB antagonists, some of which act upstream of MC159 and MC160 (36). Thus, 
vDA49 infection alone would inhibit NF-kB activation, leaving it impossible to detect 
NF-kB inhibitory effects of MC159 or MC160 during infection.  
 
The effect of MCV MC159L or MC160L genes on virus virulence in an intranasal 
mouse model of infection 
For wild-type vaccinia virus (vA49), intranasal (IN) inoculation allows 
examination of virus virulence in a system where virus initially infects the lungs and then 
spreads to the brain and other distal organs (2, 30). In the IN infection system, signs of 
illness are examined daily and quantified based on a 5-point scoring system that routinely 
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determines the extent of sickness caused by a poxvirus (1, 3). We used this same system 
to quantify virulence of vMC159 and vMC160 relative to vDA49 (Fig. 3.4). As expected, 
PBS-inoculated mice showed no signs of illness at any time point. Inoculation of mice 
with 5 x 103 PFU wild-type VACV (vDA49rev), which is genetically identical to wild-
type vaccinia virus WR, triggered clinical signs of illness similar to results reported by 
Mansur et al (24) (Fig. 4A), with clinical scores rising from days 3-8 post-infection, and 
then decreasing until day 14 post-infection. In vDA49-infected mice there was a delay 
before illness onset in agreement with Mansur et al (24). Clinical scores for vDA49-
infected mice were consistently lower than vDA49rev-infected mice and these differences 
were statistically significant on days 7-13 post-infection (Fig. 3.4A).  
vMC159 infection appeared to decrease virulence; the clinical scores from 
vMC159-infected mice were lower than vDA49-infected mice from days 8 -12 post-
infection, and these differences were statistically significant (Fig. 3.4A). We observed 
that mice infected with vMC160 had increased signs of illness (Fig. 3.4A). However, 
clinical scores for vMC160- vs. vDA49-infected mice were not significantly different at 
any time examined (Fig. 3.4A). These data suggest that the MC159L gene reduced the 
virulence of vDA49 while MC160L partially substituted for A49L.  
Weight loss is an additional measure of virus virulence (46). Wild-type VACV 
(vDA49rev) infection caused weight loss similar to that observed by Mansur et al (24) 
(Fig. 3.4B). In contrast, vDA49-infected mice lost less weight than vDA49rev-infected 
mice as expected (24), and these differences were statistically significant on days 8-12 pi. 
Neither vMC159 nor vMC160 increased weight loss as compared to vDA49 (Fig. 3.4B). 
Instead, vMC159 caused less weight loss than vDA49 at days 8-15 post-infection 
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although these differences in weight were not statistically significant. Overall, these data 
suggested that MC159 decreased virus virulence to a greater extent than vMC160 in the 
IN infection model.  
 
The MCV MC159L gene reduces virus virulence in an intradermal mouse model of 
infection 
The intradermal (ID) inoculation of a mouse ear pinna provides an alternative 
model to examine vaccinia virus virulence (23, 42). In this case, lesion formation and 
lesion size is used to quantify virulence (41). Unlike the IN route of infection, ID 
inoculation largely is localized (42). Thus, there are no generalized clinical signs of 
illness like those observed during IN infections (e.g., weight loss or fur ruffling) and little 
to no virus detection in distal organs (13, 42). We also utilized this model to investigate 
the differences of vMC159 and vMC160 compared to vDA49. 
For all virus infections, no lesions were visually detected for the first six days 
post-infection, a routine observation (6) (Fig. 5). Gross lesions were observed in 
vDA49rev-infected mice starting on day 7 pi, and lesion size increased until day 12, and 
then resolved from days 13-18 (Fig. 3.5A).  vDA49-induced lesion sizes were slightly 
smaller than vDA49rev at all times examined, but these differences were not statistically 
significant as previously reported by Mansur et al (24). vMC160-associated lesions were 
similar in size to lesions produced by vDA49rev or vDA49 infection. Surprisingly, 
vMC159 inoculation did not produce a lesion at any point in time (Fig. 3.5A and 3.5B). 




vMC159 replication during ID inoculation 
Up to this point, the most striking results observed were those for the ID model of 
infection, and that there was a complete lack of lesion formation during vMC159 
infection. There are only 2 other VACV constructs  that do not cause lesion formation in 
skin: vDA36R and NYVAC (40, 41). In both cases, the lack of lesion development 
correlated with a lack of virus replication (40, 41).  Titers were examined at 3, 5 and 11 
days post-infection to test if this was also the case for vMC159. Maximum VACV 
replication occurs at day 5 post-infection, and we chose these time points to detect virus 
replication prior to and after maximal replication (42). vMC160 titers were not examined 
because vMC160-induced ear lesions were similar to those for vDA49 and vDA49rev, 
and it was assumed that the titers would be comparable.  
Data are shown in Figure 6 as both PFU per ear (Fig. 3.6A) and PFU per gram of 
tissue (Fig. 3.6B). Viral titers are also shown in Table 1. The starting inoculum was 104 
PFU in each ear pinna. All viruses replicated in ear pinnae because virus titers were 
higher than 104 PFU on days 3 and 5 pi. However, vMC159 titers were lower than the 
wild-type (vA49rev) or parental (vDAA49) viruses at all times tested. vDA49 and 
vDA49rev titers increased to approximately 1.3 x106 by day 3 post-infection (Fig. 3.6A 
and Table 3.1). In contrast, vMC159 titers were 1.2 x 105 PFU at day 3 post-infection. All 
viruses continued to replicate during the next 48 hours because titers increased between 3 
and 5 days post-infection (Fig. 3.6A and Table 3.1). By day 11 pi, virus replication had 




This is the first report that examines MCV immune antagonists in the context of 
an animal infection. MC159 and MC160 are members of the FLIP family of proteins 
(33). Their DEDs share 43% similarity and they share some biological features, including 
inhibition of NF-kB (4). MC159 and MC160 are functional homologs of VACV A49 -- 
all three proteins inhibit NF-kB activation (24, 26, 27, 29)– but MC159 and MC160 share 
no sequence homology to A49. vDA49 is attenuated in the IN model of infection (24). 
Our initial premise was that either MC159 or MC160 expression would restore vDA49 
virulence. However, only vMC160 showed a slight increase in virulence as compared to 
vDA49 in the IN route of infection. vMC159 acted oppositely of what was predicted; 
vMC159 was less virulent in IN infections. Moving on to the ID model of infection, 
MC159 prevented disease while MC160 had no impact on lesion formation. These data 
show that MC159 and MC160, while possessing overlapping functions in vitro, likely 
have distinct roles during MCV infection in vivo. 
The ID model of VACV infection an attractive platform to learn more about 
MCV-host interactions for several reasons. First, ID inoculations most closely represent 
the location of natural, dermatotropic MCV infections. Second, some of the immune 
components that control VACV-induced lesion size are known, including IL-10 (11), 
CXCR3 (20) and type I IFN-producing CD11b+Ly6C+Ly6G+ monocytes (16). We and 
others also characterized the expression of multiple host immune genes during VACV 
infection ID (6, 20). Thus, we can use this knowledge to identify how MC159 prevents 
lesion formation. Third, there are some parallels in the immune responses to ID VACV 
infections and MCV infections. For example, type I IFN appears to be important in 
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controlling lesion size in VACV-infected ears (16) and lesion resolution during MCV 
infections (44).  Thus, we argue that continued study of VACVs lacking or containing 
MCV genes can provide new insights into MCV pathogenesis.  
Perhaps the most striking result here is the lack of lesion formation during 
vMC159 infection ID. One could make an argument that no lesions arise because 
vMC159 titers are lower in ear pinnae. However, this seems unlikely because Tscharke et 
al. show that as little as 102 PFU of VACV induces ear lesions formation (41), and 
vMC159 titers greatly exceed that amount at days 3 and 5 post-infection. So, what may 
be the mechanism for this suppression of lesion formation? It is appreciated that VACV 
lesions are due, in part, to immunopathology because smaller lesions are associated with 
decreases in expression of multiple cytokines and chemokines (6, 38). Thus, MC159 may 
either directly or indirectly prevent expression of these host cell proteins to halt pro-
inflammatory processes. In this case, the MC159 ability to inhibit NF-kB and IRF3 
activation may be relevant. MC159 inhibits apoptosis while MC160 does not (34, 35). 
Another speculation, then, is that this anti-apoptosis property of MC159 affords virus 
attenuation, perhaps by allowing virus-infected cells to survive for prolonger time 
periods. Interestingly, a mutant VACV lacking an apoptosis antagonist (DB13R) has an 
increased lesion size as compared to wild-type VACV (41), showing an instance where 
inhibition of apoptosis diminishes lesion formation.  
Only two other VACVs do not induce lesion formation in ID models of infection: 
DA36R and NYVAC (28, 40). DA36R is a WR-based VACV that lacks the A36R gene 
(41). This virus cannot spread efficiently from cell-to-cell in vitro. NYVAC is highly 
attenuated and its parental virus is VACV strain Copenhagen (40). Like DA36R, NYVAC 
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cannot spread efficiently from cell-to-cell in human cell lines (40).  It is thought that 
DA36R or NYVAC do not cause lesions because they cannot spread to neighboring cells, 
resulting in an abortive infection process (28). In contrast, vMC159 replicates both in 
vitro and in vivo. This suggests that vMC159 decouples replication from lesion 
formation. Interestingly, both DA36R and NYVAC elicit protective immune responses 
(e.g., antibody production) (39, 41). Thus, it is tempting to ask if vMC159 also retains its 
immunogenicity and, if so, if vMC159 would be useful for the vaccine field. 
 To date, there is no cell culture system or laboratory animal model to study MCV 
replication and pathogenesis. Researchers have used creative approaches to extrapolate 
the biological importance of MC159 as an immune evasion molecule. This includes the 
development of transgenic mouse strains that express MC159 (47, 48) or using murine 
cytomegalovirus (22) lacking functional homologs of MC159 as a surrogate virus (22). 
Our system uses VACV during ID mouse infections, and is perhaps the model closest to 
mimicking MCV infection at this current time. One could argue that the addition of 
MC159 to vDA49 resulted in a disease that mimics MC because, like MC, there is little 
inflammation. One future direction is to determine if vMC159, like MCV, persists in ears 
for lengthy time periods or eventually forms neoplastic lesions that are similar to MC.  
MC160 did not alter lesion formation and it is not clear what purpose MC160 may 
serve during an ID infection. In retrospect, it is not surprising that each protein affected 
viral pathogenesis in a distinct manner because, while MC159 and MC160 each possess 
tandem DEDs, each protein has distinct molecular features for controlling NF-kB 
activation (33, 49). Regardless, these data show that the functions of MC159 and MC160 
are complex and non-redundant in vivo. VACV itself expresses at least 10 different NF-
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kB inhibitory proteins, and it is thought that each protein is important for overcoming 
tissue- or cell-specific immunity. Perhaps MCV also expresses MC159 and MC160 for 
similar reasons when confronting a complex, multi-faceted anti-viral immune response. 
The current studies demonstrate the biological effects of two MCV immune 
evasion proteins in a newly-created system.  MCV encodes at least 40 other known or 
predicted immune evasion molecules (31, 32). Thus, studies of MCV immune evasion 
molecules provides a rich opportunity to identify novel aspects of virus-host interactions 
during persistent infections.  The surrogate system described here now affords these types 




















Figure 3.1 Construction of vaccinia viruses expressing either MC159 or MC160.  (A) 
A schematic of the viruses used in this study, focusing on the portion of the vaccinia 
virus WR genome (vA49 or vA49rev) containing the A49R gene and the regions flanking 
the A49R gene. DA49 is a construct in which A49R nucleotides 113-473 are deleted. 
Either the MCV MC159L or the MC160L genes, each under the control of the vaccinia 
virus P7.5 promoter, were inserted into the DA49 genome to create vMC159 or vMC160 
respectively. (B) PCR analysis of genomes isolated from virus-infected cells. BSC40 
cells were infected with the indicated viruses. After 24 h, cells were lysed and genomic 
DNA was isolated. DNA was PCR amplified using primers targeting regions in the A48R 
and A50R genes. A portion of each PCR reaction was analyzed by gel electrophoresis. 
Bands were detected by ethidium bromide staining of the gel.  
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Figure 3.2 MC159 and MC160 protein expression in vaccinia virus. BSC40 
monolayer cells in 6-well plate were either mock infected or with vDA49, vMC159 or 
vMC160 (MOI = 10). At 2, 4, 12 and 24 h post-infection, cells were collected and lysed, 
and lysates were analyzed by SDS-10%PAGE.  Proteins were transferred to PVDF 
membranes and membranes were incubated with polyclonal antiserum against the 
















Figure 3.3 Growth kinetics and plaque sizes of viruses expressing MCV genes.  
MEFs were infected at an MOI of (A and B) 10 PFU/cell or (C and D) 0.01 PFU/cell. At 
the times indicated post-infection, (A and C) infected cells and (B and D) respective cell-
free supernatants were collected. Viruses in each sample were quantified by inoculating 
BS40 cellular monolayers and using crystal violet staining. The data are expressed as the 
mean titer per sample. The dashed lines represent limits of detection only for Figure 1D 
because no viruses were detectable at the zero-hour time point. (E) MEF or BSC40 
cellular monolayers were infected with vA49, vDA49, vMC159, vMC160 or vDA49rev at 
an MOI of 50 PFU/cell. At 48 h (BSC40) or 72 h (MEF) p.i. cells were washed with PBS, 
stained with crystal violet and plaque size was measured. The diameters of at least 6-8 
plaques were measured per condition and results represented as the mean plaque size ± 




Figure 3.4 The effect of MCV genes on virus virulence using the intranasal route of 
infection. Female BALB/c mice (n = 5 per group) were inoculated intranasally with 5 X 
103 PFU vDA49, vDA49rev, vMC159, or vMC160 or PBS. (A) Clinical signs of illness 
were monitored daily for 15 days and scored from 0-5. (B) Mice were weighed daily, and 
data were expressed as the percentage of weight loss from day 0. Statistical significance 
was determined by two-way ANOVA. (A) Asterisks indicate the days on which clinical 
signs of illness induced by vDA49 were significantly different from those induced by 
vMC159 (**P < 0.005) or vDA49rev (**** P < 0.0001). (B) Asterisks indicate the days 
on which weight loss induced by vDA49 were significantly different from those induced 





Figure 3.5 The effect of MCV genes on virus virulence using the intradermal route 
of inoculation. C57BL/6 mice (n = 5 per group) were infected intradermally with 104 
PFU vDA49, vDA49rev, vMC159, or vMC160 in the left ear pinna. (A) Sizes of resulting 
lesions were measured daily for 18 days. The data are expressed as the means of lesion 
sizes ±SEM. Statistical significance was determined by two-way ANOVA. The asterisks 
indicate the days on which the lesion size caused by vMC159 was statistically 
significantly different from that caused either by vΔA49 or vΔA49rev (P £ 0.0001). (B) 
Representative images of inoculated ear pinnae at 10 days post-infection vDA49-infected 







Figure 3.6 Virus replication in ear pinnae of intradermally inoculated mice. 
C57BL/6 mice (n = 5 per group) were infected with 104 PFU of vDA49, vDA49rev, or 
vMC159 in the left ear pinna. At the indicated days p.i., ears were collected, 
homogenized, and lysed, and viral titers of the lysates were determined by plaque assay. 
Each symbol represents the virus titer from an individual animal, and the mean titer is 
indicated by a line. Data are expressed as the mean titer of virus (PFU) per gram of tissue 
(B) and as the total PFU per ear (A). Statistical significance was determined by Kruskal-
Wallis test. The asterisk indicate data points at which titers of viruses were statistically 























































vDA49 3 1.3 X 106 1.8 X 107 
vDA49 5 5.9 X 106 1.1 X 108 
vDA49 11 7.6 X 104 1.1 X 106 
vMC159 3 1.2 X 105 1.8 X 106 
vMC159 5 5.6 X 105 1.2 X 107 
vMC159 11 0.8 X 103 1.3 X 104 
vDA49rev 3 1.3 X 106 1.8 X 107 
vDA49rev 5 7.6 X 106 1.2 X 108 
vDA49rev 11 3.8 X 104 5.7 X 105 
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Chapter 4: Molluscum contagiosum virus MC159 inhibits genotoxic induced  
NF-kB activation 
4.1 Introduction 
Great advances have been made in the understanding of NF-kB signaling 
networks induced by inflammatory and immune cells (Chapters 1 and 2). Decades of 
research has revealed that external stimuli (e.g., TNF) trigger a signal transduction events 
that results in NF-kB dimers becoming active and translocating from the cytoplasm to 
nucleus to modulate gene expression and biological responses (1, 16). Recent studies 
have revealed that NF-kB also respond to DNA damaging (genotoxic) agents that cause 
damage to nuclear DNA (1, 11, 16). Unlike membrane receptor-initiated signaling 
pathways, genotoxic agent-induced NF-kB activation is incompletely understood. This is 
because many genotoxic agents induce DNA damage in the nucleus as well as cellular 
stress (e.g., oxidative stress) outside the nucleus (16). Hence, efforts are made to dissect 
both the mechanisms of activation of NF-kB induced by genotoxic agents. My 
preliminary data on MCV encoded MC159 and MC160 suggests that MCV proteins have 
an inhibitory effect on genotoxic stress induced-NF-kB which is the focus of this chapter. 
During genotoxic stress, a eukaryotic cell mounts an orchestrated and conserved 
signaling response, collectively referred to as the DNA damage response (DDR).  The 
DDR involves DNA damage repair mechanisms, cell cycle checkpoints, and 
transcriptional responses to facilitate overall cellular responses to genomic damage. Like 
the membrane receptor-signaling pathway (e.g., TNF-induced NF-kB activation)(6, 8), 
most DNA damaging agents also act through activation of the IKK complex to engage 
the NF-kB pathway (Fig. 4.1)(1, 10, 16). Activation of the classical NF-kB pathway is 
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rapid and robust. However, DNA damage-inducing agents result in delayed NF-kB 
activation and occurs in the nucleus. This delay is resultant of the time required to induce 
DNA damage in the nucleus and relay the damage to the cytoplasmic IKK complex. 
Studies have shown that nuclear kinase ataxia telangiectasia mutated (ATM) is critical for 
IKK activation as it serves as a DNA damage sensor (11, 14, 15). Thus, while the 
initiation signaling events of NF-kB activation are completely different between 
genotoxic stress and TNF signaling, both converge at IKK complex activation (14) (11). 
During the DDR, NEMO undergoes a series of post-translational modifications in the 
nucleus. First, PIASy (Protein inhibitor of activated STATy)-catalyzed (15), PIDD (p53-
inducible death domain)-assisted (12) NEMO undergoes SUMO-1 conjugation at Lys 
277 and 309. Second, phosphorylation occurs at ser-85 by ATM (26). Finally, 
monoubiquitination by cIAP1 displaces SUMO-1 attachment on NEMO(13). This 
ubiquitinated NEMO, along with ATM and ELKS (a protein rich in glutamate, leucine, 
lysine and serine) (27), is exported from the nucleus to form a complex with IKK 
catalytic subunits to activate the IKK complex.   
Data from my studies show that MC159 inhibits NF-kB activation by 
competitively inhibiting cIAP1 mediated polyubiquitination of NEMO (Chapter 2)(2). 
MC159 binds to NEMO on the N-terminus (1-250 aa) which is the site for ATM binding 
and phosphorylation(2). Additionally, MC159 is also found to be sequestered in the 
nucleus, the site for genotoxic-induced NF-kB activation. All these preliminary data 
suggest a role for MC159 inhibiting DNA damage-induced NF-kB activation. Thus, the 
function of MC159 on genotoxic-induced NF-kB activation remains a subject of 
investigation in our lab. Determining whether MC159 has an inhibitory role during 
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genotoxic stress is the focus of this chapter. Although the entire mechanistic details of 
this function of MC159 could not be elucidated, this chapter describes the approach and 
tools designed to study MC159’s inhibitory role during genotoxic damage. To our 
knowledge, this is the first preliminary report of a poxvirus showing an inhibitory effect 
on NF-kB activation mediated by DNA damage. 
4.2 Materials and Methods 
Cell and plasmids  
Human embryonic kidney 293T (293T) cells were obtained from the American 
Type Culture Collection (ATCC). Cells were cultured in Eagle’s minimal essential media 
supplemented with 10% FBS and 2mM L-glutamine. 
 Plasmids encoding the MCV MC159 gene (pMC159) or an HA epitope tagged 
MC159 gene (pMC159-HA) were described previously(2, 18, 22). pMC159ΔA lacks 
DEDA while pMC159ΔB lacks DEDB but both contain the C-terminus (Fig. 4.2)(18). 
The creation of the three remaining HA-tagged constructs (MC159A-HA, MC159B-HA 
and MC159C-HA) are described in the next section. Briefly, MC159 express only 
DEDA, MC159B expresses only DEDB and MC159C expresses the C-terminus of 
MC159. Plasmid encoding the MCV MC160 gene (pMC160) and its various mutants 
pMC160D1, pMC160D2, pMC160F, pMC160C were also previously described. A 
plasmid encoding a dominant negative IkBa (DN), whose serine residues at 32 and 36 
are mutated to alanine, was used as negative control for same assays(20). Plasmid pK1L, 
pM2L, and pM1L consists of epitope tagged K1L, M2L and M1L gene, respectively (4, 7, 
9, 19), inserted into the pCI vector. Plasmid pNF-kBluc encodes the firefly luciferase 
gene under the control of a synthetic NF-kB promoter (Promega). Plasmid pRL-null 
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(Promega) expresses constitutively low levels of sea pansy luciferase and is used to 
determine the efficiency of transfection. All plasmids were transfected into cells using 
Fugene 6 transfection reagent (Promega), following manufacturer’s protocol. 
 
Plasmid construction 
To determine the importance of MC159 DEDs and C-terminus for NF-kB 
inhibitory function during genotoxic stress, three new mutants were created; pMC159A 
(encodes MC159 DEDA region amino acids 7-81), pMC159 B (encodes MC159 DEDB 
region comprising amino acids 95-179) and pMC159C (encodes C-terminal region 
comprising of amino acids 180-241).  
MC159A was constructed by PCR amplifying MC159L nucleotides 21-243, and 
the HA epitope tag was engineered onto the N-terminus of the gene via PCR 
amplification. For this reaction, the MC159A forward primer (5’-
CACAGGAATTCGCCACCATGGAATATCCATATGATGTTCCAGATTATGCTGTC
CCTAGCCTTCCATTTTTGCGACAC-3’) and the reverse MC159A primer (5’-
ATATAATGCGGCCGCTCACTTGCTGA GCCCGAAGCGGCTCT TGAGAAG-3’) 
was used. For MC159B a similar approach was used. The HA tag was introduced onto 
the N-terminus. The forward primer and reverse primers used in this case were (5’-
GTTTGGAATTCGCCACCATGGAATATC CATATGATGTTCCAGATTATGC 
TCGCTACCGCAAGCTCATGGTTTG-3’) and (5’-GTCAGTAATGGCCGCTCATTGT 
TCGTACTCAACA AGCTGCTG-3’). To create MC159C, a portion of the MC159-HA 
plasmid was PCR amplified because the HA epitope tag was already present in the C-
terminus of the pMC159-HA plasmid. The forward primer used was (5’-
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TAAAAGGAATTCGCCACCATGG AACAAGA GCAAGCCAGGTACCGTTAC-3’). 
The reverse primer used was 5’-ATATAATGCGGCCGCTCATGCGTAGTCTGGTA 
CGTCATATGGGTA-3’. In all cases, PCR products and pCI plasmid were incubated 
with EcoRI-HF and NotI-HF (underlined) restriction enzymes (New England BioLabs) at 
37 °C for 15-20 mins. Digested products were analyzed by electrophoresis and purified 
using the QIAquick Gel Extraction Kit (Qiagen). Purified cut PCR products and vector 
plasmid (pCI) were ligated in 1:3 ratio using T4 DNA ligase (New England BioLabs) at 
room temperature for 20 min. Insertion of gene of interest into the pCI vector was 
confirmed by double digestion with EcoRI-HF and NotI-HF as well as confirmed by 
sequencing. 
To analyze the expression of mutants, subconfluent cellular monolayers of 293T 
cells in 6-well plates were transfected with 1000 ng of pCI, pMC159-HA, pMC159A-
HA, pMC159B-HA or pMC159C-HA. At 24 h post-transfection, cells were scraped and 
centrifuged (14,000 X g for 1 min) and the cellular pellet was lysed in CE buffer (10mM 
HEPES, 10mM KCl, 0.1mM EDTA pH 8.0, 0.1 mM EGTA pH 8.0, 0.05% NP-40), 
supplemented with 1X Halt, 10mM NaF and 1mM NaVO4. Clarified supernatants were 
removed to a fresh tube. The protein concentration of each lysate was determined by 
BCA assay. 15 µg of cytoplasmically-extracted protein from each sample was evaluated 
for protein expression by using immunoblotting in which immunoblots were incubated 
with mouse anti-HA antibody (1:10,000; Sigma). Blots were re-probed with anti-b actin 




Luciferase reporter assays  
The dual luciferase reporter assay was performed to quantify TNF- or VP16-
induced NF-kB activation. 293T cells were co-transfected with 225 ng of pNF-κBluc and 
25 ng of pRL-null. Additionally, these cells were co-transfected with 750 ng of pCI, 
pMC159, pMC159ΔA, pMC159ΔB, pMC159A, pMC159B, pMC159C, pMC160, 
pMC160D1, pMC160D2, pMC160F, pMC160C or pIκBαDN. FuGene 6 was used to 
transfect cells. At 24 h post-transfection, fresh medium lacking or containing either TNF 
(10 ng/ml)  or VP16 (10 µM) was added to each well of the 12-well plates. After 12 h, 
cells were lysed with Passive Lysis buffer (PLB). Luciferase activity was measured as 
relative light units by using luminometer and lysates were analyzed as mentioned 
previously(4). Student’s t-test was performed to identify statistically significant 
differences in luciferase activities. Lysates from these luciferase assays were also tested 
by immunoblotting.  
Cytoplasmic and nuclear fractionations 
1 x 106 293T cells were transfected with 1000 ng of either pCI, pMC159, 
pMC160, pMC159DA, pMC159DB, pMC159A-HA, pMC159B-HA, or pMC159C-HA. 
At 24 h post-transfection, cells were collected by scraping and centrifuged (18,0000 X g 
for 5 min). Cells were suspended in 50 µl CE buffer and incubated on ice for 15 min. 
Lysates were centrifuged at 1,000 X g for 5 min and clarified supernatants were collected 
in fresh tube. The remaining pellet was washed in 200 µl of CE buffer and centrifuged 
(1000 X g for 5 min) twice. The nuclear pellet was resuspended in 30 µl of nuclear 
extract (NE) buffer (20 mM HEPES, 0.4 M NaCl, 1 mM EDTA pH 8.0, 1 mM EGTA pH 
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8.0, 25% Glycerol) and incubated on ice for 20 min with frequent vortexing(4). Samples 
were centrifuged at 18,000 X g for 10 min. Nuclear supernatants were collected and 
stored at -80 °C. Both cytoplasmic and nuclear extracts were assessed by immunoblotting 
for the following proteins: PARP (rabbit polyclonal anti-PARP-1 antibody, 1:1,000; 
Santa Cruz ), Tubulin (mouse monoclonal anti-tubulin antibody; 1:5,000; Abcam) 
MC159 (rabbit anti-MC159 antibody; 1:1,000), MC160 (rabbit anti-MC160 antibody; 
1:1,000)  and HA (mouse monoclonal anti-HA antibody; 1:10,000; Sigma). 
Immunoblotting 
For all immunoblots, the protein concentration of each lysate was determined 
using the 660 nm protein assay (Pierce). Approximately 15-20 µg of protein from each 
sample was subjected to 16% SDS-PAGE. The proteins were electrophoretically 
transferred to a PVDF membrane (Millipore). The membranes were incubated in TBST 
containing 5%-non-fat milk, for at least 30 minutes. Membranes were incubated with the 
indicated primary antibodies overnight at 4°C. Next, membranes were washed with large 
volumes of TBST and incubated with appropriate HRP-conjugated secondary antibodies. 
Immunoblots were developed by using chemiluminiscence reagents (Thermo Scientific) 
and autoradiography. Primary antibodies used in these experiments were rabbit 
polyclonal anti-PARP-1 antibody (1:1,000; Santa Cruz), mouse monoclonal anti-b-
tubulin antibody (1:5,000; Abcam), rabbit anti-MC159 antibody (1:1,000), MC160 
(rabbit anti-MC160 antibody; 1:1,000)  and mouse monoclonal anti-HA antibody 
(1:10,000; Sigma). Secondary HRP-conjugated antibodies were obtained from either 




MC159 inhibits VP16 mediated NF-kB activation 
Previous work from our lab shows that MC159 inhibits TNF-mediated NF-kB 
activation (2, 18). I also noticed that a portion of the MC159 population localized to the 
cellular nucleus (data not shown).  Since MC159 was present in the nucleus, I was 
curious to study if MC159 antagonized genotoxic stress-mediated NF-kB activation, an 
event whose signaling originates in the nucleus (Fig. 4.1). To test my hypothesis, I first 
performed multiple experiments to optimize the conditions for testing the effect of 
MC159 during VP16-induced NF-kB activation (Fig. 4.3). I chose VP16 (etoposide) 
because it is an agent that is known to induce double-stranded DNA breaks (DSB) to 
trigger NF-kB activation (27). Results are shown in Figure 4.3. The maximal amount of 
VP16-induced NF-kB activation occurred at 12 h post-treatment, and MC159 inhibited 
NF-kB activation at 12 and 14 h post-treatment. Figure 4.3B showed that 5 or 10 µM of 
VP16 gave the highest induction of luciferase activity, and MC159 inhibited luciferase 
activities significantly at both of these VP16 concentrations.   Figure 4.3C shows that 
250-1000 ng pMC159 could inhibit VP16-induced NF-kB activation at similar amounts. 
Thus, moving forward, I chose to use a 10 µM concentration of VP16 for 12 h treatment 
using 750 ng of MC159.  
MC159 belongs to a family of proteins known as FLIP proteins(21).  They all 
have tandem death effector domains (DEDs). I then tested if other FLIP proteins had any 
effect on VP16-mediated NF-kB activation. To test this hypothesis, I performed a 
luciferase assay where all FLIP proteins were expressed ectopically. Surprisingly, only 
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MCV encoded proteins (MC159 and MC160) inhibited VP16-induced NF-kB activation 
(Fig. 4.5A). The K13 and cellular FLIP proteins did not have any inhibitory function on 
VP16-induced NF-kB activation. Thus, although FLIP proteins are very similar (21), 
only MCV encoded proteins inhibited VP16-mediated NF-kB activation (Fig. 4.5A).  
MC159 is known to inhibit TNF-induced NF-kB activation (2, 17, 18) and TNF-
induced apoptosis(22, 23). I also examined if other vaccinia virus proteins known to 
inhibit NF-kB activation (K1L, M2L) (3, 7, 9)or apoptosis (M1L)(19) inhibited VP16-
induced NF-kB activation. Figure 4.4B shows that none of the tested vaccinia viral 
proteins (M1L, M2L and K1L) inhibited VP16-mediated NF-kB activation via luciferase 
activity. Thus, in our study, only MC159 and MC160 inhibits VP16-mediated NF-kB 
activation.  
Generation of new MC159 mutants 
 The goal of this project was to identify mutant MC159 proteins that inhibited 
VP16-induced NF-kB activation. The rationale was that, if there were mutant MC159 
proteins that could inhibit VP16-induced NF-kB activation, but not TNF-induced NF-kB 
activation, then this would be strong evidence that MC159 acted in a unique manner.  
To this end, I generated MC159 mutant proteins: MC159A, MC159B and 
MC159C (Fig. 4.2). I wanted to use these because they allowed for the examination of 
individual DEDs of MC159 in isolation from the C-terminus of MC159. The predicted 
molecular weights of these mutant MC159 proteins are shown in Table 4.1. Figure 4.4 
showed that each mutant MC159 protein was expressed in 293T cells. As expected, the 
molecular weights of MC159A and MC159B were ~10 kDa each. Interestingly, the 
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molecular weight for MC159C (which was expected to be 8.1 kDa) had a mobility of ~15 
kDa. The significant difference in molecular weight could be due to post-translational 
modifications. Regardless, the next goal was to use these proteins to (i) determine their 
cellular localization and (ii) test their ability to inhibit NF-kB activation during VP16- or 
TNF-induced NF-kB activation. 
MC159 translocates to the nucleus independent of stimulation   
I observed that a portion of the wild-type MC159 protein population was present 
in the nuclei of unstimulated cells (Fig. 4.4A). This is despite the fact that MC159 lacks a 
nuclear localization sequence (NLS). Unlike MC159, the homologous MC160 protein 
was detected only in the cytoplasm of transfected cells (Fig. 4.4A). Thus, this property of 
locating to the nucleus appears to be unique to MC159.  
Next, the subcellular location of mutant MC159 proteins was also investigated. 
Like MC159, MC159DA localized to the cytoplasm as well as the nucleus (Fig. 4.3A and 
B). In contrast, MC159DB was present only in the cytoplasm (Fig. 4.4 and B). These data 
suggested that the DEDB was critical for the nuclear translocation of MC159. To further 
confirm this, I found that, while MC159A, MC159B and MC159C were each detected in 
the cytoplasm (Fig 4.3B), only the MC159B mutant was present in the nucleus.  Note that 
MC159 does not contain any obvious nuclear localization signals (NLS). Small molecular 
weight proteins are known to diffuse easily into the nucleus. However, the molecular 
weight of both MC159A and MC159B are similar (Table 4.1), but only MC159B 
localized to the nucleus. Thus, we suspect that the DEDB of MC159 enters the nucleus 
because it is binding to a cellular protein that has an NLS.   
	 151	
Next, I wanted to compare the effect of wild-type and mutant MC159 proteins on 
TNF- or VP16-mediated NF-kB activation. As seen previously, MC159 inhibited TNF- 
as well as VP16- mediated NF-kB activation (Fig. 4.6A and B). For VP16-induced NF-
kB activation, each mutant MC159 protein inhibited luciferase activity. However, 
MC159A and MC159C did not inhibit TNF-induced NF-kB activation (Fig. 4.6B). These 
data suggested that MC159A and MC159C have different targets of the NF-kB activation 
pathway, and thus can be used to tease the function of MC159 during genotoxic effect 
(Fig. 4.6A and B).  
A similar approach was used to test the inhibitory effect of MC160 during VP16-
mediated NF-kB activation (Fig. 4.7). Unlike MC159, we were not able to identify a 
mutant MC160 that specifically inhibited VP16-induced NF-kB activation. For example, 
MC160D1 was able to inhibit TNF-mediated NF-kB activation but had loss-of-function 
during VP16-mediated NF-kB activation. MC160F was found to be inhibitory during 
both the stimulations. Thus, due to lack of a mutant which inhibited during VP16 
treatment and has loss of function during TNF treatment, further investigation of MC160 
effect on genotoxic-stress mediated NF-kB activation using this approach is impeded.  
4.4 Discussion 
My work here showed that MC159 and MC160 inhibited genotoxic stress-induced 
NF-kB activation. To the best of my knowledge, this is the first demonstration of a 
poxviral protein inhibiting genotoxic stress-induced NF-kB activation. There are reports 
showing how viruses manipulate the DNA-damage-induced NF-kB activation for 
survival and growth. Human neurotropic polyomavirus JC (JCV) activates the nucleus to 
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cytoplasm NF-kB activation by phosphorylation and activation of ATM which leads to 
NEMO sumoylation (25). This NF-kB activation is necessary for JCV replication and 
gene expression (25). Human cytomegalovirus (HCMV) encoded IE1-72 protein is 
important for ATM-dependent phosphorylation of p53 which facilitates viral replication 
(5). Thus, perhaps MCV also utilizes one of these mechanisms to shutdown NF-kB 
activation by targeting the DNA-damage pathway and establishing its persistence. 
Here I show that MC159 and MC160 inhibited genotoxic-stress induced NF-kB 
activation. MC159 and MC160 are the only FLIP proteins that inhibited VP16-mediated 
NF-kB activation. K13 and cellular homologs of FLIP proteins (cFLIPs) did not inhibit 
VP16-mediated NF-kB activation and thus this inhibitory function is unique to MCV 
encoded proteins. When a few vaccinia viral proteins, known to inhibit TNF-mediated 
NF-kB activation (K1L, M2L) and TNF-mediated apoptosis (M1L) were tested for VP16 
mediated NF-kB activation, no inhibition was detected.  Thus, it is possible that MCV is 
unique in manipulating this genotoxic-stress induced NF-kB pathway to subvert the 
immune responses of host and develop its persistence.  Interestingly, MCV infections are 
dermatotropic whereas vaccinia virus infections are not (21).  One possibility is that 
MCV needs MC159 and MC160 to inhibit genotoxic stress induced by UV irradiation of 
skin cells from the sun. 
Here I also show the generation of new mutants of MC159 comprising of small 
domains of MC159. I show that wild-type MC159 is present in the cytoplasm as well as 
the nucleus, while MC160 is detected in the cytoplasm only. With the use of MC159 
mutants, I showed that the DEDB is sufficient and required for nuclear localization. At 
first, we can speculate that MC159B can diffuse easily into the nucleus as it is a small 
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protein. However, MC159A, a similar molecular weight protein, failed to migrate into the 
nucleus. Hence, it is possible that the DEDB domain of MC159 binds to another binding 
partner, containing NLS motif, to migrate into the nucleus. Thus, the exact mechanism 
how DEDB domain of MC159 facilitates nuclear localization remains the subject of 
future investigation.  
With the help of MC159 mutants, we observe different phenotypes when cells 
were stimulated with TNF and VP16. Since there is much cross-talk between the 
signaling pathways leading to NF-kB activation (16), it is important to have functionally 
different mutants to tease apart the signaling mechanisms. MC159A and MC159C are 
two new important MC159 mutants because they inhibited VP16-mediated NF-kB 
activation whereas, had loss of function when treated with TNF. Thus, with the help of 
these mutants, we can perform functional assays to determine which key signaling events 
are modulated by MC159 during genotoxic stress-induced NF-kB activation. Although 
MC159B (containing DEDB) was shown to be critical for nuclear translocation, it 
showed inhibitory effects when treated with both TNF and VP16. Hence, it is possible 
that DEDB is the sufficient domain required for NF-kB inhibition during TNF- and 
genotoxic-induced stress signaling. Thus, this opens a whole area of investigation to 






4.5 Figures and Tables 
 
Figure 4.1 Schematic representation of NF-kB activation triggered by TNF 
(extrinsic stress) or VP16 (genotoxic stress). During TNF-induced NF-kB activation, a 
series of signaling events occur in the cytoplasm after TNF-TNF-R1 interactions that lead 
to IKK activation (Refer Figure 1.3). In contrast, during genotoxic stress, signaling events 
begin in the nucleus. A double-stranded break of the genes lead to activation of ATM 
which facilitates the sumoylation of NEMO by PIASy. Next, NEMO is phosphorylated at 
S85 by ATM, followed by monoubiquitination of NEMO. The monoubiquitination 
replaces the SUMO to Ub by cIAP1. This ATM-NEMO complex then migrates to the 










Figure 4.2 Schematic of MC159 mutants. The wild-type MC159 possesses two DED’s, 
DEDA (green box) and DEDB (blue box) and a C-terminus (white box). Each mutant of 
















Figure 4.3 MC159 Optimization of inhibition of VP16 mediated NF-kB activation. 
293T cells were transfected for 24 h with luciferase reporter plasmids (125 ng pNF-
kBluc, 12.5 ng pRLnull) and 1000 ng pCI or pMC159 (A and B) or increasing amounts 
of MC159 as indicated (C). Next, cells were incubated in medium lacking or containing 
VP16 (10 µM) for different times as indicated (A) or 12 h (B and C) or varying 
concentration of VP16 (B). In all conditions, results are presented as fold-induction of 
luciferase activity relative to those of untreated, pCI transfected cells. Lysates were also 
examined for MC159 protein expression. *P < 0.05, **P < 0.01 compared with control, 
pCI-transfected cells.
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Figure 4.4 MCV proteins inhibit VP16 mediated NF-kB activation. 293T cells were 
transfected for 24 h with luciferase reporter plasmids (125 ng pNF-kBluc, 12.5 ng 
pRLnull) and 1000 ng pCI, pMC159, pMC160, pK13, pcFLIPL and pcFLIPS (A) or 
1000 ng pCI, pMC159, pMC160, pK1L, pM1L and pM2L (B). Next, cells were 
incubated in media containing DMSO (Control) or VP16 (10 µM) for 12 h. Results are 
presented as fold-induction of luciferase activity relative to those of control, pCI 
transfected cells. *P < 0.05, compared with control, pCI-transfected cells.
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Figure 4.5 MC159 colocalizes in cytoplasm and nucleus. 293T cells were transfected 
for 24 h with 1000 ng pCI, pMC159, pMC159DB, pMC159DA, or pMC160 (A) or 1000 
ng pCI, pMC159, pMC159DB, pMC159DA, pMC159A, pMC159B or pMC159C (B). 
After 24 h, cells were lysed, the cytoplasmic proteins were separated from nuclear 
proteins. A portion of each extract containing cytoplasmic or nuclear proteins was probed 
with anti-b-Tubulin and anti-PARP antibodies by immunoblotting to serve as markers of 
cytoplasmic content and nuclear content, respectively. The same samples were also 
probed for the presence of wild-type or mutant MC159 or MC160 proteins by 
immunoblotting. 
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Figure 4.6 MC159A and MC159C proteins that inhibit VP16-mediated NF-kB 
activation are different from those that inhibit TNF-mediated NF-kB activation. 
293T cells were transfected for 24 h with luciferase reporter plasmids (125 ng pNF-
kBluc, 12.5 ng pRLnull) and 1000 ng pCI, MC159, MC159DB, MC159DA, MC159A, 
MC159B, MC159C, or IkBaDN. Next, cells were incubated in regular media or media 
containing DMSO [Control (C)] or VP16 (V) (10 µM) (A) or media containing 10 ng/mL 
TNF (B) for 12 h. Results are presented as fold-induction of luciferase activity relative to 
those of control, pCI transfected cells. Lysates were also examined for MC159 and its 





















Figure 4.7 MC160 mutant proteins has no loss of function during VP16/TNF 
mediated NF-kB activation. 293T cells were transfected for 24 h with luciferase 
reporter plasmids (125 ng pNF-kBluc, 12.5 ng pRLnull) and 1000 ng pCI, Mc160, 
MC160D1, MC160D2, MC160F, MC160C, or IkBaDN. Next, cells were incubated in 
regular media or media containing 10 ng/mL TNF (A) or media containing DMSO 
(Control) or VP16 (10 µM) (B) for 12 h. Results are presented as fold-induction of 









Table 4.1 The number of base pairs, amino acids, expected and observed molecular 
vaccinia weights of wild type and mutants of MC159. 
 
The conversion from amino acids to kDa was done by using the information from 
Promega Plasmid and Protein Quantification that 333 amino acids of coding capacity 













Mutants Base pair 
number 








723 241 25 31 
MC159-HA 756 252 28 35 
MC159A-HA 272 75 9.5 ~10 
MC159B-HA 300 85 10.5 ~10 
MC159C-HA 225 62 8.1 ~15 
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MC159  Inhibits Inhibits Yes Yes 
MC159DB Inhibits Inhibits Yes No 
MC159DA Inhibits Inhibits Yes Yes 
MC159A Does not 
inhibit 
Inhibits Yes No 
MC159B Inhibits Inhibits Yes Yes 
MC159C Does not 
inhibit 
Inhibits Yes No 
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Chapter 5: Summary and Future Directions 
5.1 Summary 
This thesis project describes several novel findings about the functions of MCV 
MC159 protein in vitro and in vivo. Our lab has previously published that MC159 could 
inhibit TNF-mediated apoptosis and NF-kB activation (4, 6, 9). MC159 is shown to bind 
to NEMO to prevent IKK activation and NF-kB pathway(6). All these studies were 
performed by expressing MC159 independent of infection as there is no culture system to 
propagate MCV nor an animal model(8). Here, I discovered a novel mechanism by which 
MC159 antagonizes the NF-kB signaling pathway(1). Also, I developed a novel 
surrogate virus system to study the functions of MC159 in two animal models of 
infection.  
The MC159 protein is known to inhibit NF-kB activation by binding to NEMO of 
the IKK complex(6). This MC159-NEMO interaction does not disrupt the complex (6). 
NEMO undergoes various post-translational modifications to activate the IKK 
complex(3, 7). I hypothesized that binding of MC159 to NEMO prevents some critical 
post-translational modification of NEMO like polyubiquitination. cIAP1 is an E3 ligase 
required for polyubiquitination of NEMO that results in IKK activation (2). With 
mutational analyses, I found that MC159 binds to N-terminus (1-250aa) of NEMO, the 
same region for cIAP1-NEMO interaction. Thus, I found that MC159 competitively 
binds to NEMO to prevent cIAP1-induced NEMO polyubiquitination and NF-kB 
activation(1). This is the first report of a viral protein to disrupt NEMO-cIAP1 
interactions to strategically suppress IKK activation (1). 
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Although MC159 has been shown to inhibit multiple anti-viral immune responses 
such as NF-kB, apoptosis and IFN-b in cell culture models of infection, no studies have 
investigated these effects in vivo (1, 5, 6, 8).  This is because MCV is refractive to growth 
in standard tissue culture, and there is no relevant animal model of infection (8). Here, I 
have developed a surrogate vaccinia virus (vDA49) expressing MCV genes to study the 
effects in mice using two routes of infection. I show that recombinant virus expressing 
MC159L gene (vMC159) is less virulent in intranasal (IN) and intradermal (ID) models 
of infection. The effect was dramatic during ID infection where vMC159 did not produce 
any lesions in infected mice despite harboring infections vMC159 as late as 11 days post-
infection. Thus, this is the first report that examines MCV immune antagonists in the 
context of an animal infection.  
During my research, I also detected MC159 localization in the nucleus. This led 
to investigating if MC159 antagonized genotoxic stress-mediated NF-kB activation, an 
event whose signaling originates in the nucleus. I discovered that MCV encoded proteins 
MC159 and MC160 are unique in inhibiting genotoxic-stress induced NF-kB activation. 
With the help of mutational analyses, I also discovered that DEDB domain of MC159 is 
sufficient and required for nuclear localization of MC159. Further, I developed mutants 
which will help in elucidating the molecular mechanism of NF-kB inhibition when 




5.2 Future Directions 
 
 
Which DED of MC159 is important for inhibiting cIAP1-NEMO interactions? 
 
In Chapter 2, I have discovered a novel mechanism that MC159 employs in 
inhibiting the NF-kB activation (1). I found that MC159 antagonizes cIAP1-NEMO 
interactions to inhibit NEMO polyubiquitination and thus NF-kB activation. I also found 
that MC159 interacts with N-terminus of NEMO, the site for NEMO-cIAP1 interactions 
(1). Although we know the exact residues of NEMO (1-250 aa) important for cIAP1-
NEMO interactions, little is known about the specific domains of MC159 important for 
this inhibition. Using mutational analyses of MC159, we can determine which DEDs are 
critical for this inhibitory function. Preliminary data showed that DEDB is able to interact 
with NEMO and inhibit NF-kB activation. My current hypothesis is that the DEDB 
domain of MC159 is the region required for MC159-NEMO interactions which abrogates 
cIAP1-NEMO interactions for NF-kB inhibition. 
 
Why is vMC159 attenuated during intradermal infections? 
 
Chapter 3 describes the novel animal model system developed to study MCV 
pathogenesis in mice. I showed that recombinant vMC159 virus was less virulent during 
intranasal (IN) and intradermal (ID) models of infection. The effect was striking during 
ID route of infection as vMC159 did not produce any lesions on ear pinnae despite 
harboring infectious vMC159 particles as late as 11 days post-infection.  MC159 is 
known to inhibit the innate immune responses like NF-kB activation, apoptosis and IFN-
b production (8). It will be beneficial to determine the exact mechanism by which 
vMC159 inhibited inflammatory response of the host. Using flow cytometry and q-PCR, 
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one can determine if vMC159 leads to less infiltration of immune cells than wild-type 
virus, which could help to understand why vMC159 infection results in decreased 
pathogenesis. My current hypothesis is that vMC159 hijacks multiple host immune 
responses to gain survival and persistence.     
 
MC159’s nuclear localization 
 
I have found that the MC159 protein localizes to the cytoplasm and nucleus when 
either unstimulated or stimulated with TNF.  With the help of MC159 mutants, I also 
showed that DEDB domain of MC159 is sufficient and required for nuclear localization. 
It is unclear how MC159 localizes to nucleus as it lacks nuclear localization signal 
(NLS). One can argue stating the small molecular proteins can easily diffuse into the 
nucleus. However, when MC159 mutants were used for nuclear localization assay, only 
MC159B was detected in the nucleus and not MC159A. MC159A and MC159B are 
proteins of similar size. Therefore, we suspect that DEDB domain of MC159 interacts 
with some cellular binding partners for nuclear translocation. To investigate this 
hypothesis, the mutants generated in the Chapter 4 could be utilized to detect any binding 
partners involved in this translocation. NEMO is known to migrate to nucleus for the 
mediating genotoxic-stress induced NF-kB activation. Therefore, another possibility is 
that DEDB domain of MC159 binds to NEMO and translocates into the nucleus as part of 
a complex.  
 
How does MC159 and MC160 inhibit genotoxic-stress induced NF-kB activation? 
I discovered that MCV encoded proteins, MC159 and MC160, possess a unique 
function of inhibiting the genotoxic-stress induced NF-kB pathway.  This signaling 
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pathway is different from the TNF-mediated NF-kB activation. With the help of MC159 
mutants generated in Chapter 4 (MC159A and MC159C), we can dissect the molecular 
mechanisms involved in inhibiting genotoxic-stress vs TNF-stress mediated NF-kB 
activation. These mutants have different functional phenotypes when triggered with 
different stimuli via luciferase activity. Since the genotoxic-stress induced signaling 
events occur in the nucleus, the cellular localization of wild-type and mutant MC159 
should also be checked during VP16 treatment. Although MC160 does not localize into 
the nucleus, it inhibited the VP16-mediated NF-kB activation. It is possible that MC160 
antagonizes the ATM-NEMO complex after it migrates out of nucleus into the cytoplasm 
to activate IKK complex. Thus, elucidating the mechanism of genotoxic-stress mediated 
NF-kB inhibition by MCV proteins will demonstrate novel strategies employed by 
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